Dailymed.01b14603-8f29-4fa3-8d7e-9d523f802e0b.s.11	Dailymed.01b14603-8f29-4fa3-8d7e-9d523f802e0b.s.11.e.0	Decrease_Interaction	C54356	The metabolism of <LABELDRUG> to its active metabolite can be impaired by genetic variations in CYP2C19 [see Boxed Warning] and by concomitant <PRECIPITANT>.
Dailymed.01b14603-8f29-4fa3-8d7e-9d523f802e0b.s.34	Dailymed.01b14603-8f29-4fa3-8d7e-9d523f802e0b.s.34.e.0	Decrease_Interaction	C54358	Concomitant use of certain <PRECIPITANT> results in reduced plasma concentrations of the active metabolite of <LABELDRUG> and a reduction in platelet inhibition [see Warnings and Precautions (5.1) and Dosage and Administration (2.4)].
Dailymed.01b388a0-7dfb-11de-bc4e-0002a5d5c51b.s.65	Dailymed.01b388a0-7dfb-11de-bc4e-0002a5d5c51b.s.65.e.3	Increase_Interaction	C54357	"In healthy subjects, coadministration of <LABELDRUG> was associated with significant reduction in the renal clearance of <PRECIPITANT>, with corresponding increases in the AUC. "
Dailymed.01b388a0-7dfb-11de-bc4e-0002a5d5c51b.s.67	Dailymed.01b388a0-7dfb-11de-bc4e-0002a5d5c51b.s.67.e.0	Increase_Interaction	C54357	"Because <LABELDRUG> and <PRECIPITANT>s compete for secretion by renal tubules, patients receiving high doses of <PRECIPITANT>s may experience <PRECIPITANT> toxicity when <LABELDRUG> is concomitantly administered. "
Dailymed.01b388a0-7dfb-11de-bc4e-0002a5d5c51b.s.72	Dailymed.01b388a0-7dfb-11de-bc4e-0002a5d5c51b.s.72.e.0	Increase_Interaction	C54355	"Coadministration of <PRECIPITANT> is reported to increase the area under the curve for <LABELDRUG> by 50%, but dose adjustment of <LABELDRUG> is not necessary."
Dailymed.01b388a0-7dfb-11de-bc4e-0002a5d5c51b.s.73	Dailymed.01b388a0-7dfb-11de-bc4e-0002a5d5c51b.s.73.e.0	Decrease_Interaction	C54356	"Concomitant use of <LABELDRUG> and <PRECIPITANT> has not been studied in humans but, in a study in animals, coadministration of <PRECIPITANT> decreased the absorption of orally administered <LABELDRUG>. "
Dailymed.01b388a0-7dfb-11de-bc4e-0002a5d5c51b.s.76	Dailymed.01b388a0-7dfb-11de-bc4e-0002a5d5c51b.s.76.e.0	Increase_Interaction	C54357	"Other <PRECIPITANT> are known to reduce the renal clearance of lithium, inducing a high risk of lithium toxicity, so coadministration of lithium and <PRECIPITANT> should be undertaken with great caution, if at all. "
Dailymed.01b388a0-7dfb-11de-bc4e-0002a5d5c51b.s.76	Dailymed.01b388a0-7dfb-11de-bc4e-0002a5d5c51b.s.76.e.3	Increase_Interaction	C54357	"Other diuretics are known to reduce the renal clearance of <PRECIPITANT>, inducing a high risk of <PRECIPITANT> toxicity, so coadministration of <PRECIPITANT> and diuretics should be undertaken with great caution, if at all. "
Dailymed.02438044-d6a3-49e9-a1ac-3aad21ef2c8c.s.7	Dailymed.02438044-d6a3-49e9-a1ac-3aad21ef2c8c.s.7.e.0	Increase_Interaction	C54355	<LABELDRUG> is metabolized to a small degree by the CYP3A4 isoenzyme of the cytochrome P450 system and an <PRECIPITANT> could increase systemic <LABELDRUG> exposure. 
Dailymed.02438044-d6a3-49e9-a1ac-3aad21ef2c8c.s.8	Dailymed.02438044-d6a3-49e9-a1ac-3aad21ef2c8c.s.8.e.2	Increase_Interaction	C54355	"More important, <LABELDRUG> is eliminated by cationic renal secretion, and three <PRECIPITANT> have been shown to increase systemic <LABELDRUG> exposure. "
Dailymed.02438044-d6a3-49e9-a1ac-3aad21ef2c8c.s.21	Dailymed.02438044-d6a3-49e9-a1ac-3aad21ef2c8c.s.21.e.0	Increase_Interaction	C54355	<PRECIPITANT> at 400 mg BID (the usual prescription dose) co-administered with <LABELDRUG> (500 mcg BID) for 7 days has been shown to increase <LABELDRUG> plasma levels by 58%. 
Dailymed.02438044-d6a3-49e9-a1ac-3aad21ef2c8c.s.22	Dailymed.02438044-d6a3-49e9-a1ac-3aad21ef2c8c.s.22.e.0	Increase_Interaction	C54355	<PRECIPITANT> at doses of 100 mg BID (OTC dose) resulted in a 13% increase in <LABELDRUG> plasma levels (500 mcg single dose). 
Dailymed.02438044-d6a3-49e9-a1ac-3aad21ef2c8c.s.27	Dailymed.02438044-d6a3-49e9-a1ac-3aad21ef2c8c.s.27.e.0	Increase_Interaction	C54355	"Co-administration of <LABELDRUG> with <PRECIPITANT> resulted in increases in <LABELDRUG> peak plasma levels of 42%, although overall exposure to <LABELDRUG> was not significantly increased. "
Dailymed.02438044-d6a3-49e9-a1ac-3aad21ef2c8c.s.31	Dailymed.02438044-d6a3-49e9-a1ac-3aad21ef2c8c.s.31.e.0	Increase_Interaction	C54602	"<PRECIPITANT> at 400 mg daily (the maximum approved prescription dose) co-administered with <LABELDRUG> (500 mcg BID) for 7 days has been shown to increase <LABELDRUG> Cmax by 53% in males and 97% in females, and AUC by 41% in males and 69% in females."
Dailymed.02438044-d6a3-49e9-a1ac-3aad21ef2c8c.s.38	Dailymed.02438044-d6a3-49e9-a1ac-3aad21ef2c8c.s.38.e.2	Increase_Interaction	C54602	"In patients receiving <PRECIPITANT> alone, <LABELDRUG> AUC increased by 27% and Cmax by 21%. "
Dailymed.02438044-d6a3-49e9-a1ac-3aad21ef2c8c.s.40	Dailymed.02438044-d6a3-49e9-a1ac-3aad21ef2c8c.s.40.e.0	Increase_Interaction	C54602	"In patients receiving <PRECIPITANT>, <LABELDRUG> AUC increased by 30% and Cmax by 16%. "
Dailymed.02438044-d6a3-49e9-a1ac-3aad21ef2c8c.s.48	Dailymed.02438044-d6a3-49e9-a1ac-3aad21ef2c8c.s.48.e.8	Increase_Interaction	C54355	"In addition, <PRECIPITANT> this route (e.g., triamterene, metformin, and amiloride) should be co-administered with care as they might increase <LABELDRUG> levels."
Dailymed.02438044-d6a3-49e9-a1ac-3aad21ef2c8c.s.50	Dailymed.02438044-d6a3-49e9-a1ac-3aad21ef2c8c.s.50.e.0	Increase_Interaction	C54355	<PRECIPITANT> could increase systemic <LABELDRUG> exposure. 
Dailymed.02438044-d6a3-49e9-a1ac-3aad21ef2c8c.s.66	Dailymed.02438044-d6a3-49e9-a1ac-3aad21ef2c8c.s.66.e.0	Increase_Interaction	C54355	"The mean clearances of <LABELDRUG> were 16% and 15% lower in patients on <PRECIPITANT> and inhibitors of tubular organic cation transport, respectively."
Dailymed.02438044-d6a3-49e9-a1ac-3aad21ef2c8c.s.66	Dailymed.02438044-d6a3-49e9-a1ac-3aad21ef2c8c.s.66.e.1	Increase_Interaction	C54355	"The mean clearances of <LABELDRUG> were 16% and 15% lower in patients on thiazide diuretics and <PRECIPITANT>, respectively."
Dailymed.0581fd65-63f9-4705-adbd-602fe7b55874.s.38	Dailymed.0581fd65-63f9-4705-adbd-602fe7b55874.s.38.e.3	Increase_Interaction	C54611	"Because the half-life of <PRECIPITANT> (given frequently to pre-term infants with patent ductus arteriosus and associated cardiac failure) may be prolonged when given concomitantly with <LABELDRUG>, the neonate should be observed closely, frequent ECGs and serum <PRECIPITANT> levels may be required to prevent or detect <PRECIPITANT> toxicity early. "
Dailymed.0581fd65-63f9-4705-adbd-602fe7b55874.s.39	Dailymed.0581fd65-63f9-4705-adbd-602fe7b55874.s.39.e.1	Increase_Interaction	C54357	"Furthermore, in one study of premature infants treated with <LABELDRUG> I.V. and also receiving either gentamicin or amikacin, both peak and trough levels of these <PRECIPITANT> were significantly elevated."
Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.56	Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.56.e.2	Increase_Interaction	C54357	"It has been reported that <LABELDRUG> decreases neuromuscular transmission in patients with Duchenne""s muscular dystrophy, and that <LABELDRUG> prolongs recovery from the neuromuscular blocking agent <PRECIPITANT> and causes a worsening of myasthenia gravis. "
Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.69	Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.69.e.1	Increase_Interaction	C54355	"Clinically significant interactions have been reported with <PRECIPITANT> (eg, erythromycin, ritonavir) causing elevation of plasma levels of <LABELDRUG> while inducers of CYP3A4 (eg, rifampin) have caused a lowering of plasma levels of <LABELDRUG>. "
Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.69	Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.69.e.9	Decrease_Interaction	C54358	"Clinically significant interactions have been reported with inhibitors of CYP3A4 (eg, erythromycin, ritonavir) causing elevation of plasma levels of <LABELDRUG> while <PRECIPITANT> (eg, rifampin) have caused a lowering of plasma levels of <LABELDRUG>. "
Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.73	Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.73.e.2	Increase_Interaction	C54355	Co-administration of multiple doses of 10 mg of <LABELDRUG> with 80 mg <PRECIPITANT> resulted in exposure to <PRECIPITANT> 2.5-fold that following <PRECIPITANT> alone. 
Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.84	Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.84.e.3	Increase_Interaction	C54357	A decrease in <PRECIPITANT> clearance has been reported when <LABELDRUG> and <PRECIPITANT> were administered together. 
Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.92	Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.92.e.2	Increase_Interaction	C54357	"Chronic <LABELDRUG> treatment can increase serum <PRECIPITANT> levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity. "
Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.92	Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.92.e.6	Increase_Interaction	C54357	"Chronic <LABELDRUG> treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in <PRECIPITANT> toxicity. "
Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.93	Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.93.e.4	Increase_Interaction	C54357	In patients with hepatic cirrhosis the influence of <LABELDRUG> on <PRECIPITANT> pharmacokinetics is magnified. 
Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.94	Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.94.e.3	Increase_Interaction	C54357	"<LABELDRUG> may reduce total body clearance and extrarenal clearance of <PRECIPITANT> by 27% and 29%, respectively. "
Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.110	Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.110.e.4	Increase_Interaction	C54357	There has been a report of increased <PRECIPITANT> levels during <LABELDRUG> therapy.
Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.113	Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.113.e.2	Increase_Interaction	C54357	Alcohol: <LABELDRUG> has been found to significantly inhibit <PRECIPITANT> elimination resulting in elevated blood <PRECIPITANT> concentrations that may prolong the intoxicating effects of alcohol. 
Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.119	Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.119.e.2	Increase_Interaction	C54355	Grapefruit Juice: <PRECIPITANT> may significantly increase concentrations of <LABELDRUG>. 
Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.120	Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.120.e.3	Increase_Interaction	C54605	"<PRECIPITANT> given to nine healthy volunteers increased S- and R- <LABELDRUG> AUC0-12 by 36% and 28%, respectively. "
Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.121	Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.121.e.2	Increase_Interaction	C54602	"Steady state Cmax and Cmin of S-<LABELDRUG> increased by 57% and 16.7%, respectively with <PRECIPITANT> compared to control. "
Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.127	Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.127.e.2	Decrease_Interaction	C54356	The former may result in a lowering of serum <PRECIPITANT> levels in patients receiving chronic stable oral <PRECIPITANT> therapy. 
Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.130	Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.130.e.3	Increase_Interaction	C54357	Carbamazepine: <LABELDRUG> therapy may increase <PRECIPITANT> concentrations during combined therapy. 
Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.132	Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.132.e.3	Decrease_Interaction	C54356	Rifampin: Therapy with <PRECIPITANT> may markedly reduce oral <LABELDRUG> bioavailability.
Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.133	Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.133.e.3	Decrease_Interaction	C54356	<PRECIPITANT>: <PRECIPITANT> therapy may increase <LABELDRUG> clearance.
Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.134	Dailymed.0742cf97-601b-4c13-a6c3-1a6a616ed292.s.134.e.2	Increase_Interaction	C54357	Cyclosporine: <LABELDRUG> therapy may increase serum levels of <PRECIPITANT>.
Dailymed.0a4b5599-eded-4f96-8a0b-09bf114efd3b.s.126	Dailymed.0a4b5599-eded-4f96-8a0b-09bf114efd3b.s.126.e.0	Increase_Interaction	C54357	Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving <PRECIPITANT> during therapy with lithium. 
Dailymed.0a4b5599-eded-4f96-8a0b-09bf114efd3b.s.126	Dailymed.0a4b5599-eded-4f96-8a0b-09bf114efd3b.s.126.e.6	Increase_Interaction	C54357	Increased serum <PRECIPITANT> levels and symptoms of <PRECIPITANT> toxicity have been reported in patients receiving ACE inhibitors during therapy with <PRECIPITANT>. 
Dailymed.0a4b5599-eded-4f96-8a0b-09bf114efd3b.s.128	Dailymed.0a4b5599-eded-4f96-8a0b-09bf114efd3b.s.128.e.0	Increase_Interaction	C54357	"If a <PRECIPITANT> is also used, the risk of lithium toxicity may be increased."
Dailymed.0a4b5599-eded-4f96-8a0b-09bf114efd3b.s.128	Dailymed.0a4b5599-eded-4f96-8a0b-09bf114efd3b.s.128.e.1	Increase_Interaction	C54357	"If a diuretic is also used, the risk of <PRECIPITANT> toxicity may be increased."
Dailymed.0a5c7e83-3b17-4412-89fb-ff2235cbe77c.s.75	Dailymed.0a5c7e83-3b17-4412-89fb-ff2235cbe77c.s.75.e.0	Increase_Interaction	C54355	"When <LABELDRUG> was given with <PRECIPITANT> or itraconazole, the blood concentrations of <LABELDRUG> were significantly increased. "
Dailymed.0a5c7e83-3b17-4412-89fb-ff2235cbe77c.s.75	Dailymed.0a5c7e83-3b17-4412-89fb-ff2235cbe77c.s.75.e.1	Increase_Interaction	C54355	"When <LABELDRUG> was given with cyclosporine or <PRECIPITANT>, the blood concentrations of <LABELDRUG> were significantly increased. "
Dailymed.0a5c7e83-3b17-4412-89fb-ff2235cbe77c.s.102	Dailymed.0a5c7e83-3b17-4412-89fb-ff2235cbe77c.s.102.e.3	Increase_Interaction	C54357	Simvastatin: Co-administration of <PRECIPITANT> with <LABELDRUG> increases the systemic exposure of <PRECIPITANT>. 
Dailymed.0a5c7e83-3b17-4412-89fb-ff2235cbe77c.s.111	Dailymed.0a5c7e83-3b17-4412-89fb-ff2235cbe77c.s.111.e.0	Increase_Interaction	C54357	Lithium: <PRECIPITANT> increase the risk of lithium toxicity. 
Dailymed.0a5c7e83-3b17-4412-89fb-ff2235cbe77c.s.111	Dailymed.0a5c7e83-3b17-4412-89fb-ff2235cbe77c.s.111.e.3	Increase_Interaction	C54357	Lithium: Diuretic agents increase the risk of <PRECIPITANT> toxicity. 
Dailymed.0d91895e-c869-4b33-9b83-d55c1ad6317e.s.96	Dailymed.0d91895e-c869-4b33-9b83-d55c1ad6317e.s.96.e.3	Decrease_Interaction	C54358	@item <PRECIPITANT> and colestipol: Reduced absorption of thiazides
Dailymed.0d91895e-c869-4b33-9b83-d55c1ad6317e.s.96	Dailymed.0d91895e-c869-4b33-9b83-d55c1ad6317e.s.96.e.4	Decrease_Interaction	C54358	@item Cholestyramine and <PRECIPITANT>: Reduced absorption of thiazides
Dailymed.0d91895e-c869-4b33-9b83-d55c1ad6317e.s.96	Dailymed.0d91895e-c869-4b33-9b83-d55c1ad6317e.s.96.e.2	Decrease_Interaction	C54358	@item Cholestyramine and colestipol: Reduced absorption of <PRECIPITANT>
Dailymed.0d91895e-c869-4b33-9b83-d55c1ad6317e.s.97	Dailymed.0d91895e-c869-4b33-9b83-d55c1ad6317e.s.97.e.3	Increase_Interaction	C54357	@item Lithium: Reduced renal clearance and high risk of lithium toxicity when used with <PRECIPITANT>. 
Dailymed.0d91895e-c869-4b33-9b83-d55c1ad6317e.s.97	Dailymed.0d91895e-c869-4b33-9b83-d55c1ad6317e.s.97.e.2	Increase_Interaction	C54357	@item Lithium: Reduced renal clearance and high risk of <PRECIPITANT> toxicity when used with diuretics. 
Dailymed.0d91895e-c869-4b33-9b83-d55c1ad6317e.s.119	Dailymed.0d91895e-c869-4b33-9b83-d55c1ad6317e.s.119.e.5	Decrease_Interaction	C54356	"Single doses of either <PRECIPITANT> or colestipol resins bind the <LABELDRUG> and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively. "
Dailymed.0d91895e-c869-4b33-9b83-d55c1ad6317e.s.119	Dailymed.0d91895e-c869-4b33-9b83-d55c1ad6317e.s.119.e.6	Decrease_Interaction	C54356	"Single doses of either cholestyramine or <PRECIPITANT> resins bind the <LABELDRUG> and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively. "
Dailymed.0d91895e-c869-4b33-9b83-d55c1ad6317e.s.122	Dailymed.0d91895e-c869-4b33-9b83-d55c1ad6317e.s.122.e.5	Decrease_Interaction	C54358	"Pressor Amines ( e.g., Norepinephrine): possible decreased response to <PRECIPITANT> but not sufficient to preclude their use."
Dailymed.0d91895e-c869-4b33-9b83-d55c1ad6317e.s.125	Dailymed.0d91895e-c869-4b33-9b83-d55c1ad6317e.s.125.e.2	Increase_Interaction	C54357	<PRECIPITANT> reduce the renal clearance of lithium and add a high risk of lithium toxicity. 
Dailymed.0d91895e-c869-4b33-9b83-d55c1ad6317e.s.125	Dailymed.0d91895e-c869-4b33-9b83-d55c1ad6317e.s.125.e.3	Increase_Interaction	C54357	Diuretic agents reduce the renal clearance of <PRECIPITANT> and add a high risk of <PRECIPITANT> toxicity. 
Dailymed.0ebcca1e-ca16-4483-429a-aec5dcacd1dc.s.97	Dailymed.0ebcca1e-ca16-4483-429a-aec5dcacd1dc.s.97.e.1	Increase_Interaction	C54357	<LABELDRUG> may potentiate the action of other <PRECIPITANT> used concomitantly. 
Dailymed.0ebcca1e-ca16-4483-429a-aec5dcacd1dc.s.99	Dailymed.0ebcca1e-ca16-4483-429a-aec5dcacd1dc.s.99.e.0	Increase_Interaction	C54357	<PRECIPITANT> may also have an additive effect when given with <LABELDRUG>. 
Dailymed.0ebcca1e-ca16-4483-429a-aec5dcacd1dc.s.106	Dailymed.0ebcca1e-ca16-4483-429a-aec5dcacd1dc.s.106.e.0	Increase_Interaction	C54357	<PRECIPITANT> may increase the responsiveness to tubocurarine.
Dailymed.0ebcca1e-ca16-4483-429a-aec5dcacd1dc.s.106	Dailymed.0ebcca1e-ca16-4483-429a-aec5dcacd1dc.s.106.e.1	Increase_Interaction	C54357	Thiazides may increase the responsiveness to <PRECIPITANT>.
Dailymed.0ebcca1e-ca16-4483-429a-aec5dcacd1dc.s.108	Dailymed.0ebcca1e-ca16-4483-429a-aec5dcacd1dc.s.108.e.10	Increase_Interaction	C54357	Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of <PRECIPITANT> toxicity. 
Dailymed.0fc34cd8-86e6-4034-73bd-4263a68ba046.s.119	Dailymed.0fc34cd8-86e6-4034-73bd-4263a68ba046.s.119.e.2	Increase_Interaction	C54357	"Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving <PRECIPITANT> during therapy with lithium, therefore, frequent monitoring of serum lithium levels is recommended. "
Dailymed.0fc34cd8-86e6-4034-73bd-4263a68ba046.s.119	Dailymed.0fc34cd8-86e6-4034-73bd-4263a68ba046.s.119.e.3	Increase_Interaction	C54357	"Increased serum <PRECIPITANT> levels and symptoms of <PRECIPITANT> toxicity have been reported in patients receiving ACE inhibitors during therapy with <PRECIPITANT>, therefore, frequent monitoring of serum <PRECIPITANT> levels is recommended. "
Dailymed.0fc34cd8-86e6-4034-73bd-4263a68ba046.s.120	Dailymed.0fc34cd8-86e6-4034-73bd-4263a68ba046.s.120.e.2	Increase_Interaction	C54357	"If a <PRECIPITANT> is also used, the risk of lithium toxicity may be increased."
Dailymed.0fc34cd8-86e6-4034-73bd-4263a68ba046.s.120	Dailymed.0fc34cd8-86e6-4034-73bd-4263a68ba046.s.120.e.3	Increase_Interaction	C54357	"If a diuretic is also used, the risk of <PRECIPITANT> toxicity may be increased."
Dailymed.0fed2822-3a03-4b64-9857-c682fcd462bc.s.63	Dailymed.0fed2822-3a03-4b64-9857-c682fcd462bc.s.63.e.0	Increase_Interaction	C54357	<PRECIPITANT> reduce the renal clearance of lithium and add a high risk of lithium toxicity.
Dailymed.0fed2822-3a03-4b64-9857-c682fcd462bc.s.63	Dailymed.0fed2822-3a03-4b64-9857-c682fcd462bc.s.63.e.3	Increase_Interaction	C54357	Diuretic agents reduce the renal clearance of <PRECIPITANT> and add a high risk of <PRECIPITANT> toxicity.
Dailymed.0fed2822-3a03-4b64-9857-c682fcd462bc.s.69	Dailymed.0fed2822-3a03-4b64-9857-c682fcd462bc.s.69.e.1	Increase_Interaction	C54611	<LABELDRUG> has been shown to increase the half-life of <PRECIPITANT>. 
Dailymed.0fed2822-3a03-4b64-9857-c682fcd462bc.s.70	Dailymed.0fed2822-3a03-4b64-9857-c682fcd462bc.s.70.e.2	Increase_Interaction	C54357	This may result in increased serum <PRECIPITANT> levels and subsequent digitalis toxicity. 
Dailymed.0fed2822-3a03-4b64-9857-c682fcd462bc.s.70	Dailymed.0fed2822-3a03-4b64-9857-c682fcd462bc.s.70.e.3	Increase_Interaction	C54357	This may result in increased serum digoxin levels and subsequent <PRECIPITANT> toxicity. 
Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.46	Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.46.e.3	Increase_Interaction	C54610	"Studies showed that <LABELDRUG> increased the AUC of <PRECIPITANT> and triazolam by 3- to 4-fold and the Cmax by 2-fold, compared to placebo. "
Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.46	Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.46.e.4	Increase_Interaction	C54610	"Studies showed that <LABELDRUG> increased the AUC of midazolam and <PRECIPITANT> by 3- to 4-fold and the Cmax by 2-fold, compared to placebo. "
Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.47	Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.47.e.2	Increase_Interaction	C54611	The elimination half-life of <PRECIPITANT> and triazolam also increased (1.5- to 2.5-fold) during coadministration with <LABELDRUG>. 
Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.47	Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.47.e.4	Increase_Interaction	C54611	The elimination half-life of midazolam and <PRECIPITANT> also increased (1.5- to 2.5-fold) during coadministration with <LABELDRUG>. 
Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.51	Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.51.e.2	Increase_Interaction	C54357	Administration of CARDIZEM (<LABELDRUG>) concomitantly with <PRECIPITANT> in five normal volunteers resulted in increased <PRECIPITANT> levels in all subjects and bioavailability of <PRECIPITANT> was increased approximately 50%. 
Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.55	Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.55.e.4	Increase_Interaction	C54610	"In nine healthy subjects, <LABELDRUG> significantly increased the mean <PRECIPITANT> AUC 5.5-fold and Cmax 4.1-fold compared to placebo. "
Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.57	Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.57.e.3	Increase_Interaction	C54357	Enhanced effects and increased toxicity of <PRECIPITANT> may be possible during concomitant administration with <LABELDRUG>. 
Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.60	Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.60.e.3	Increase_Interaction	C54357	"Concomitant administration of <LABELDRUG> with <PRECIPITANT> has been reported to result in elevated serum levels of <PRECIPITANT> (40% to 72% increase), resulting in toxicity in some cases. "
Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.63	Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.63.e.2	Increase_Interaction	C54355	A study in six healthy volunteers has shown a significant increase in peak <LABELDRUG> plasma levels (58%) and area-under-the-curve (53%) after a 1-week course of <PRECIPITANT> at 1200 mg per day and a single dose of <LABELDRUG> 60 mg. 
Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.73	Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.73.e.4	Increase_Interaction	C54357	"In renal and cardiac transplant recipients, a reduction of <PRECIPITANT> dose ranging from 15% to 48% was necessary to maintain <PRECIPITANT> trough concentrations similar to those seen prior to the addition of <LABELDRUG>. "
Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.77	Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.77.e.4	Increase_Interaction	C54357	Administration of <PRECIPITANT> with digoxin in 24 healthy male subjects increased plasma digoxin concentrations approximately 20%. 
Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.77	Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.77.e.3	Increase_Interaction	C54357	Administration of CARDIZEM with <PRECIPITANT> in 24 healthy male subjects increased plasma <PRECIPITANT> concentrations approximately 20%. 
Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.81	Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.81.e.2	Increase_Interaction	C54357	"<LABELDRUG> significantly increases the AUC(0 ) of <PRECIPITANT> by 51%, T1/2 by 36%, and decreases its CLoral by 33%. "
Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.84	Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.84.e.3	Decrease_Interaction	C54356	Coadministration of <PRECIPITANT> with <LABELDRUG> lowered the <LABELDRUG> plasma concentrations to undetectable levels. 
Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.87	Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.87.e.2	Increase_Interaction	C54357	<LABELDRUG> is an inhibitor of CYP3A4 and has been shown to increase significantly the AUC of some <PRECIPITANT>. 
Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.90	Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.90.e.4	Increase_Interaction	C54355	"In a healthy volunteer cross-over study (N 10), co-administration of a single 20 mg dose of <PRECIPITANT> at the end of a 14 day regimen with 120 mg BID <LABELDRUG> SR resulted in a 5-fold increase in mean <PRECIPITANT> AUC versus <PRECIPITANT> alone. "
Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.92	Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.92.e.3	Increase_Interaction	C54355	"Computer-based simulations showed that at a daily dose of 480 mg of <LABELDRUG>, an 8- to 9-fold mean increase in <PRECIPITANT> AUC can be expected. "
Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.94	Dailymed.1042fa13-e6af-46b9-8008-6c941f0978b1.s.94.e.3	Increase_Interaction	C54610	"In a ten-subject randomized, open label, 4-way cross-over study, co-administration of <LABELDRUG> (120 mg BID <LABELDRUG> SR for 2 weeks) with a single 20 mg dose of <PRECIPITANT> resulted in 3- to 4-fold increase in mean <PRECIPITANT> AUC and Cmax versus <PRECIPITANT> alone. "
Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81	Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.1	Increase_Interaction	C54355	"In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (<PRECIPITANT>, ritonavir, clarithromycin, erythromycin and fluconazole), increases in <LABELDRUG> exposure and pharmacodynamic effects (i.e., factor <LABELDRUG>a inhibition and PT prolongation) were observed. "
Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81	Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.3	Increase_Interaction	C54355	"In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, <PRECIPITANT>, erythromycin and fluconazole), increases in <LABELDRUG> exposure and pharmacodynamic effects (i.e., factor <LABELDRUG>a inhibition and PT prolongation) were observed. "
Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81	Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.4	Increase_Interaction	C54355	"In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, <PRECIPITANT> and fluconazole), increases in <LABELDRUG> exposure and pharmacodynamic effects (i.e., factor <LABELDRUG>a inhibition and PT prolongation) were observed. "
Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81	Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.2	Increase_Interaction	C54355	"In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, <PRECIPITANT>, clarithromycin, erythromycin and fluconazole), increases in <LABELDRUG> exposure and pharmacodynamic effects (i.e., factor <LABELDRUG>a inhibition and PT prolongation) were observed. "
Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81	Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.81.e.5	Increase_Interaction	C54355	"In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin and <PRECIPITANT>), increases in <LABELDRUG> exposure and pharmacodynamic effects (i.e., factor <LABELDRUG>a inhibition and PT prolongation) were observed. "
Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.87	Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.87.e.1	Decrease_Interaction	C54356	"Results from drug interaction studies and population PK analyses from clinical studies indicate coadministration of <LABELDRUG> with a <PRECIPITANT> (e.g., rifampicin, phenytoin) decreased <LABELDRUG> exposure by up to 50%. "
Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100	Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.100.e.2	Increase_Interaction	C54357	"Patients with renal impairment receiving full dose <LABELDRUG> in combination with drugs classified as <PRECIPITANT> (e.g., amiodarone, diltiazem, verapamil, quinidine, ranolazine, dronedarone, felodipine, erythromycin, and azithromycin) may have increases in exposure compared with patients with normal renal function and no inhibitor use, since both pathways of <LABELDRUG> elimination are affected."
Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.104	Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.104.e.0	Increase_Interaction	C54355	"Concomitant use of drugs that are <PRECIPITANT> (e.g., ketoconazole and ritonavir) increases <LABELDRUG> exposure and may increase bleeding risk [see Drug Interactions (7.1)]."
Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139	Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.11	Increase_Interaction	C54355	"In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, <PRECIPITANT> and fluconazole), increases in <LABELDRUG> exposure and pharmacodynamic effects (i.e., factor <LABELDRUG>a inhibition and PT prolongation) were observed. "
Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139	Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.16	Increase_Interaction	C54355	"In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin and <PRECIPITANT>), increases in <LABELDRUG> exposure and pharmacodynamic effects (i.e., factor <LABELDRUG>a inhibition and PT prolongation) were observed. "
Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139	Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.10	Increase_Interaction	C54355	"In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, <PRECIPITANT>, erythromycin and fluconazole), increases in <LABELDRUG> exposure and pharmacodynamic effects (i.e., factor <LABELDRUG>a inhibition and PT prolongation) were observed. "
Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139	Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.0	Increase_Interaction	C54355	"In drug interaction studies evaluating the concomitant use with drugs that are <PRECIPITANT> (ketoconazole, ritonavir, clarithromycin, erythromycin and fluconazole), increases in <LABELDRUG> exposure and pharmacodynamic effects (i.e., factor <LABELDRUG>a inhibition and PT prolongation) were observed. "
Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139	Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.8	Increase_Interaction	C54355	"In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (<PRECIPITANT>, ritonavir, clarithromycin, erythromycin and fluconazole), increases in <LABELDRUG> exposure and pharmacodynamic effects (i.e., factor <LABELDRUG>a inhibition and PT prolongation) were observed. "
Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139	Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.139.e.9	Increase_Interaction	C54355	"In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, <PRECIPITANT>, clarithromycin, erythromycin and fluconazole), increases in <LABELDRUG> exposure and pharmacodynamic effects (i.e., factor <LABELDRUG>a inhibition and PT prolongation) were observed. "
Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.145	Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.145.e.1	Decrease_Interaction	C54356	"Results from drug interaction studies and population PK analyses from clinical studies indicate coadministration of <LABELDRUG> with a <PRECIPITANT> (e.g., rifampicin, phenytoin) decreased <LABELDRUG> exposure by up to 50%. "
Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158	Dailymed.10db92f9-2300-4a80-836b-673e1ae91610.s.158.e.2	Increase_Interaction	C54357	"Patients with renal impairment receiving full dose <LABELDRUG> in combination with drugs classified as <PRECIPITANT> (e.g., amiodarone, diltiazem, verapamil, quinidine, ranolazine, dronedarone, felodipine, erythromycin, and azithromycin) may have increases in exposure compared with patients with normal renal function and no inhibitor use, since both pathways of <LABELDRUG> elimination are affected."
Dailymed.11d14362-8f69-4c30-b487-5d05f6462bd7.s.25	Dailymed.11d14362-8f69-4c30-b487-5d05f6462bd7.s.25.e.3	Increase_Interaction	C54355	"Altered pharmacokinetics of <LABELDRUG>: <PRECIPITANT> (carbonic anhydrase inhibitors, sodium bicarbonate, thiazide diuretics ) reduce renal elimination of <LABELDRUG>."
Dailymed.11d14362-8f69-4c30-b487-5d05f6462bd7.s.26	Dailymed.11d14362-8f69-4c30-b487-5d05f6462bd7.s.26.e.2	Increase_Interaction	C54355	"By pharmacokinetic mechanisms that are not well understood, <LABELDRUG> levels are increased by coadministration of <PRECIPITANT> or cimetidine. "
Dailymed.11d14362-8f69-4c30-b487-5d05f6462bd7.s.26	Dailymed.11d14362-8f69-4c30-b487-5d05f6462bd7.s.26.e.3	Increase_Interaction	C54355	"By pharmacokinetic mechanisms that are not well understood, <LABELDRUG> levels are increased by coadministration of amiodarone or <PRECIPITANT>. "
Dailymed.11d14362-8f69-4c30-b487-5d05f6462bd7.s.27	Dailymed.11d14362-8f69-4c30-b487-5d05f6462bd7.s.27.e.3	Decrease_Interaction	C54356	"Very rarely, and again by mechanisms not understood, <LABELDRUG> levels are decreased by coadministration of <PRECIPITANT>."
Dailymed.11d14362-8f69-4c30-b487-5d05f6462bd7.s.29	Dailymed.11d14362-8f69-4c30-b487-5d05f6462bd7.s.29.e.3	Increase_Interaction	C54355	"Perhaps because of competition of the P450IIIA4 metabolic pathway, <LABELDRUG> levels rise when <PRECIPITANT> is coadministered."
Dailymed.11d14362-8f69-4c30-b487-5d05f6462bd7.s.32	Dailymed.11d14362-8f69-4c30-b487-5d05f6462bd7.s.32.e.3	Increase_Interaction	C54611	"Hepatic clearance of <LABELDRUG> is significantly reduced during coadministration of <PRECIPITANT>, with corresponding increases in serum levels and half life."
Dailymed.11d14362-8f69-4c30-b487-5d05f6462bd7.s.33	Dailymed.11d14362-8f69-4c30-b487-5d05f6462bd7.s.33.e.3	Increase_Interaction	C54357	Altered pharmacokinetics of other drugs: <LABELDRUG> slows the elimination of <PRECIPITANT> and simultaneously reduces <PRECIPITANT>'s apparent volume of distribution. 
Dailymed.11d14362-8f69-4c30-b487-5d05f6462bd7.s.34	Dailymed.11d14362-8f69-4c30-b487-5d05f6462bd7.s.34.e.2	Increase_Interaction	C54357	"As a result, serum <PRECIPITANT> levels may be as much as doubled. "
Dailymed.11d14362-8f69-4c30-b487-5d05f6462bd7.s.35	Dailymed.11d14362-8f69-4c30-b487-5d05f6462bd7.s.35.e.3	Increase_Interaction	C54357	"When <LABELDRUG> and <PRECIPITANT> are coadministered, <PRECIPITANT> doses usually need to be reduced. "
Dailymed.11d14362-8f69-4c30-b487-5d05f6462bd7.s.36	Dailymed.11d14362-8f69-4c30-b487-5d05f6462bd7.s.36.e.3	Increase_Interaction	C54357	"Serum levels of <PRECIPITANT> are also raised when <LABELDRUG> is coadministered, although the effect appears to be smaller."
Dailymed.11d14362-8f69-4c30-b487-5d05f6462bd7.s.46	Dailymed.11d14362-8f69-4c30-b487-5d05f6462bd7.s.46.e.3	Increase_Interaction	C54357	"Perhaps by competing for pathways of renal clearance, coadministration of <LABELDRUG> causes an increase in serum levels of <PRECIPITANT>."
Dailymed.11d14362-8f69-4c30-b487-5d05f6462bd7.s.47	Dailymed.11d14362-8f69-4c30-b487-5d05f6462bd7.s.47.e.3	Increase_Interaction	C54357	Serum levels of <PRECIPITANT> are increased when <LABELDRUG> is coadministered.
Dailymed.11d14362-8f69-4c30-b487-5d05f6462bd7.s.48	Dailymed.11d14362-8f69-4c30-b487-5d05f6462bd7.s.48.e.2	Decrease_Interaction	C54358	"Presumably because both drugs are metabolized by cyctochrome P450IIIA4, coadministration of <LABELDRUG> causes variable slowing of the metabolism of <PRECIPITANT>. "
Dailymed.11d14362-8f69-4c30-b487-5d05f6462bd7.s.54	Dailymed.11d14362-8f69-4c30-b487-5d05f6462bd7.s.54.e.4	Decrease_Interaction	C54356	"In addition, in vitro addition of <LABELDRUG> to the serum of pregnant women reduces the activity of <PRECIPITANT>, an enzyme that is essential to the metabolism of succinylcholine."
Dailymed.11d14362-8f69-4c30-b487-5d05f6462bd7.s.55	Dailymed.11d14362-8f69-4c30-b487-5d05f6462bd7.s.55.e.3	Increase_Interaction	C54357	"<PRECIPITANT> significantly decreases the clearance and increases the t of <LABELDRUG>, but <LABELDRUG> does not alter the kinetics of diltiazem. "
Dailymed.13b13720-f64d-11df-93a0-0002a5d5c51b.s.31	Dailymed.13b13720-f64d-11df-93a0-0002a5d5c51b.s.31.e.2	Increase_Interaction	C54355	<PRECIPITANT> has been shown to increase <LABELDRUG> plasma concentrations with oral <LABELDRUG> administration. 
Dailymed.13b13720-f64d-11df-93a0-0002a5d5c51b.s.35	Dailymed.13b13720-f64d-11df-93a0-0002a5d5c51b.s.35.e.3	Increase_Interaction	C54357	Concomitant administration of oral <LABELDRUG> and <PRECIPITANT> results in elevated plasma <PRECIPITANT> levels. 
Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.41	Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.41.e.1	Increase_Interaction	C54357	<PRECIPITANT> may add to or potentiate the action of other antihypertensive drugs. 
Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.41	Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.41.e.0	Increase_Interaction	C54357	Thiazides may add to or potentiate the action of other <PRECIPITANT>. 
Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.42	Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.42.e.0	Increase_Interaction	C54357	Potentiation occurs with <PRECIPITANT>.
Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.73	Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.73.e.0	Increase_Interaction	C54357	"Lopressor: <PRECIPITANT> (e.g., reserpine) may have an additive effect when given with beta-blocking agents. "
Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.73	Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.73.e.3	Increase_Interaction	C54357	"Lopressor: Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with <PRECIPITANT>. "
Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.82	Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.82.e.0	Increase_Interaction	C54357	<PRECIPITANT> may increase the plasma concentration of Lopressor. 
Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.82	Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.82.e.1	Increase_Interaction	C54357	Potent inhibitors of the CYP2D6 enzyme may increase the plasma concentration of <PRECIPITANT>. 
Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.93	Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.93.e.0	Increase_Interaction	C54357	<PRECIPITANT> may increase the responsiveness to tubocurarine.
Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.93	Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.93.e.1	Increase_Interaction	C54357	Thiazides may increase the responsiveness to <PRECIPITANT>.
Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.94	Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.94.e.1	Increase_Interaction	C54357	"Lithium renal clearance is reduced by <PRECIPITANT>, increasing the risk of lithium toxicity."
Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.94	Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.94.e.0	Increase_Interaction	C54357	"<PRECIPITANT> renal clearance is reduced by thiazides, increasing the risk of lithium toxicity."
Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.94	Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.94.e.6	Increase_Interaction	C54357	"Lithium renal clearance is reduced by thiazides, increasing the risk of <PRECIPITANT> toxicity."
Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.97	Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.97.e.1	Decrease_Interaction	C54358	Cholestyramine and colestipol resins: Absorption of hydrochlorothiazide is impaired in the presence of <PRECIPITANT>. 
Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.97	Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.97.e.0	Decrease_Interaction	C54358	Cholestyramine and colestipol resins: Absorption of <PRECIPITANT> is impaired in the presence of anionic exchange resins. 
Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.98	Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.98.e.1	Decrease_Interaction	C54356	"Single doses of either cholestyramine or <PRECIPITANT> bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively."
Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.98	Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.98.e.0	Decrease_Interaction	C54356	"Single doses of either <PRECIPITANT> or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively."
Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.98	Dailymed.146d5da7-8c9e-43a2-9a2a-19c0409a6e40.s.98.e.2	Decrease_Interaction	C54356	"Single doses of either cholestyramine or colestipol resins bind the <PRECIPITANT> and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively."
Dailymed.16026409-e821-4680-a114-24c1761d6690.s.71	Dailymed.16026409-e821-4680-a114-24c1761d6690.s.71.e.0	Increase_Interaction	C54357	"In general, <PRECIPITANT> should not be given concomitantly with lithium because they reduce its renal clearance and add a high risk of lithium toxicity. "
Dailymed.16026409-e821-4680-a114-24c1761d6690.s.71	Dailymed.16026409-e821-4680-a114-24c1761d6690.s.71.e.8	Increase_Interaction	C54357	"In general, diuretics should not be given concomitantly with <PRECIPITANT> because they reduce its renal clearance and add a high risk of <PRECIPITANT> toxicity. "
Dailymed.16026409-e821-4680-a114-24c1761d6690.s.127	Dailymed.16026409-e821-4680-a114-24c1761d6690.s.127.e.2	Increase_Interaction	C54357	Serum <PRECIPITANT> levels may increase (see WARNINGS).
Dailymed.18d7820d-471f-4ee2-9ec6-25d8d27c77de.s.88	Dailymed.18d7820d-471f-4ee2-9ec6-25d8d27c77de.s.88.e.3	Increase_Interaction	C54357	Simvastatin: Coadministration of <PRECIPITANT> with <LABELDRUG> increases the systemic exposure of <PRECIPITANT>. 
Dailymed.18d7820d-471f-4ee2-9ec6-25d8d27c77de.s.112	Dailymed.18d7820d-471f-4ee2-9ec6-25d8d27c77de.s.112.e.3	Increase_Interaction	C54357	Lithium: <PRECIPITANT> increase the risk of lithium toxicity. 
Dailymed.18d7820d-471f-4ee2-9ec6-25d8d27c77de.s.112	Dailymed.18d7820d-471f-4ee2-9ec6-25d8d27c77de.s.112.e.2	Increase_Interaction	C54357	Lithium: Diuretic agents increase the risk of <PRECIPITANT> toxicity. 
Dailymed.18d7820d-471f-4ee2-9ec6-25d8d27c77de.s.121	Dailymed.18d7820d-471f-4ee2-9ec6-25d8d27c77de.s.121.e.2	Decrease_Interaction	C54358	@item Cholestyramine and <PRECIPITANT>: Reduced absorption of thiazides (12.3).
Dailymed.18d7820d-471f-4ee2-9ec6-25d8d27c77de.s.121	Dailymed.18d7820d-471f-4ee2-9ec6-25d8d27c77de.s.121.e.4	Decrease_Interaction	C54358	@item <PRECIPITANT> and colestipol: Reduced absorption of thiazides (12.3).
Dailymed.18d7820d-471f-4ee2-9ec6-25d8d27c77de.s.121	Dailymed.18d7820d-471f-4ee2-9ec6-25d8d27c77de.s.121.e.3	Decrease_Interaction	C54358	@item Cholestyramine and colestipol: Reduced absorption of <PRECIPITANT> (12.3).
Dailymed.18d7820d-471f-4ee2-9ec6-25d8d27c77de.s.122	Dailymed.18d7820d-471f-4ee2-9ec6-25d8d27c77de.s.122.e.3	Increase_Interaction	C54357	@item Lithium: <PRECIPITANT> increase risk of lithium toxicity. 
Dailymed.18d7820d-471f-4ee2-9ec6-25d8d27c77de.s.122	Dailymed.18d7820d-471f-4ee2-9ec6-25d8d27c77de.s.122.e.2	Increase_Interaction	C54357	@item Lithium: Diuretics increase risk of <PRECIPITANT> toxicity. 
Dailymed.18fb1c2b-0c1e-436c-a5b6-d4840b5da228.s.46	Dailymed.18fb1c2b-0c1e-436c-a5b6-d4840b5da228.s.46.e.3	Increase_Interaction	C54355	@item <PRECIPITANT> increases <LABELDRUG> plasma levels (7.3).
Dailymed.18fb1c2b-0c1e-436c-a5b6-d4840b5da228.s.47	Dailymed.18fb1c2b-0c1e-436c-a5b6-d4840b5da228.s.47.e.3	Increase_Interaction	C54357	@item <LABELDRUG> increases <PRECIPITANT> plasma levels. 
Dailymed.18fb1c2b-0c1e-436c-a5b6-d4840b5da228.s.55	Dailymed.18fb1c2b-0c1e-436c-a5b6-d4840b5da228.s.55.e.2	Increase_Interaction	C54355	<PRECIPITANT> has been shown to increase <LABELDRUG> plasma concentrations with oral <LABELDRUG> administration. 
Dailymed.18fb1c2b-0c1e-436c-a5b6-d4840b5da228.s.61	Dailymed.18fb1c2b-0c1e-436c-a5b6-d4840b5da228.s.61.e.2	Increase_Interaction	C54357	Concomitant administration of oral <LABELDRUG> and <PRECIPITANT> results in elevated plasma <PRECIPITANT> levels. 
Dailymed.1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6.s.43	Dailymed.1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6.s.43.e.0	Increase_Interaction	C54602	Coadministration of <PRECIPITANT> and <LABELDRUG> has been reported to result in increased <LABELDRUG> maximum concentrations by as much as 67% and AUC by 73% when administered as a single dose. 
Dailymed.1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6.s.47	Dailymed.1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6.s.47.e.0	Decrease_Interaction	C54358	Plasma levels of <PRECIPITANT> are reduced when coadministered with <LABELDRUG>. 
Dailymed.1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6.s.54	Dailymed.1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6.s.54.e.1	Increase_Interaction	C54357	Oral administration of <LABELDRUG> markedly decreases the first-pass metabolism of <PRECIPITANT> and subsequently increases its oral bioavailability. 
Dailymed.21aea811-f47d-4a44-a552-dfc46d2773bf.s.128	Dailymed.21aea811-f47d-4a44-a552-dfc46d2773bf.s.128.e.3	Decrease_Interaction	C54358	"<PRECIPITANT> such as salbutamol, terbutaline and isoprenaline may have to be administered in increased dosages when used concomitantly with <LABELDRUG>."
Dailymed.21aea811-f47d-4a44-a552-dfc46d2773bf.s.135	Dailymed.21aea811-f47d-4a44-a552-dfc46d2773bf.s.135.e.1	Decrease_Interaction	C54606	"Administration of <LABELDRUG> within 2 hours of <PRECIPITANT> should be avoided because it may result in a reduction in Cmax and AUC of 26% and 20%, respectively and consequently in a 25% reduction in the bradycardic effect at rest. "
Dailymed.238176e5-df10-457b-a5cf-c950a583e748.s.74	Dailymed.238176e5-df10-457b-a5cf-c950a583e748.s.74.e.1	Increase_Interaction	C54357	<LABELDRUG> may potentiate the action of other <PRECIPITANT> used concomitantly. 
Dailymed.238176e5-df10-457b-a5cf-c950a583e748.s.82	Dailymed.238176e5-df10-457b-a5cf-c950a583e748.s.82.e.0	Decrease_Interaction	C54607	"Concurrent use of <PRECIPITANT> increases the metabolic clearance of <LABELDRUG>, shortening its elimination half-life. "
Dailymed.238176e5-df10-457b-a5cf-c950a583e748.s.93	Dailymed.238176e5-df10-457b-a5cf-c950a583e748.s.93.e.0	Increase_Interaction	C54357	Other <PRECIPITANT> - additive effect or potentiation.
Dailymed.238176e5-df10-457b-a5cf-c950a583e748.s.95	Dailymed.238176e5-df10-457b-a5cf-c950a583e748.s.95.e.0	Decrease_Interaction	C54356	"Single doses of <PRECIPITANT> and colestipol resins bind the <LABELDRUG> and reduce its absorption in the gastrointestinal tract by up to 85 percent and 43 percent, respectively."
Dailymed.238176e5-df10-457b-a5cf-c950a583e748.s.95	Dailymed.238176e5-df10-457b-a5cf-c950a583e748.s.95.e.1	Decrease_Interaction	C54356	"Single doses of cholestyramine and <PRECIPITANT> bind the <LABELDRUG> and reduce its absorption in the gastrointestinal tract by up to 85 percent and 43 percent, respectively."
Dailymed.238176e5-df10-457b-a5cf-c950a583e748.s.97	Dailymed.238176e5-df10-457b-a5cf-c950a583e748.s.97.e.5	Decrease_Interaction	C54358	"Pressor amines (e.g., norepinephrine) - possible decreased response to <PRECIPITANT> but not sufficient to preclude their use."
Dailymed.238176e5-df10-457b-a5cf-c950a583e748.s.100	Dailymed.238176e5-df10-457b-a5cf-c950a583e748.s.100.e.0	Increase_Interaction	C54357	<PRECIPITANT> reduce the renal clearance of lithium and add a high risk of lithium toxicity. 
Dailymed.238176e5-df10-457b-a5cf-c950a583e748.s.100	Dailymed.238176e5-df10-457b-a5cf-c950a583e748.s.100.e.5	Increase_Interaction	C54357	Diuretic agents reduce the renal clearance of <PRECIPITANT> and add a high risk of <PRECIPITANT> toxicity. 
Dailymed.23ab5537-5d5b-41d6-618c-974930319a48.s.82	Dailymed.23ab5537-5d5b-41d6-618c-974930319a48.s.82.e.0	Increase_Interaction	C54357	"<PRECIPITANT> (eg, reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. "
Dailymed.23ab5537-5d5b-41d6-618c-974930319a48.s.82	Dailymed.23ab5537-5d5b-41d6-618c-974930319a48.s.82.e.5	Increase_Interaction	C54357	"Catecholamine-depleting drugs (eg, reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with <PRECIPITANT>. "
Dailymed.23ab5537-5d5b-41d6-618c-974930319a48.s.84	Dailymed.23ab5537-5d5b-41d6-618c-974930319a48.s.84.e.0	Increase_Interaction	C54355	"<PRECIPITANT> such as quinidine, fluoxetine, paroxetine, and propafenone are likely to increase <LABELDRUG> concentration. "
Dailymed.23ab5537-5d5b-41d6-618c-974930319a48.s.85	Dailymed.23ab5537-5d5b-41d6-618c-974930319a48.s.85.e.1	Increase_Interaction	C54603	"In healthy subjects with CYP2D6 extensive metabolizer phenotype, coadministration of <PRECIPITANT> 100 mg and immediate release <LABELDRUG> 200 mg tripled the concentration of S <LABELDRUG> and doubled the <LABELDRUG> elimination half life. "
Dailymed.23ab5537-5d5b-41d6-618c-974930319a48.s.86	Dailymed.23ab5537-5d5b-41d6-618c-974930319a48.s.86.e.0	Increase_Interaction	C54355	"In four patients with cardiovascular disease, coadministration of <PRECIPITANT> 150 mg t.i.d. with immediate release <LABELDRUG> 50 mg t.i.d. resulted in two  to five-fold increases in the steady-state concentration of <LABELDRUG>. "
Dailymed.23ab5537-5d5b-41d6-618c-974930319a48.s.96	Dailymed.23ab5537-5d5b-41d6-618c-974930319a48.s.96.e.0	Increase_Interaction	C54357	Other <PRECIPITANT>   Additive effect or potentiation.
Dailymed.23ab5537-5d5b-41d6-618c-974930319a48.s.97	Dailymed.23ab5537-5d5b-41d6-618c-974930319a48.s.97.e.0	Decrease_Interaction	C54356	Cholestyramine and colestipol resins   Absorption of <LABELDRUG> is impaired in the presence of <PRECIPITANT>. 
Dailymed.23ab5537-5d5b-41d6-618c-974930319a48.s.98	Dailymed.23ab5537-5d5b-41d6-618c-974930319a48.s.98.e.0	Decrease_Interaction	C54356	"Single doses of either <PRECIPITANT> or colestipol resins bind the <LABELDRUG> and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively."
Dailymed.23ab5537-5d5b-41d6-618c-974930319a48.s.98	Dailymed.23ab5537-5d5b-41d6-618c-974930319a48.s.98.e.1	Decrease_Interaction	C54356	"Single doses of either cholestyramine or <PRECIPITANT> bind the <LABELDRUG> and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively."
Dailymed.23ab5537-5d5b-41d6-618c-974930319a48.s.100	Dailymed.23ab5537-5d5b-41d6-618c-974930319a48.s.100.e.0	Decrease_Interaction	C54358	"<PRECIPITANT> (eg, norepinephrine)   Possible decreased response to pressor amines but not sufficient to preclude their use."
Dailymed.23ab5537-5d5b-41d6-618c-974930319a48.s.103	Dailymed.23ab5537-5d5b-41d6-618c-974930319a48.s.103.e.0	Increase_Interaction	C54357	<PRECIPITANT> reduce the renal clearance of lithium and add a high risk of lithium toxicity. 
Dailymed.23ab5537-5d5b-41d6-618c-974930319a48.s.103	Dailymed.23ab5537-5d5b-41d6-618c-974930319a48.s.103.e.3	Increase_Interaction	C54357	Diuretic agents reduce the renal clearance of <PRECIPITANT> and add a high risk of <PRECIPITANT> toxicity. 
Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.18	Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.18.e.1	Increase_Interaction	C54355	Pharmacokinetic studies have demonstrated that omeprazole and <PRECIPITANT> significantly increased the systemic exposure of <LABELDRUG> and/or its major metabolites. 
Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.18	Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.18.e.0	Increase_Interaction	C54355	Pharmacokinetic studies have demonstrated that <PRECIPITANT> and erythromycin significantly increased the systemic exposure of <LABELDRUG> and/or its major metabolites. 
Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.19	Dailymed.24d75b58-bafb-4440-b8d7-4f4079c08b0b.s.19.e.1	Increase_Interaction	C54357	"Population pharmacokinetic studies showed higher concentrations of <LABELDRUG> among patients concurrently treated with <PRECIPITANT>, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions). "
Dailymed.2aad9cdf-6431-4661-5cb4-f69e735f47e4.s.27	Dailymed.2aad9cdf-6431-4661-5cb4-f69e735f47e4.s.27.e.1	Increase_Interaction	C54355	"Co-administration of <PRECIPITANT> (eg, ketoconazole, itraconazole, erythromycin, grapefruit juice, cimetidine) with <LABELDRUG> may lead to several-fold increases in the plasma levels of <LABELDRUG>, either due to an increase in bioavailability or due to a decrease in metabolism. "
Dailymed.2aad9cdf-6431-4661-5cb4-f69e735f47e4.s.33	Dailymed.2aad9cdf-6431-4661-5cb4-f69e735f47e4.s.33.e.3	Increase_Interaction	C54602	"@item Itraconazole Co-administration of another extended release formulation of <LABELDRUG> with <PRECIPITANT> resulted in approximately 8-fold increase in the AUC, more than 6-fold increase in the Cmax, and 2-fold prolongation in the half-life of <LABELD"
Dailymed.2aad9cdf-6431-4661-5cb4-f69e735f47e4.s.34	Dailymed.2aad9cdf-6431-4661-5cb4-f69e735f47e4.s.34.e.2	Increase_Interaction	C54602	"@item Erythromycin Co-administration of <LABELDRUG> (<LABELDRUG>) with <PRECIPITANT> resulted in approximately 2.5-fold increase in the AUC and Cmax, and about 2-fold prolongation in the half-life of <LABELDRUG>."
Dailymed.2aad9cdf-6431-4661-5cb4-f69e735f47e4.s.35	Dailymed.2aad9cdf-6431-4661-5cb4-f69e735f47e4.s.35.e.2	Increase_Interaction	C54602	"@item Grapefruit juice Co-administration of <LABELDRUG> with <PRECIPITANT> resulted in more than 2-fold increase in the AUC and Cmax, but no prolongation in the half-life of <LABELDRUG>."
Dailymed.2aad9cdf-6431-4661-5cb4-f69e735f47e4.s.36	Dailymed.2aad9cdf-6431-4661-5cb4-f69e735f47e4.s.36.e.2	Increase_Interaction	C54602	"@item Cimetidine Co-administration of <LABELDRUG> with <PRECIPITANT> (a non-specific CYP-450 inhibitor) resulted in an increase of approximately 50% in the AUC and the Cmax, of <LABELDRUG>."
Dailymed.2aad9cdf-6431-4661-5cb4-f69e735f47e4.s.38	Dailymed.2aad9cdf-6431-4661-5cb4-f69e735f47e4.s.38.e.2	Increase_Interaction	C54610	"The AUC and Cmax of <PRECIPITANT>, however, were increased approximately 31 and 38%, respectively. "
Dailymed.2aad9cdf-6431-4661-5cb4-f69e735f47e4.s.41	Dailymed.2aad9cdf-6431-4661-5cb4-f69e735f47e4.s.41.e.3	Decrease_Interaction	C54615	"@item Anticonvulsants In a pharmacokinetic study, maximum plasma concentrations of <LABELDRUG> were considerably lower in epileptic patients on long-term <PRECIPITANT> therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers. "
Dailymed.2aad9cdf-6431-4661-5cb4-f69e735f47e4.s.44	Dailymed.2aad9cdf-6431-4661-5cb4-f69e735f47e4.s.44.e.2	Increase_Interaction	C54357	@item Tacrolimus <LABELDRUG> may increase the blood concentration of <PRECIPITANT>. 
Dailymed.2abb091b-a53e-46b0-9b84-e5ee8f2bdd8e.s.96	Dailymed.2abb091b-a53e-46b0-9b84-e5ee8f2bdd8e.s.96.e.0	Increase_Interaction	C54357	Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving <PRECIPITANT> (including <LABELDRUG>) during therapy with lithium. 
Dailymed.2abb091b-a53e-46b0-9b84-e5ee8f2bdd8e.s.96	Dailymed.2abb091b-a53e-46b0-9b84-e5ee8f2bdd8e.s.96.e.7	Increase_Interaction	C54357	Lithium: Increased serum <PRECIPITANT> levels and symptoms of <PRECIPITANT> toxicity have been reported in patients receiving ACE inhibitors (including <LABELDRUG>) during therapy with <PRECIPITANT>. 
Dailymed.2afe7385-2441-4e22-b63e-ab8614b275df.s.75	Dailymed.2afe7385-2441-4e22-b63e-ab8614b275df.s.75.e.2	Decrease_Interaction	C54358	Such patients may be unresponsive to the usual doses of <PRECIPITANT> used to treat the allergic reaction.
Dailymed.2afe7385-2441-4e22-b63e-ab8614b275df.s.94	Dailymed.2afe7385-2441-4e22-b63e-ab8614b275df.s.94.e.0	Decrease_Interaction	C54358	"<PRECIPITANT> such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with <LABELDRUG>."
Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.9	Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.9.e.2	Increase_Interaction	C54357	Such concomitant therapy can be associated with rapid increases in serum <PRECIPITANT> levels. 
Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.55	Dailymed.2b70cf0c-45be-428f-b396-5001ed4e30fc.s.55.e.10	Increase_Interaction	C54357	Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of <PRECIPITANT> toxicity. 
Dailymed.2d545c2f-29a4-432f-bea9-2aeda6592a62.s.78	Dailymed.2d545c2f-29a4-432f-bea9-2aeda6592a62.s.78.e.2	Increase_Interaction	C54355	"When <LABELDRUG> was given with cyclosporine or <PRECIPITANT>, the blood concentrations of <LABELDRUG> were significantly increased. "
Dailymed.2d545c2f-29a4-432f-bea9-2aeda6592a62.s.78	Dailymed.2d545c2f-29a4-432f-bea9-2aeda6592a62.s.78.e.3	Increase_Interaction	C54355	"When <LABELDRUG> was given with <PRECIPITANT> or itraconazole, the blood concentrations of <LABELDRUG> were significantly increased. "
Dailymed.2d545c2f-29a4-432f-bea9-2aeda6592a62.s.102	Dailymed.2d545c2f-29a4-432f-bea9-2aeda6592a62.s.102.e.3	Increase_Interaction	C54357	Lithium : <PRECIPITANT> increase the risk of lithium toxicity. 
Dailymed.2d545c2f-29a4-432f-bea9-2aeda6592a62.s.102	Dailymed.2d545c2f-29a4-432f-bea9-2aeda6592a62.s.102.e.2	Increase_Interaction	C54357	Lithium : Diuretic agents increase the risk of <PRECIPITANT> toxicity. 
Dailymed.2d545c2f-29a4-432f-bea9-2aeda6592a62.s.111	Dailymed.2d545c2f-29a4-432f-bea9-2aeda6592a62.s.111.e.2	Decrease_Interaction	C54358	@item Cholestyramine and <PRECIPITANT>: Reduced absorption of thiazides (7).
Dailymed.2d545c2f-29a4-432f-bea9-2aeda6592a62.s.111	Dailymed.2d545c2f-29a4-432f-bea9-2aeda6592a62.s.111.e.4	Decrease_Interaction	C54358	@item <PRECIPITANT> and Colestipol: Reduced absorption of thiazides (7).
Dailymed.2d545c2f-29a4-432f-bea9-2aeda6592a62.s.111	Dailymed.2d545c2f-29a4-432f-bea9-2aeda6592a62.s.111.e.3	Decrease_Interaction	C54358	@item Cholestyramine and Colestipol: Reduced absorption of <PRECIPITANT> (7).
Dailymed.2d545c2f-29a4-432f-bea9-2aeda6592a62.s.112	Dailymed.2d545c2f-29a4-432f-bea9-2aeda6592a62.s.112.e.3	Increase_Interaction	C54357	@item Lithium: Increased risk of lithium toxicity when used with <PRECIPITANT>. 
Dailymed.2d545c2f-29a4-432f-bea9-2aeda6592a62.s.112	Dailymed.2d545c2f-29a4-432f-bea9-2aeda6592a62.s.112.e.2	Increase_Interaction	C54357	@item Lithium: Increased risk of <PRECIPITANT> toxicity when used with diuretics. 
Dailymed.316f9345-118c-4bc3-adea-a46e3fe6dc48.s.37	Dailymed.316f9345-118c-4bc3-adea-a46e3fe6dc48.s.37.e.2	Decrease_Interaction	C54355	"If a patient receiving <LABELDRUG> hydrochloride is also taking <PRECIPITANT>, the hypotensive effect of <LABELDRUG> may be reduced, necessitating an increase in the <LABELDRUG> dose."
Dailymed.316f9345-118c-4bc3-adea-a46e3fe6dc48.s.41	Dailymed.316f9345-118c-4bc3-adea-a46e3fe6dc48.s.41.e.2	Increase_Interaction	C54357	"Alcohol: Based on in vitro studies, high concentration of <PRECIPITANT> may increase the rate of release of <LABELDRUG>."
Dailymed.316f9345-118c-4bc3-adea-a46e3fe6dc48.s.44	Dailymed.316f9345-118c-4bc3-adea-a46e3fe6dc48.s.44.e.2	Increase_Interaction	C54355	"@item <PRECIPITANT>: May reduce the hypotensive effect of <LABELDRUG>, necessitating an increase in <LABELDRUG> dose. "
Dailymed.333ee96f-66b6-415f-9ea3-0710b3eee1dd.s.43	Dailymed.333ee96f-66b6-415f-9ea3-0710b3eee1dd.s.43.e.0	Increase_Interaction	C54357	"The thiazide component of <LABELDRUG> may potentiate the action of other <PRECIPITANT>, especially ganglionic or peripheral adrenergic-blocking drugs. "
Dailymed.333ee96f-66b6-415f-9ea3-0710b3eee1dd.s.138	Dailymed.333ee96f-66b6-415f-9ea3-0710b3eee1dd.s.138.e.0	Increase_Interaction	C54357	Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving <PRECIPITANT> during therapy with lithium. 
Dailymed.333ee96f-66b6-415f-9ea3-0710b3eee1dd.s.138	Dailymed.333ee96f-66b6-415f-9ea3-0710b3eee1dd.s.138.e.1	Increase_Interaction	C54357	Increased serum <PRECIPITANT> levels and symptoms of <PRECIPITANT> toxicity have been reported in patients receiving ACE inhibitors during therapy with <PRECIPITANT>. 
Dailymed.333ee96f-66b6-415f-9ea3-0710b3eee1dd.s.139	Dailymed.333ee96f-66b6-415f-9ea3-0710b3eee1dd.s.139.e.1	Increase_Interaction	C54357	"Because renal clearance of lithium is reduced by <PRECIPITANT>, the risk of lithium toxicity is presumably raised further when, as in therapy with <LABELDRUG>, a thiazide diuretic is coadministered with the ACE inhibitor. "
Dailymed.333ee96f-66b6-415f-9ea3-0710b3eee1dd.s.139	Dailymed.333ee96f-66b6-415f-9ea3-0710b3eee1dd.s.139.e.0	Increase_Interaction	C54357	"Because renal clearance of <PRECIPITANT> is reduced by thiazides, the risk of <PRECIPITANT> toxicity is presumably raised further when, as in therapy with <LABELDRUG>, a thiazide diuretic is coadministered with the ACE inhibitor. "
Dailymed.333ee96f-66b6-415f-9ea3-0710b3eee1dd.s.139	Dailymed.333ee96f-66b6-415f-9ea3-0710b3eee1dd.s.139.e.8	Increase_Interaction	C54357	"Because renal clearance of lithium is reduced by thiazides, the risk of lithium toxicity is presumably raised further when, as in therapy with <LABELDRUG>, a <PRECIPITANT>. "
Dailymed.333ee96f-66b6-415f-9ea3-0710b3eee1dd.s.150	Dailymed.333ee96f-66b6-415f-9ea3-0710b3eee1dd.s.150.e.3	Decrease_Interaction	C54356	"Single doses of either <PRECIPITANT> or colestipol resins bind the <LABELDRUG> and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively."
Dailymed.333ee96f-66b6-415f-9ea3-0710b3eee1dd.s.150	Dailymed.333ee96f-66b6-415f-9ea3-0710b3eee1dd.s.150.e.4	Decrease_Interaction	C54356	"Single doses of either cholestyramine or <PRECIPITANT> bind the <LABELDRUG> and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively."
Dailymed.333ee96f-66b6-415f-9ea3-0710b3eee1dd.s.157	Dailymed.333ee96f-66b6-415f-9ea3-0710b3eee1dd.s.157.e.0	Increase_Interaction	C54357	<PRECIPITANT> may increase the responsiveness to tubocurarine.
Dailymed.333ee96f-66b6-415f-9ea3-0710b3eee1dd.s.157	Dailymed.333ee96f-66b6-415f-9ea3-0710b3eee1dd.s.157.e.1	Increase_Interaction	C54357	Thiazide diuretics may increase the responsiveness to <PRECIPITANT>.
Dailymed.333ee96f-66b6-415f-9ea3-0710b3eee1dd.s.173	Dailymed.333ee96f-66b6-415f-9ea3-0710b3eee1dd.s.173.e.1	Increase_Interaction	C54355	Coadministration of propantheline or <PRECIPITANT> increased the absorption of <LABELDRUG>.
Dailymed.333ee96f-66b6-415f-9ea3-0710b3eee1dd.s.173	Dailymed.333ee96f-66b6-415f-9ea3-0710b3eee1dd.s.173.e.0	Increase_Interaction	C54355	Coadministration of <PRECIPITANT> or guanabenz increased the absorption of <LABELDRUG>.
Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.87	Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.87.e.1	Decrease_Interaction	C54606	Concurrent administration of bile acid sequestering agent <PRECIPITANT> reduces the systemic exposure and peak plasma concentration of <LABELDRUG>. 
Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.28	Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.28.e.1	Decrease_Interaction	C54358	<LABELDRUG>  may decrease the bioavailability of <PRECIPITANT> or fluoroquinolones via this mechanism.
Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.28	Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.28.e.2	Decrease_Interaction	C54358	<LABELDRUG>  may decrease the bioavailability of tetracyclines or <PRECIPITANT> via this mechanism.
Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.34	Dailymed.34a29fae-b549-41ed-bd7d-e98fe2110bef.s.34.e.1	Decrease_Interaction	C54358	"In a study of 15 healthy subjects, a co-administered single dose of 4 <LABELDRUG> tablets approximately 2.7 g, decreased the bioavailability of <PRECIPITANT> by approximately 50%."
Dailymed.38a78eca-f770-49a3-8a3a-3f536f3039ec.s.39	Dailymed.38a78eca-f770-49a3-8a3a-3f536f3039ec.s.39.e.3	Decrease_Interaction	C54356	<LABELDRUG> increases the volume of distribution of <PRECIPITANT> in normal subjects. 
Dailymed.38a78eca-f770-49a3-8a3a-3f536f3039ec.s.40	Dailymed.38a78eca-f770-49a3-8a3a-3f536f3039ec.s.40.e.4	Decrease_Interaction	C54358	This could result in a requirement for higher loading doses of <PRECIPITANT>.
Dailymed.39631f1f-5d19-43c1-b504-bf56d991ed97.s.140	Dailymed.39631f1f-5d19-43c1-b504-bf56d991ed97.s.140.e.0	Increase_Interaction	C54357	"Lithium toxicity has been reported in patients receiving lithium concomitantly with <PRECIPITANT>, including ACE inhibitors. "
Dailymed.39631f1f-5d19-43c1-b504-bf56d991ed97.s.140	Dailymed.39631f1f-5d19-43c1-b504-bf56d991ed97.s.140.e.5	Increase_Interaction	C54357	"<PRECIPITANT> toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. "
Dailymed.39631f1f-5d19-43c1-b504-bf56d991ed97.s.141	Dailymed.39631f1f-5d19-43c1-b504-bf56d991ed97.s.141.e.0	Increase_Interaction	C54357	A few cases of <PRECIPITANT> toxicity have been reported in patients receiving concomitant <LABELDRUG> and <PRECIPITANT> and were reversible upon discontinuation of both drugs. 
Dailymed.3a4d74d7-2e63-4789-b50e-af17ced92462.s.23	Dailymed.3a4d74d7-2e63-4789-b50e-af17ced92462.s.23.e.1	Increase_Interaction	C54357	"The action of <PRECIPITANT> (epinephrine, isoproterenol, phenylephrine, metaraminol) may be prolonged when given to patients taking <LABELDRUG>. "
Dailymed.3a4d74d7-2e63-4789-b50e-af17ced92462.s.24	Dailymed.3a4d74d7-2e63-4789-b50e-af17ced92462.s.24.e.1	Decrease_Interaction	C54358	"The action of <PRECIPITANT> (ephedrine, tyramine, amphetamines) is inhibited."
Dailymed.3f11df27-710b-4903-a985-74ee4674a844.s.33	Dailymed.3f11df27-710b-4903-a985-74ee4674a844.s.33.e.6	Increase_Interaction	C54357	"Lithium generally should not be given with diuretics, <PRECIPITANT> reduce the renal clearance of lithium and add a high risk of lithium toxicity. "
Dailymed.3f11df27-710b-4903-a985-74ee4674a844.s.33	Dailymed.3f11df27-710b-4903-a985-74ee4674a844.s.33.e.7	Increase_Interaction	C54357	"Lithium generally should not be given with diuretics, diuretic agents reduce the renal clearance of <PRECIPITANT> and add a high risk of <PRECIPITANT> toxicity. "
Dailymed.3f11df27-710b-4903-a985-74ee4674a844.s.87	Dailymed.3f11df27-710b-4903-a985-74ee4674a844.s.87.e.2	Increase_Interaction	C54357	@item <PRECIPITANT> enhanced possibility of digitalis toxicity associated with hypokalemia. 
Dailymed.3f11df27-710b-4903-a985-74ee4674a844.s.87	Dailymed.3f11df27-710b-4903-a985-74ee4674a844.s.87.e.3	Increase_Interaction	C54357	@item Cardiac glycosides enhanced possibility of <PRECIPITANT> toxicity associated with hypokalemia. 
Dailymed.3f11df27-710b-4903-a985-74ee4674a844.s.89	Dailymed.3f11df27-710b-4903-a985-74ee4674a844.s.89.e.2	Decrease_Interaction	C54356	@item <PRECIPITANT> and colestipol HCl may delay or decrease absorption of <LABELDRUG>. 
Dailymed.3f11df27-710b-4903-a985-74ee4674a844.s.89	Dailymed.3f11df27-710b-4903-a985-74ee4674a844.s.89.e.3	Decrease_Interaction	C54356	@item Cholestyramine resin and <PRECIPITANT> may delay or decrease absorption of <LABELDRUG>. 
Dailymed.3f11df27-710b-4903-a985-74ee4674a844.s.93	Dailymed.3f11df27-710b-4903-a985-74ee4674a844.s.93.e.1	Increase_Interaction	C54357	@item Lithium salts may enhance <PRECIPITANT> toxicity due to reduced renal clearance. 
Dailymed.45806bf7-893a-4dd6-b9ab-c4dc6ce53946.s.54	Dailymed.45806bf7-893a-4dd6-b9ab-c4dc6ce53946.s.54.e.2	Increase_Interaction	C54357	Plasma <LABELDRUG> levels may increase with acute <PRECIPITANT> consumption and decrease upon chronic <PRECIPITANT> use.
Dailymed.45806bf7-893a-4dd6-b9ab-c4dc6ce53946.s.61	Dailymed.45806bf7-893a-4dd6-b9ab-c4dc6ce53946.s.61.e.0	Increase_Interaction	C54355	<PRECIPITANT> increases the concentration of <LABELDRUG> and produces greater degrees of clinical beta-blockade and may cause postural hypotension.
Dailymed.45806bf7-893a-4dd6-b9ab-c4dc6ce53946.s.63	Dailymed.45806bf7-893a-4dd6-b9ab-c4dc6ce53946.s.63.e.1	Increase_Interaction	C54357	The clearance of lidocaine and <PRECIPITANT> are significantly reduced with administration of <LABELDRUG>. 
Dailymed.45806bf7-893a-4dd6-b9ab-c4dc6ce53946.s.63	Dailymed.45806bf7-893a-4dd6-b9ab-c4dc6ce53946.s.63.e.0	Increase_Interaction	C54357	The clearance of <PRECIPITANT> and bupivacaine are significantly reduced with administration of <LABELDRUG>. 
Dailymed.45806bf7-893a-4dd6-b9ab-c4dc6ce53946.s.64	Dailymed.45806bf7-893a-4dd6-b9ab-c4dc6ce53946.s.64.e.2	Increase_Interaction	C54357	<PRECIPITANT> and bupivacaine toxicity has been reported following coadministration with <LABELDRUG>. 
Dailymed.45806bf7-893a-4dd6-b9ab-c4dc6ce53946.s.64	Dailymed.45806bf7-893a-4dd6-b9ab-c4dc6ce53946.s.64.e.3	Increase_Interaction	C54357	Lidocaine and <PRECIPITANT> toxicity has been reported following coadministration with <LABELDRUG>. 
Dailymed.45806bf7-893a-4dd6-b9ab-c4dc6ce53946.s.79	Dailymed.45806bf7-893a-4dd6-b9ab-c4dc6ce53946.s.79.e.2	Increase_Interaction	C54357	"The clearance of <PRECIPITANT> (e.g., lidocaine, bupivacaine, mepivacaine) is reduced with administration of <LABELDRUG>. "
Dailymed.45806bf7-893a-4dd6-b9ab-c4dc6ce53946.s.80	Dailymed.45806bf7-893a-4dd6-b9ab-c4dc6ce53946.s.80.e.3	Increase_Interaction	C54357	Lidocaine and <PRECIPITANT> toxicity has been reported following coadministration with <LABELDRUG>. 
Dailymed.45806bf7-893a-4dd6-b9ab-c4dc6ce53946.s.80	Dailymed.45806bf7-893a-4dd6-b9ab-c4dc6ce53946.s.80.e.2	Increase_Interaction	C54357	<PRECIPITANT> and bupivacaine toxicity has been reported following coadministration with <LABELDRUG>. 
Dailymed.45806bf7-893a-4dd6-b9ab-c4dc6ce53946.s.85	Dailymed.45806bf7-893a-4dd6-b9ab-c4dc6ce53946.s.85.e.0	Decrease_Interaction	C54356	Administration of <PRECIPITANT> with <LABELDRUG> may reduce the efficacy of <LABELDRUG> in reducing blood pressure and heart rate.
Dailymed.45806bf7-893a-4dd6-b9ab-c4dc6ce53946.s.87	Dailymed.45806bf7-893a-4dd6-b9ab-c4dc6ce53946.s.87.e.3	Increase_Interaction	C54357	<LABELDRUG> when administered with <PRECIPITANT> increases the concentration of <PRECIPITANT>. 
Dailymed.45c45f61-b20b-41ba-af07-1f977163d39b.s.11	Dailymed.45c45f61-b20b-41ba-af07-1f977163d39b.s.11.e.3	Increase_Interaction	C54357	Coadministration of <LABELDRUG> and <PRECIPITANT> led to an increase of about 18% in AUC of <LABELDRUG> but did not affect the pharmacokinetics of its active metabolite. 
Dailymed.45c45f61-b20b-41ba-af07-1f977163d39b.s.12	Dailymed.45c45f61-b20b-41ba-af07-1f977163d39b.s.12.e.3	Decrease_Interaction	C54606	Coadministration of <LABELDRUG> and <PRECIPITANT> led to a reduction of about 20% in the AUC of <LABELDRUG> and that of its active metabolite. 
Dailymed.45c45f61-b20b-41ba-af07-1f977163d39b.s.13	Dailymed.45c45f61-b20b-41ba-af07-1f977163d39b.s.13.e.2	Decrease_Interaction	C54614	A somewhat greater interaction (approximately 40% reduction in the AUC of active metabolite and approximately 30% reduction in the AUC of <LABELDRUG>) has been reported with <PRECIPITANT>. 
Dailymed.45c45f61-b20b-41ba-af07-1f977163d39b.s.14	Dailymed.45c45f61-b20b-41ba-af07-1f977163d39b.s.14.e.3	Increase_Interaction	C54357	"<PRECIPITANT>, an inhibitor of cytochrome P450 2C9, decreased the AUC of the active metabolite by approximately 40%, but increased the AUC of <LABELDRUG> by approximately 70% following multiple doses. "
Dailymed.45c45f61-b20b-41ba-af07-1f977163d39b.s.16	Dailymed.45c45f61-b20b-41ba-af07-1f977163d39b.s.16.e.2	Increase_Interaction	C54355	"The AUC of active metabolite following oral <LABELDRUG> was not affected by <PRECIPITANT>, another inhibitor of P450 3A4, but the AUC of <LABELDRUG> was increased by 30%."
Dailymed.45c45f61-b20b-41ba-af07-1f977163d39b.s.116	Dailymed.45c45f61-b20b-41ba-af07-1f977163d39b.s.116.e.2	Decrease_Interaction	C54356	"<PRECIPITANT>, an inducer of drug metabolism, decreased the concentrations of <LABELDRUG> and its active metabolite. "
Dailymed.45c45f61-b20b-41ba-af07-1f977163d39b.s.120	Dailymed.45c45f61-b20b-41ba-af07-1f977163d39b.s.120.e.2	Increase_Interaction	C54355	"<PRECIPITANT>, an inhibitor of P450 2C9, decreased active metabolite concentration and increased <LABELDRUG> concentration. "
Dailymed.45c45f61-b20b-41ba-af07-1f977163d39b.s.125	Dailymed.45c45f61-b20b-41ba-af07-1f977163d39b.s.125.e.2	Increase_Interaction	C54357	"Lithium: As with other <PRECIPITANT>, lithium excretion may be reduced. "
Dailymed.45c45f61-b20b-41ba-af07-1f977163d39b.s.125	Dailymed.45c45f61-b20b-41ba-af07-1f977163d39b.s.125.e.3	Increase_Interaction	C54357	"Lithium: As with other drugs which affect the excretion of sodium, <PRECIPITANT> excretion may be reduced. "
Dailymed.45c45f61-b20b-41ba-af07-1f977163d39b.s.136	Dailymed.45c45f61-b20b-41ba-af07-1f977163d39b.s.136.e.5	Decrease_Interaction	C54356	"Single doses of either <PRECIPITANT> or colestipol resins bind the <LABELDRUG> and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively."
Dailymed.45c45f61-b20b-41ba-af07-1f977163d39b.s.136	Dailymed.45c45f61-b20b-41ba-af07-1f977163d39b.s.136.e.6	Decrease_Interaction	C54356	"Single doses of either cholestyramine or <PRECIPITANT> resins bind the <LABELDRUG> and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively."
Dailymed.45c45f61-b20b-41ba-af07-1f977163d39b.s.138	Dailymed.45c45f61-b20b-41ba-af07-1f977163d39b.s.138.e.5	Decrease_Interaction	C54358	"@item Pressor amines (e.g., norepinephrine) possible decreased response to <PRECIPITANT> but not sufficient to preclude their use."
Dailymed.45c45f61-b20b-41ba-af07-1f977163d39b.s.141	Dailymed.45c45f61-b20b-41ba-af07-1f977163d39b.s.141.e.3	Increase_Interaction	C54357	<PRECIPITANT> reduce the renal clearance of lithium and add a high risk of lithium toxicity. 
Dailymed.45c45f61-b20b-41ba-af07-1f977163d39b.s.141	Dailymed.45c45f61-b20b-41ba-af07-1f977163d39b.s.141.e.2	Increase_Interaction	C54357	Diuretic agents reduce the renal clearance of <PRECIPITANT> and add a high risk of <PRECIPITANT> toxicity. 
Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.55	Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.55.e.4	Increase_Interaction	C54610	"Studies showed that <LABELDRUG> increased the AUC of midazolam and <PRECIPITANT> by 3- to 4-fold and the Cmax by 2-fold, compared to placebo. "
Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.55	Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.55.e.3	Increase_Interaction	C54610	"Studies showed that <LABELDRUG> increased the AUC of <PRECIPITANT> and triazolam by 3- to 4-fold and the Cmax by 2-fold, compared to placebo. "
Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.56	Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.56.e.3	Increase_Interaction	C54611	The elimination half-life of midazolam and <PRECIPITANT> also increased (1.5- to 2.5-fold) during coadministration with <LABELDRUG>. 
Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.56	Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.56.e.2	Increase_Interaction	C54611	The elimination half-life of <PRECIPITANT> and triazolam also increased (1.5- to 2.5-fold) during coadministration with <LABELDRUG>. 
Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.61	Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.61.e.0	Increase_Interaction	C54357	"Administration of <LABELDRUG> (<LABELDRUG>) concomitantly with <PRECIPITANT> in five normal volunteers resulted in increased <PRECIPITANT> levels in all subjects, and bioavailability of <PRECIPITANT> was increased approximately 50%. "
Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.65	Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.65.e.6	Increase_Interaction	C54610	"In nine healthy subjects, <LABELDRUG> significantly increased the mean <PRECIPITANT> AUC 5.5-fold and Cmax 4.1-fold compared to placebo. "
Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.67	Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.67.e.4	Increase_Interaction	C54357	Enhanced effects and increased toxicity of <PRECIPITANT> may be possible during concomitant administration with <LABELDRUG>. 
Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.70	Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.70.e.2	Increase_Interaction	C54357	Concomitant administration of <LABELDRUG> with <PRECIPITANT> has been reported to result in elevated serum levels of <PRECIPITANT> (40% to 72% increase) resulting in toxicity in some cases. 
Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.73	Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.73.e.6	Increase_Interaction	C54355	A study in six healthy volunteers has shown a significant increase in peak <LABELDRUG> plasma levels (58%) and area-under-the-curve (53%) after a 1-week course of <PRECIPITANT> at 1200 mg per day and a single dose of <LABELDRUG> 60 mg. 
Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.83	Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.83.e.2	Increase_Interaction	C54357	"In renal and cardiac transplant recipients, a reduction of <PRECIPITANT> trough dose ranging from 15% to 48% was necessary to maintain concentrations similar to those seen prior to the addition of <LABELDRUG>. "
Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.87	Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.87.e.3	Increase_Interaction	C54357	Administration of <LABELDRUG> with <PRECIPITANT> in 24 healthy male subjects increased plasma <PRECIPITANT> concentrations approximately 20%. 
Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.91	Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.91.e.3	Increase_Interaction	C54357	"<LABELDRUG> significantly increases the AUC (0 ) of <PRECIPITANT> by 51%, T1/2 by 36%, and decreases its CLoral by 33%. "
Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.94	Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.94.e.0	Decrease_Interaction	C54356	Coadministration of <PRECIPITANT> with <LABELDRUG> lowered the <LABELDRUG> plasma concentrations to undetectable levels. 
Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.97	Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.97.e.5	Increase_Interaction	C54357	<LABELDRUG> is an inhibitor of CYP3A4 and has been shown to increase significantly the AUC of some <PRECIPITANT>. 
Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.100	Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.100.e.4	Increase_Interaction	C54355	"In a healthy volunteer cross-over study (N 10), co-administration of a single 20 mg dose of <PRECIPITANT> at the end of a 14 day regimen with 120 mg BID <LABELDRUG> SR resulted in a 5-fold increase in mean <PRECIPITANT> AUC versus <PRECIPITANT> alone. "
Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.102	Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.102.e.2	Increase_Interaction	C54355	"Computer-based simulations showed that at a daily dose of 480 mg of <LABELDRUG>, an 8- to 9-fold mean increase in <PRECIPITANT> AUC can be expected. "
Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.104	Dailymed.461fe23f-4453-4e3f-9621-0e3fda057d14.s.104.e.6	Increase_Interaction	C54610	"In a ten-subject randomized, open label, 4-way cross-over study, co-administration of <LABELDRUG> (120 mg BID <LABELDRUG> SR for 2 weeks) with a single 20 mg dose of <PRECIPITANT> resulted in 3- to 4-fold increase in mean <PRECIPITANT> AUC and Cmax versus <PRECIPITANT> alone. "
Dailymed.46c2cb4b-eb65-45f5-891f-5e574adc962d.s.10	Dailymed.46c2cb4b-eb65-45f5-891f-5e574adc962d.s.10.e.3	Increase_Interaction	C54357	Coadministration of <LABELDRUG> and <PRECIPITANT> led to an increase of about 18% in AUC of <LABELDRUG> but did not affect the pharmacokinetics of its active metabolite. 
Dailymed.46c2cb4b-eb65-45f5-891f-5e574adc962d.s.11	Dailymed.46c2cb4b-eb65-45f5-891f-5e574adc962d.s.11.e.3	Decrease_Interaction	C54606	Coadministration of <LABELDRUG> and <PRECIPITANT> led to a reduction of about 20% in the AUC of <LABELDRUG> and that of its active metabolite. 
Dailymed.46c2cb4b-eb65-45f5-891f-5e574adc962d.s.12	Dailymed.46c2cb4b-eb65-45f5-891f-5e574adc962d.s.12.e.2	Decrease_Interaction	C54614	A somewhat greater interaction (approximately 40% reduction in the AUC of active metabolite and approximately 30% reduction in the AUC of <LABELDRUG>) has been reported with <PRECIPITANT>. 
Dailymed.46c2cb4b-eb65-45f5-891f-5e574adc962d.s.13	Dailymed.46c2cb4b-eb65-45f5-891f-5e574adc962d.s.13.e.2	Increase_Interaction	C54605	"<PRECIPITANT>, an inhibitor of cytochrome P450 2C9, decreased the AUC of the active metabolite by approximately 40%, but increased the AUC of <LABELDRUG> by approximately 70% following multiple doses. "
Dailymed.46c2cb4b-eb65-45f5-891f-5e574adc962d.s.15	Dailymed.46c2cb4b-eb65-45f5-891f-5e574adc962d.s.15.e.2	Increase_Interaction	C54355	"The AUC of active metabolite following oral <LABELDRUG> was not affected by <PRECIPITANT>, another inhibitor of P450 3A4, but the AUC of <LABELDRUG> was increased by 30%."
Dailymed.46c2cb4b-eb65-45f5-891f-5e574adc962d.s.64	Dailymed.46c2cb4b-eb65-45f5-891f-5e574adc962d.s.64.e.3	Decrease_Interaction	C54356	"<PRECIPITANT>, an inducer of drug metabolism, decreased the concentrations of <LABELDRUG> and its active metabolite. "
Dailymed.46c2cb4b-eb65-45f5-891f-5e574adc962d.s.68	Dailymed.46c2cb4b-eb65-45f5-891f-5e574adc962d.s.68.e.2	Increase_Interaction	C54355	"<PRECIPITANT>, an inhibitor of P450 2C9, decreased active metabolite concentration and increased <LABELDRUG> concentration. "
Dailymed.46c2cb4b-eb65-45f5-891f-5e574adc962d.s.73	Dailymed.46c2cb4b-eb65-45f5-891f-5e574adc962d.s.73.e.3	Increase_Interaction	C54357	"Lithium: As with other <PRECIPITANT>, lithium excretion may be reduced. "
Dailymed.46c2cb4b-eb65-45f5-891f-5e574adc962d.s.73	Dailymed.46c2cb4b-eb65-45f5-891f-5e574adc962d.s.73.e.2	Increase_Interaction	C54357	"Lithium: As with other drugs which affect the excretion of sodium, <PRECIPITANT> excretion may be reduced. "
Dailymed.46f17ba7-a78c-4a9e-7597-27654f097bd3.s.43	Dailymed.46f17ba7-a78c-4a9e-7597-27654f097bd3.s.43.e.1	Increase_Interaction	C54355	"If symptomatic hypotension develops, a dose reduction or discontinuation of <LABELDRUG> or concomitant <PRECIPITANT> may be necessary."
Dailymed.46f17ba7-a78c-4a9e-7597-27654f097bd3.s.102	Dailymed.46f17ba7-a78c-4a9e-7597-27654f097bd3.s.102.e.3	Increase_Interaction	C54357	Studies with ACE inhibitors in combination with <PRECIPITANT>s indicate that the dose of the ACE inhibitor can be reduced when it is given with a <PRECIPITANT> (See DOSAGE AND ADMINISTRATION).
Dailymed.46f17ba7-a78c-4a9e-7597-27654f097bd3.s.102	Dailymed.46f17ba7-a78c-4a9e-7597-27654f097bd3.s.102.e.2	Increase_Interaction	C54357	Studies with <PRECIPITANT>s in combination with diuretics indicate that the dose of the <PRECIPITANT> can be reduced when it is given with a diuretic (See DOSAGE AND ADMINISTRATION).
Dailymed.46f17ba7-a78c-4a9e-7597-27654f097bd3.s.123	Dailymed.46f17ba7-a78c-4a9e-7597-27654f097bd3.s.123.e.3	Increase_Interaction	C54357	"Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with <PRECIPITANT>, including ACE inhibitors. "
Dailymed.46f17ba7-a78c-4a9e-7597-27654f097bd3.s.123	Dailymed.46f17ba7-a78c-4a9e-7597-27654f097bd3.s.123.e.0	Increase_Interaction	C54357	"<PRECIPITANT>: <PRECIPITANT> toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. "
Dailymed.46f17ba7-a78c-4a9e-7597-27654f097bd3.s.124	Dailymed.46f17ba7-a78c-4a9e-7597-27654f097bd3.s.124.e.2	Increase_Interaction	C54357	Lithium toxicity was usually reversible upon discontinuation of lithium and the <PRECIPITANT>. 
Dailymed.46f17ba7-a78c-4a9e-7597-27654f097bd3.s.124	Dailymed.46f17ba7-a78c-4a9e-7597-27654f097bd3.s.124.e.3	Increase_Interaction	C54357	<PRECIPITANT> toxicity was usually reversible upon discontinuation of lithium and the ACE inhibitor. 
Dailymed.48b021e4-5897-42fd-12be-3190a9b087e8.s.93	Dailymed.48b021e4-5897-42fd-12be-3190a9b087e8.s.93.e.2	Increase_Interaction	C54357	Lithium   Renal clearance of lithium is reduced by <PRECIPITANT> and increases the risk of lithium toxicity. 
Dailymed.48b021e4-5897-42fd-12be-3190a9b087e8.s.93	Dailymed.48b021e4-5897-42fd-12be-3190a9b087e8.s.93.e.5	Increase_Interaction	C54357	Lithium   Renal clearance of <PRECIPITANT> is reduced by thiazides and increases the risk of <PRECIPITANT> toxicity. 
Dailymed.48b021e4-5897-42fd-12be-3190a9b087e8.s.94	Dailymed.48b021e4-5897-42fd-12be-3190a9b087e8.s.94.e.2	Increase_Interaction	C54357	"Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some <PRECIPITANT>. "
Dailymed.48b021e4-5897-42fd-12be-3190a9b087e8.s.94	Dailymed.48b021e4-5897-42fd-12be-3190a9b087e8.s.94.e.1	Increase_Interaction	C54357	"Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with <PRECIPITANT>, and with some angiotensin II receptor antagonists. "
Dailymed.48b021e4-5897-42fd-12be-3190a9b087e8.s.94	Dailymed.48b021e4-5897-42fd-12be-3190a9b087e8.s.94.e.7	Increase_Interaction	C54357	"Reversible increases in serum <PRECIPITANT> concentrations and toxicity have been reported during concomitant administration of <PRECIPITANT> with ACE inhibitors, and with some angiotensin II receptor antagonists. "
Dailymed.48b021e4-5897-42fd-12be-3190a9b087e8.s.95	Dailymed.48b021e4-5897-42fd-12be-3190a9b087e8.s.95.e.2	Increase_Interaction	C54357	An increase in serum <PRECIPITANT> concentration has been reported during concomitant administration of <PRECIPITANT> with cand<LABELDRUG>. 
Dailymed.48b021e4-5897-42fd-12be-3190a9b087e8.s.106	Dailymed.48b021e4-5897-42fd-12be-3190a9b087e8.s.106.e.0	Decrease_Interaction	C54356	"Ion Exchange resins   Single doses of either <PRECIPITANT> or colestipol resins bind the <LABELDRUG> and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively. "
Dailymed.48b021e4-5897-42fd-12be-3190a9b087e8.s.106	Dailymed.48b021e4-5897-42fd-12be-3190a9b087e8.s.106.e.1	Decrease_Interaction	C54356	"Ion Exchange resins   Single doses of either cholestyramine or <PRECIPITANT> bind the <LABELDRUG> and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively. "
Dailymed.48b021e4-5897-42fd-12be-3190a9b087e8.s.108	Dailymed.48b021e4-5897-42fd-12be-3190a9b087e8.s.108.e.3	Increase_Interaction	C54357	"Skeletal <PRECIPITANT>, nondepolarizing (eg, tubocurarine)  Possible increased responsiveness to <PRECIPITANT> such as curare derivatives."
Dailymed.48b021e4-5897-42fd-12be-3190a9b087e8.s.109	Dailymed.48b021e4-5897-42fd-12be-3190a9b087e8.s.109.e.3	Increase_Interaction	C54357	Digitalis: <PRECIPITANT>-induced hypokalemia or hypomagnesemia may predispose to digoxin toxicity.
Dailymed.48b021e4-5897-42fd-12be-3190a9b087e8.s.109	Dailymed.48b021e4-5897-42fd-12be-3190a9b087e8.s.109.e.0	Increase_Interaction	C54357	Digitalis: Thiazide-induced hypokalemia or hypomagnesemia may predispose to <PRECIPITANT> toxicity.
Dailymed.4a5762c6-d7a2-4e4c-10b7-8832b36fa5f4.s.84	Dailymed.4a5762c6-d7a2-4e4c-10b7-8832b36fa5f4.s.84.e.3	Increase_Interaction	C54357	@item <PRECIPITANT> may have an additive effect when given with beta-blocking agents. 
Dailymed.4a5762c6-d7a2-4e4c-10b7-8832b36fa5f4.s.84	Dailymed.4a5762c6-d7a2-4e4c-10b7-8832b36fa5f4.s.84.e.2	Increase_Interaction	C54357	@item Catecholamine-depleting drugs may have an additive effect when given with <PRECIPITANT>. 
Dailymed.4a5762c6-d7a2-4e4c-10b7-8832b36fa5f4.s.86	Dailymed.4a5762c6-d7a2-4e4c-10b7-8832b36fa5f4.s.86.e.2	Increase_Interaction	C54355	@item <PRECIPITANT> are likely to increase <LABELDRUG> concentration. 
Dailymed.4a5762c6-d7a2-4e4c-10b7-8832b36fa5f4.s.93	Dailymed.4a5762c6-d7a2-4e4c-10b7-8832b36fa5f4.s.93.e.1	Increase_Interaction	C54357	"<PRECIPITANT> (eg, reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. "
Dailymed.4a5762c6-d7a2-4e4c-10b7-8832b36fa5f4.s.93	Dailymed.4a5762c6-d7a2-4e4c-10b7-8832b36fa5f4.s.93.e.7	Increase_Interaction	C54357	"Catecholamine depleting drugs (eg, reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with <PRECIPITANT>. "
Dailymed.4a5762c6-d7a2-4e4c-10b7-8832b36fa5f4.s.96	Dailymed.4a5762c6-d7a2-4e4c-10b7-8832b36fa5f4.s.96.e.1	Increase_Interaction	C54355	"<PRECIPITANT> such as quinidine, fluoxetine, paroxetine, and propafenone are likely to increase <LABELDRUG> concentration. "
Dailymed.4a5762c6-d7a2-4e4c-10b7-8832b36fa5f4.s.97	Dailymed.4a5762c6-d7a2-4e4c-10b7-8832b36fa5f4.s.97.e.3	Increase_Interaction	C54603	"In healthy subjects with CYP2D6 extensive metabolizer phenotype, coadministration of <PRECIPITANT> 100 mg and immediate-release <LABELDRUG> 200 mg tripled the concentration of S-<LABELDRUG> and doubled the <LABELDRUG> elimination half-life. "
Dailymed.4a5762c6-d7a2-4e4c-10b7-8832b36fa5f4.s.98	Dailymed.4a5762c6-d7a2-4e4c-10b7-8832b36fa5f4.s.98.e.5	Increase_Interaction	C54355	"In four patients with cardiovascular disease, coadministration of <PRECIPITANT> 150 mg t.i.d. with immediate-release <LABELDRUG> 50 mg t.i.d. resulted in two- to five-fold increases in the steady-state concentration of <LABELDRUG>. "
Dailymed.5012f997-9fb2-4c3d-99fd-4f7efd7c39af.s.30	Dailymed.5012f997-9fb2-4c3d-99fd-4f7efd7c39af.s.30.e.3	Increase_Interaction	C54357	Caution should be used when lithium and <PRECIPITANT> are used concomitantly because diuretic-induced sodium loss may reduce the renal clearance of lithium and increase serum lithium levels with risk of lithium toxicity. 
Dailymed.5012f997-9fb2-4c3d-99fd-4f7efd7c39af.s.30	Dailymed.5012f997-9fb2-4c3d-99fd-4f7efd7c39af.s.30.e.2	Increase_Interaction	C54357	Caution should be used when <PRECIPITANT> and diuretics are used concomitantly because diuretic-induced sodium loss may reduce the renal clearance of <PRECIPITANT> and increase serum <PRECIPITANT> levels with risk of <PRECIPITANT> toxicity. 
Dailymed.53b6f198-e4a7-4505-9672-efb8c64073ae.s.85	Dailymed.53b6f198-e4a7-4505-9672-efb8c64073ae.s.85.e.2	Increase_Interaction	C54357	<PRECIPITANT> may add to or potentiate the action of other antihypertensive drugs.
Dailymed.53b6f198-e4a7-4505-9672-efb8c64073ae.s.85	Dailymed.53b6f198-e4a7-4505-9672-efb8c64073ae.s.85.e.3	Increase_Interaction	C54357	Thiazides may add to or potentiate the action of other <PRECIPITANT>.
Dailymed.53b6f198-e4a7-4505-9672-efb8c64073ae.s.88	Dailymed.53b6f198-e4a7-4505-9672-efb8c64073ae.s.88.e.3	Increase_Interaction	C54357	Thiazides have also been shown to increase the responsiveness to <PRECIPITANT>.
Dailymed.53b6f198-e4a7-4505-9672-efb8c64073ae.s.88	Dailymed.53b6f198-e4a7-4505-9672-efb8c64073ae.s.88.e.2	Increase_Interaction	C54357	<PRECIPITANT> have also been shown to increase the responsiveness to tubocurarine.
Dailymed.53b6f198-e4a7-4505-9672-efb8c64073ae.s.89	Dailymed.53b6f198-e4a7-4505-9672-efb8c64073ae.s.89.e.3	Increase_Interaction	C54357	Lithium generally should not be given with <PRECIPITANT> because they reduce its renal clearance and add a high risk of lithium toxicity. 
Dailymed.53b6f198-e4a7-4505-9672-efb8c64073ae.s.89	Dailymed.53b6f198-e4a7-4505-9672-efb8c64073ae.s.89.e.8	Increase_Interaction	C54357	Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of <PRECIPITANT> toxicity. 
Dailymed.5526617c-c7b9-4556-886d-729bbabbc566.s.25	Dailymed.5526617c-c7b9-4556-886d-729bbabbc566.s.25.e.2	Increase_Interaction	C54355	<PRECIPITANT> 200 mg administered with <LABELDRUG> increased <LABELDRUG> exposure by 5 fold. 
Dailymed.5526617c-c7b9-4556-886d-729bbabbc566.s.38	Dailymed.5526617c-c7b9-4556-886d-729bbabbc566.s.38.e.2	Increase_Interaction	C54357	@item Consider dose reduction if co-administered with <PRECIPITANT> (5.5)
Dailymed.5526617c-c7b9-4556-886d-729bbabbc566.s.73	Dailymed.5526617c-c7b9-4556-886d-729bbabbc566.s.73.e.2	Increase_Interaction	C54355	"<PRECIPITANT> can lead to a marked increase in <LABELDRUG> concentrations see Dosage and Administration (2.3), Drug Interactions (7.1). "
Dailymed.5526617c-c7b9-4556-886d-729bbabbc566.s.76	Dailymed.5526617c-c7b9-4556-886d-729bbabbc566.s.76.e.2	Decrease_Interaction	C54356	"Avoid co-administration of <PRECIPITANT> (e.g., rifampin, rifabutin, rifapentin, barbiturates, phenytoin, carbamazepine, St. John's Wort) with <LABELDRUG>, as this can lead to a reduction in the plasma concentration of <LABELDRUG> and decreased effectiveness of <LABELDRUG> treatment. "
Dailymed.5526617c-c7b9-4556-886d-729bbabbc566.s.88	Dailymed.5526617c-c7b9-4556-886d-729bbabbc566.s.88.e.3	Increase_Interaction	C54355	Co-administration of <LABELDRUG> and <PRECIPITANT> 200 mg daily results in a 5 fold increase in exposure to <LABELDRUG>. 
Dailymed.5526617c-c7b9-4556-886d-729bbabbc566.s.89	Dailymed.5526617c-c7b9-4556-886d-729bbabbc566.s.89.e.1	Increase_Interaction	C54355	"Co-administration of <LABELDRUG> with 400 mg ketoconazole daily or with other <PRECIPITANT> (e.g., clarithromycin, itraconazole, telithromycin, saquinavir, nelfinavir, ritonavir and nefazodone) at the highest labeled dose would be expected to cause an even greater increase in <LABELDRUG> exposure. "
Dailymed.5526617c-c7b9-4556-886d-729bbabbc566.s.96	Dailymed.5526617c-c7b9-4556-886d-729bbabbc566.s.96.e.2	Increase_Interaction	C54355	Co-administration of <PRECIPITANT> and <LABELDRUG> results in a 1.8 fold increase in exposure to <LABELDRUG> see Dose and Administration (2.3) and Warnings and Precautions (5.5).
Dailymed.5526617c-c7b9-4556-886d-729bbabbc566.s.101	Dailymed.5526617c-c7b9-4556-886d-729bbabbc566.s.101.e.3	Decrease_Interaction	C54356	Co-administration of <PRECIPITANT> and <LABELDRUG> reduces exposure to <LABELDRUG> by 85%. 
Dailymed.5526617c-c7b9-4556-886d-729bbabbc566.s.109	Dailymed.5526617c-c7b9-4556-886d-729bbabbc566.s.109.e.3	Increase_Interaction	C54610	Co-administration of <LABELDRUG> with <PRECIPITANT> increased <PRECIPITANT> AUC by 20% and Cmax by 30%.
Dailymed.5526617c-c7b9-4556-886d-729bbabbc566.s.114	Dailymed.5526617c-c7b9-4556-886d-729bbabbc566.s.114.e.3	Increase_Interaction	C54357	"Co-administration of <PRECIPITANT> and <LABELDRUG> increases the exposure to <PRECIPITANT> and its active metabolite <PRECIPITANT>- hydroxyacid by factors of 1.4 and 1.3, respectively. "
Dailymed.5526617c-c7b9-4556-886d-729bbabbc566.s.114	Dailymed.5526617c-c7b9-4556-886d-729bbabbc566.s.114.e.2	Increase_Interaction	C54357	"Co-administration of lovastatin and <LABELDRUG> increases the exposure to lovastatin and its active metabolite <PRECIPITANT> by factors of 1.4 and 1.3, respectively. "
Dailymed.5562b3f5-8757-11de-8a39-0800200c9a66.s.141	Dailymed.5562b3f5-8757-11de-8a39-0800200c9a66.s.141.e.3	Decrease_Interaction	C54358	@item Cholestyramine and <PRECIPITANT>: Reduced absorption of thiazides.
Dailymed.5562b3f5-8757-11de-8a39-0800200c9a66.s.141	Dailymed.5562b3f5-8757-11de-8a39-0800200c9a66.s.141.e.2	Decrease_Interaction	C54356	@item <PRECIPITANT> and colestipol: Reduced absorption of thiazides.
Dailymed.5562b3f5-8757-11de-8a39-0800200c9a66.s.141	Dailymed.5562b3f5-8757-11de-8a39-0800200c9a66.s.141.e.4	Decrease_Interaction	C54356	@item Cholestyramine and colestipol: Reduced absorption of <PRECIPITANT>.
Dailymed.5562b3f5-8757-11de-8a39-0800200c9a66.s.143	Dailymed.5562b3f5-8757-11de-8a39-0800200c9a66.s.143.e.4	Increase_Interaction	C54357	@item Lithium: Reduced renal clearance and high risk of lithium toxicity when used with <PRECIPITANT>. 
Dailymed.5562b3f5-8757-11de-8a39-0800200c9a66.s.143	Dailymed.5562b3f5-8757-11de-8a39-0800200c9a66.s.143.e.6	Increase_Interaction	C54357	@item <PRECIPITANT>: Reduced renal clearance and high risk of lithium toxicity when used with diuretics. 
Dailymed.5562b3f5-8757-11de-8a39-0800200c9a66.s.143	Dailymed.5562b3f5-8757-11de-8a39-0800200c9a66.s.143.e.5	Increase_Interaction	C54357	@item Lithium: Reduced renal clearance and high risk of <PRECIPITANT> toxicity when used with diuretics. 
Dailymed.5562b3f5-8757-11de-8a39-0800200c9a66.s.164	Dailymed.5562b3f5-8757-11de-8a39-0800200c9a66.s.164.e.1	Decrease_Interaction	C54606	Concurrent administration of bile acid sequestering agent <PRECIPITANT> reduces the systemic exposure and peak plasma concentration of <LABELDRUG>. 
Dailymed.5562b3f5-8757-11de-8a39-0800200c9a66.s.180	Dailymed.5562b3f5-8757-11de-8a39-0800200c9a66.s.180.e.3	Increase_Interaction	C54355	Simvastatin: Co-administration of multiple doses of 10 mg of <LABELDRUG> with 80 mg <PRECIPITANT> resulted in a 77% increase in exposure to <PRECIPITANT> compared to <PRECIPITANT> alone. 
Dailymed.5562b3f5-8757-11de-8a39-0800200c9a66.s.186	Dailymed.5562b3f5-8757-11de-8a39-0800200c9a66.s.186.e.0	Increase_Interaction	C54357	Other <PRECIPITANT>:Additive effect or potentiation.. 
Dailymed.5562b3f5-8757-11de-8a39-0800200c9a66.s.187	Dailymed.5562b3f5-8757-11de-8a39-0800200c9a66.s.187.e.5	Decrease_Interaction	C54356	Cholestyramine and Colestipol Resins:Absorption of <LABELDRUG> is impaired in the presence of <PRECIPITANT>. 
Dailymed.5562b3f5-8757-11de-8a39-0800200c9a66.s.188	Dailymed.5562b3f5-8757-11de-8a39-0800200c9a66.s.188.e.4	Decrease_Interaction	C54356	"Single dose of either <PRECIPITANT> or colestipol resins bind the <LABELDRUG> and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively.. "
Dailymed.5562b3f5-8757-11de-8a39-0800200c9a66.s.188	Dailymed.5562b3f5-8757-11de-8a39-0800200c9a66.s.188.e.5	Decrease_Interaction	C54356	"Single dose of either cholestyramine or <PRECIPITANT> bind the <LABELDRUG> and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively.. "
Dailymed.5562b3f5-8757-11de-8a39-0800200c9a66.s.190	Dailymed.5562b3f5-8757-11de-8a39-0800200c9a66.s.190.e.5	Decrease_Interaction	C54358	"Pressor Amines (e.g., Norepinephrine):Possible decreased response to <PRECIPITANT> but not sufficient to preclude their use.. "
Dailymed.5562b3f5-8757-11de-8a39-0800200c9a66.s.193	Dailymed.5562b3f5-8757-11de-8a39-0800200c9a66.s.193.e.0	Increase_Interaction	C54357	<PRECIPITANT> reduce the renal clearance of lithium and add a high risk of lithium toxicity. 
Dailymed.5562b3f5-8757-11de-8a39-0800200c9a66.s.193	Dailymed.5562b3f5-8757-11de-8a39-0800200c9a66.s.193.e.3	Increase_Interaction	C54357	Diuretic agents reduce the renal clearance of <PRECIPITANT> and add a high risk of <PRECIPITANT> toxicity. 
Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.57	Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.57.e.3	Increase_Interaction	C54357	"It has been reported that <LABELDRUG> decreases neuromuscular transmission in patients with Duchenne's muscular dystrophy, prolongs recovery from the neuromuscular blocking agent <PRECIPITANT>, and causes a worsening of myasthenia gravis. "
Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.67	Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.67.e.0	Increase_Interaction	C54355	"Clinically significant interactions have been reported with <PRECIPITANT> (e.g., erythromycin, ritonavir) causing elevation of plasma levels of <LABELDRUG> while inducers of CYP3A4 (e.g., rifampin) have caused a lowering of plasma levels of <LABELDRUG>."
Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.67	Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.67.e.8	Decrease_Interaction	C54358	"Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g., erythromycin, ritonavir) causing elevation of plasma levels of <LABELDRUG> while <PRECIPITANT> (e.g., rifampin) have caused a lowering of plasma levels of <LABELDRUG>."
Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.70	Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.70.e.3	Increase_Interaction	C54355	Co-administration of multiple doses of 10 mg of <LABELDRUG> with 80 mg <PRECIPITANT> resulted in exposure to <PRECIPITANT> 2.5-fold that following <PRECIPITANT> alone. 
Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.77	Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.77.e.0	Increase_Interaction	C54355	<PRECIPITANT> may increase plasma levels of <LABELDRUG>.
Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.79	Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.79.e.1	Increase_Interaction	C54357	<LABELDRUG> may increase blood <PRECIPITANT> concentrations and prolong its effects.
Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.93	Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.93.e.2	Increase_Interaction	C54357	A decrease in <PRECIPITANT> and propranolol clearance has been observed when either drug is administered concomitantly with <LABELDRUG>. 
Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.93	Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.93.e.3	Increase_Interaction	C54357	A decrease in metoprolol and <PRECIPITANT> clearance has been observed when either drug is administered concomitantly with <LABELDRUG>. 
Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.97	Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.97.e.3	Increase_Interaction	C54357	"However, chronic <LABELDRUG> treatment can increase serum <PRECIPITANT> levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity. "
Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.97	Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.97.e.6	Increase_Interaction	C54357	"However, chronic <LABELDRUG> treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in <PRECIPITANT> toxicity. "
Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.99	Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.99.e.4	Increase_Interaction	C54357	"<LABELDRUG> may reduce total body clearance and extrarenal clearance of <PRECIPITANT> by 27% and 29%, respectively. "
Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.119	Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.119.e.2	Increase_Interaction	C54357	There has been a report of increased <PRECIPITANT> levels during <LABELDRUG> therapy.
Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.133	Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.133.e.2	Increase_Interaction	C54357	<LABELDRUG> therapy may increase <PRECIPITANT> concentrations during combined therapy. 
Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.136	Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.136.e.0	Decrease_Interaction	C54356	Therapy with <PRECIPITANT> may markedly reduce oral <LABELDRUG> bioavailability.
Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.138	Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.138.e.0	Decrease_Interaction	C54356	<PRECIPITANT> therapy may increase <LABELDRUG> clearance.
Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.140	Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.140.e.1	Increase_Interaction	C54357	<LABELDRUG> therapy may increase serum levels of <PRECIPITANT>.
Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.142	Dailymed.55d5f933-42ff-4c80-a102-0ccb7f76b082.s.142.e.1	Increase_Interaction	C54357	<LABELDRUG> may inhibit the clearance and increase the plasma levels of <PRECIPITANT>.
Dailymed.595cc3d5-1306-4828-aefa-5595219ffd62.s.71	Dailymed.595cc3d5-1306-4828-aefa-5595219ffd62.s.71.e.2	Increase_Interaction	C54357	@item Diabetes mellitus: Increases the effect of <PRECIPITANT> and masks hypoglycemic tachycardia (5.6)
Dailymed.595cc3d5-1306-4828-aefa-5595219ffd62.s.92	Dailymed.595cc3d5-1306-4828-aefa-5595219ffd62.s.92.e.0	Increase_Interaction	C54357	Concomitant use of <PRECIPITANT> and antidiabetic agents can enhance the effect of antidiabetic agents (blood glucose lowering).
Dailymed.595cc3d5-1306-4828-aefa-5595219ffd62.s.92	Dailymed.595cc3d5-1306-4828-aefa-5595219ffd62.s.92.e.3	Increase_Interaction	C54357	Concomitant use of beta blockers and <PRECIPITANT> can enhance the effect of <PRECIPITANT> (blood glucose lowering).
Dailymed.595cc3d5-1306-4828-aefa-5595219ffd62.s.122	Dailymed.595cc3d5-1306-4828-aefa-5595219ffd62.s.122.e.2	Increase_Interaction	C54357	@item Digitalis glycosides: Concomitant administration of <PRECIPITANT> and <LABELDRUG> leads to an approximate 10% to 20% increase of <PRECIPITANT> blood levels at some time points. 
Dailymed.595cc3d5-1306-4828-aefa-5595219ffd62.s.126	Dailymed.595cc3d5-1306-4828-aefa-5595219ffd62.s.126.e.1	Increase_Interaction	C54357	@item Anticholinesterases: <LABELDRUG> prolonged the duration of succinylcholine-induced neuromuscular blockade and moderately prolonged clinical duration and recovery index of <PRECIPITANT>.
Dailymed.5ad67ea2-409c-4f52-a9b8-38216209609a.s.118	Dailymed.5ad67ea2-409c-4f52-a9b8-38216209609a.s.118.e.6	Increase_Interaction	C54357	Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and <PRECIPITANT> therapy. 
Dailymed.5ad67ea2-409c-4f52-a9b8-38216209609a.s.118	Dailymed.5ad67ea2-409c-4f52-a9b8-38216209609a.s.118.e.4	Increase_Interaction	C54357	Increased serum <PRECIPITANT> levels and symptoms of <PRECIPITANT> toxicity have been reported in patients receiving concomitant <PRECIPITANT> and ACE inhibitor therapy. 
Dailymed.5ad67ea2-409c-4f52-a9b8-38216209609a.s.120	Dailymed.5ad67ea2-409c-4f52-a9b8-38216209609a.s.120.e.0	Increase_Interaction	C54357	"If a <PRECIPITANT> is also used, the risk of lithium toxicity may be increased."
Dailymed.5ad67ea2-409c-4f52-a9b8-38216209609a.s.120	Dailymed.5ad67ea2-409c-4f52-a9b8-38216209609a.s.120.e.3	Increase_Interaction	C54357	"If a diuretic is also used, the risk of <PRECIPITANT> toxicity may be increased."
Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.39	Dailymed.5ddba454-f3e6-43c2-a7a6-58365d297213.s.39.e.0	Increase_Interaction	C54355	"Coadministration of <PRECIPITANT> (rifampin, cyclosporine) or efflux transporter (ritonavir) may increase the systemic exposure to <LABELDRUG>."
Dailymed.5e30120b-f2bf-43a0-86b2-44ae996dc681.s.17	Dailymed.5e30120b-f2bf-43a0-86b2-44ae996dc681.s.17.e.4	Decrease_Interaction	C54358	"In preclinical studies in rats and dogs, <PRECIPITANT> reduced vitamins D, E, and K (coagulation parameters) and folic acid levels at doses of 6-10 times the recommended human dose. "
Dailymed.5e30120b-f2bf-43a0-86b2-44ae996dc681.s.17	Dailymed.5e30120b-f2bf-43a0-86b2-44ae996dc681.s.17.e.2	Decrease_Interaction	C54358	"In preclinical studies in rats and dogs, sevelamer hydrochloride reduced <PRECIPITANT>, E, and K (coagulation parameters) and folic acid levels at doses of 6-10 times the recommended human dose. "
Dailymed.5e30120b-f2bf-43a0-86b2-44ae996dc681.s.17	Dailymed.5e30120b-f2bf-43a0-86b2-44ae996dc681.s.17.e.6	Decrease_Interaction	C54358	"In preclinical studies in rats and dogs, sevelamer hydrochloride reduced vitamins D, E, and K (coagulation parameters) and <PRECIPITANT> levels at doses of 6-10 times the recommended human dose. "
Dailymed.5e30120b-f2bf-43a0-86b2-44ae996dc681.s.19	Dailymed.5e30120b-f2bf-43a0-86b2-44ae996dc681.s.19.e.2	Decrease_Interaction	C54358	"However, in a one-year clinical trial, 25-hydroxyvitamin D (normal range 10 to 55 ng/mL) fell from 39 22 ng/mL to 34 22 ng/mL (p 0.01) with <PRECIPITANT> treatment. "
Dailymed.5e30120b-f2bf-43a0-86b2-44ae996dc681.s.19	Dailymed.5e30120b-f2bf-43a0-86b2-44ae996dc681.s.19.e.4	Decrease_Interaction	C54358	"However, in a one-year clinical trial, <PRECIPITANT> (normal range 10 to 55 ng/mL) fell from 39 22 ng/mL to 34 22 ng/mL (p 0.01) with sevelamer hydrochloride treatment. "
Dailymed.5e30120b-f2bf-43a0-86b2-44ae996dc681.s.23	Dailymed.5e30120b-f2bf-43a0-86b2-44ae996dc681.s.23.e.2	Decrease_Interaction	C54358	@item Decreases the bioavailability of <PRECIPITANT> by approximately 50%. 
Dailymed.5e30120b-f2bf-43a0-86b2-44ae996dc681.s.30	Dailymed.5e30120b-f2bf-43a0-86b2-44ae996dc681.s.30.e.4	Decrease_Interaction	C54358	"In a study of 15 healthy subjects, a co-administered single dose of 7 <LABELDRUG> capsules (approximately 2.8 g) decreased the bioavailability of <PRECIPITANT> by approximately 50%."
Dailymed.60f6da2c-35d0-47bb-b4eb-40ef8d8cff1b.s.55	Dailymed.60f6da2c-35d0-47bb-b4eb-40ef8d8cff1b.s.55.e.2	Decrease_Interaction	C54358	<LABELDRUG> may decrease absorption of <PRECIPITANT>.
Dailymed.60f6da2c-35d0-47bb-b4eb-40ef8d8cff1b.s.57	Dailymed.60f6da2c-35d0-47bb-b4eb-40ef8d8cff1b.s.57.e.3	Decrease_Interaction	C54358	<LABELDRUG> may decrease absorption of <PRECIPITANT>.
Dailymed.62069120-e894-42fd-8927-f1d74e449ca6.s.64	Dailymed.62069120-e894-42fd-8927-f1d74e449ca6.s.64.e.4	Increase_Interaction	C54357	Administration of <LABELDRUG> with <PRECIPITANT> increased <PRECIPITANT> levels in nine of twelve normal volunteers. 
Dailymed.62069120-e894-42fd-8927-f1d74e449ca6.s.68	Dailymed.62069120-e894-42fd-8927-f1d74e449ca6.s.68.e.2	Increase_Interaction	C54357	"Since there have been isolated reports of patients with elevated <PRECIPITANT> levels, it is recommended that <PRECIPITANT> levels be monitored when initiating, adjusting, and discontinuing <LABELDRUG> to avoid possible over- or under-digitalization."
Dailymed.62069120-e894-42fd-8927-f1d74e449ca6.s.73	Dailymed.62069120-e894-42fd-8927-f1d74e449ca6.s.73.e.3	Increase_Interaction	C54355	"A study in six healthy volunteers has shown a significant increase in peak <LABELDRUG> plasma levels (80%) and area-under-the-curve (74%), after a one week course of <PRECIPITANT> at 1000 mg per day and <LABELDRUG> at 40 mg per day. "
Dailymed.62069120-e894-42fd-8927-f1d74e449ca6.s.74	Dailymed.62069120-e894-42fd-8927-f1d74e449ca6.s.74.e.2	Increase_Interaction	C54355	"<PRECIPITANT> produced smaller, non-significant increases. "
Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.52	Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.52.e.0	Increase_Interaction	C54357	<PRECIPITANT> are a major contributing factor to digitalis toxicity. 
Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.52	Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.52.e.3	Increase_Interaction	C54357	Potassium-depleting diuretics are a major contributing factor to <PRECIPITANT> toxicity. 
Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.54	Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.54.e.3	Increase_Interaction	C54355	"Quinidine, verapamil, amiodarone, <PRECIPITANT>, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum <LABELDRUG> concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result. "
Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.54	Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.54.e.0	Increase_Interaction	C54355	"<PRECIPITANT>, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum <LABELDRUG> concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result. "
Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.54	Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.54.e.5	Increase_Interaction	C54355	"Quinidine, verapamil, amiodarone, propafenone, indomethacin, <PRECIPITANT>, alprazolam, and spironolactone raise the serum <LABELDRUG> concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result. "
Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.54	Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.54.e.2	Increase_Interaction	C54355	"Quinidine, verapamil, <PRECIPITANT>, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum <LABELDRUG> concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result. "
Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.54	Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.54.e.7	Increase_Interaction	C54355	"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and <PRECIPITANT> raise the serum <LABELDRUG> concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result. "
Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.54	Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.54.e.1	Increase_Interaction	C54355	"Quinidine, <PRECIPITANT>, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum <LABELDRUG> concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result. "
Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.54	Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.54.e.4	Increase_Interaction	C54355	"Quinidine, verapamil, amiodarone, propafenone, <PRECIPITANT>, itraconazole, alprazolam, and spironolactone raise the serum <LABELDRUG> concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result. "
Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.54	Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.54.e.6	Increase_Interaction	C54355	"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, <PRECIPITANT>, and spironolactone raise the serum <LABELDRUG> concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result. "
Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.54	Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.54.e.17	Increase_Interaction	C54355	"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum <LABELDRUG> concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that <PRECIPITANT> intoxication may result. "
Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.55	Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.55.e.1	Increase_Interaction	C54355	"<PRECIPITANT> and clarithromycin (and possibly other macrolide antibiotics ) and tetracycline may increase <LABELDRUG> absorption in patients who inactivate <LABELDRUG> by bacterial metabolism in the lower intestine, so that digitalis intoxication may result (see CLINICAL PHARMACOLOGY: Absorption). "
Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.55	Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.55.e.2	Increase_Interaction	C54355	"Erythromycin and <PRECIPITANT> (and possibly other macrolide antibiotics ) and tetracycline may increase <LABELDRUG> absorption in patients who inactivate <LABELDRUG> by bacterial metabolism in the lower intestine, so that digitalis intoxication may result (see CLINICAL PHARMACOLOGY: Absorption). "
Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.55	Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.55.e.5	Increase_Interaction	C54355	"Erythromycin and clarithromycin (and possibly other macrolide antibiotics ) and <PRECIPITANT> may increase <LABELDRUG> absorption in patients who inactivate <LABELDRUG> by bacterial metabolism in the lower intestine, so that digitalis intoxication may result (see CLINICAL PHARMACOLOGY: Absorption). "
Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.55	Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.55.e.10	Increase_Interaction	C54355	"Erythromycin and clarithromycin (and possibly other macrolide antibiotics ) and tetracycline may increase <LABELDRUG> absorption in patients who inactivate <LABELDRUG> by bacterial metabolism in the lower intestine, so that <PRECIPITANT> intoxication may result (see CLINICAL PHARMACOLOGY: Absorption). "
Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.56	Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.56.e.1	Increase_Interaction	C54355	"Propantheline and <PRECIPITANT>, by decreasing gut motility, may increase <LABELDRUG> absorption. "
Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.56	Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.56.e.0	Increase_Interaction	C54355	"<PRECIPITANT> and diphenoxylate, by decreasing gut motility, may increase <LABELDRUG> absorption. "
Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.57	Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.57.e.8	Decrease_Interaction	C54356	"Antacids, kaolin-pectin, sulfasalazine, <PRECIPITANT>, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal <LABELDRUG> absorption, resulting in unexpectedly low serum concentrations. "
Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.57	Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.57.e.7	Decrease_Interaction	C54356	"Antacids, kaolin-pectin, <PRECIPITANT>, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal <LABELDRUG> absorption, resulting in unexpectedly low serum concentrations. "
Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.57	Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.57.e.11	Decrease_Interaction	C54356	"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and <PRECIPITANT> may interfere with intestinal <LABELDRUG> absorption, resulting in unexpectedly low serum concentrations. "
Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.57	Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.57.e.10	Decrease_Interaction	C54356	"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain <PRECIPITANT>, and metoclopramide may interfere with intestinal <LABELDRUG> absorption, resulting in unexpectedly low serum concentrations. "
Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.57	Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.57.e.9	Decrease_Interaction	C54356	"Antacids, kaolin-pectin, sulfasalazine, neomycin, <PRECIPITANT>, certain anticancer drugs, and metoclopramide may interfere with intestinal <LABELDRUG> absorption, resulting in unexpectedly low serum concentrations. "
Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.57	Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.57.e.6	Decrease_Interaction	C54356	"Antacids, <PRECIPITANT>, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal <LABELDRUG> absorption, resulting in unexpectedly low serum concentrations. "
Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.57	Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.57.e.5	Decrease_Interaction	C54356	"<PRECIPITANT>, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal <LABELDRUG> absorption, resulting in unexpectedly low serum concentrations. "
Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.58	Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.58.e.0	Decrease_Interaction	C54356	"<PRECIPITANT> may decrease serum <LABELDRUG> concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of <LABELDRUG>. "
Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.66	Dailymed.625c3b7b-f1cf-4125-9680-4541a3f2d011.s.66.e.3	Increase_Interaction	C54355	<LABELDRUG> concentrations are increased by about 15% when digoxin and <PRECIPITANT> are administered concomitantly. 
Dailymed.627146d8-fa8e-4c8b-b703-29ee080a6d5b.s.86	Dailymed.627146d8-fa8e-4c8b-b703-29ee080a6d5b.s.86.e.3	Increase_Interaction	C54357	"Digoxin: When <LABELDRUG> was co-administered with <PRECIPITANT>, median increases in <PRECIPITANT> peak plasma concentration (49%) and in trough concentration (20%) were observed. "
Dailymed.627146d8-fa8e-4c8b-b703-29ee080a6d5b.s.88	Dailymed.627146d8-fa8e-4c8b-b703-29ee080a6d5b.s.88.e.3	Increase_Interaction	C54357	Lithium: Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with <PRECIPITANT> including <LABELDRUG>. 
Dailymed.627146d8-fa8e-4c8b-b703-29ee080a6d5b.s.88	Dailymed.627146d8-fa8e-4c8b-b703-29ee080a6d5b.s.88.e.2	Increase_Interaction	C54357	Lithium: Reversible increases in serum <PRECIPITANT> concentrations and toxicity have been reported during concomitant administration of <PRECIPITANT> with angiotensin II receptor antagonists including <LABELDRUG>. 
Dailymed.627146d8-fa8e-4c8b-b703-29ee080a6d5b.s.94	Dailymed.627146d8-fa8e-4c8b-b703-29ee080a6d5b.s.94.e.2	Increase_Interaction	C54610	"Ramipril and Ramiprilat: Co-administration of <LABELDRUG> 80 mg once daily and <PRECIPITANT> 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of <PRECIPITANT> 2.3- and 2.1-fold, respectively, and Cmax and AUC of <PRECIPITANT>at 2.4- and 1.5-fold, respectively. "
Dailymed.627146d8-fa8e-4c8b-b703-29ee080a6d5b.s.94	Dailymed.627146d8-fa8e-4c8b-b703-29ee080a6d5b.s.94.e.8	Increase_Interaction	C54602	"Ramipril and Ramiprilat: Co-administration of <LABELDRUG> 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of <PRECIPITANT> 2.4- and 1.5-fold, respectively. "
Dailymed.627146d8-fa8e-4c8b-b703-29ee080a6d5b.s.96	Dailymed.627146d8-fa8e-4c8b-b703-29ee080a6d5b.s.96.e.7	Increase_Interaction	C54357	"When co-administering <LABELDRUG> and <PRECIPITANT>, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to <PRECIPITANT> and <PRECIPITANT>at in the presence of <LABELDRUG>. "
Dailymed.627146d8-fa8e-4c8b-b703-29ee080a6d5b.s.96	Dailymed.627146d8-fa8e-4c8b-b703-29ee080a6d5b.s.96.e.8	Increase_Interaction	C54357	"When co-administering <LABELDRUG> and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and <PRECIPITANT> in the presence of <LABELDRUG>. "
Dailymed.627146d8-fa8e-4c8b-b703-29ee080a6d5b.s.100	Dailymed.627146d8-fa8e-4c8b-b703-29ee080a6d5b.s.100.e.2	Decrease_Interaction	C54358	"<LABELDRUG> is not expected to interact with drugs that inhibit cytochrome P450 enzymes, it is also not expected to interact with drugs metabolized by cytochrome P450 enzymes, except for possible inhibition of the metabolism of <PRECIPITANT>."
Dailymed.627146d8-fa8e-4c8b-b703-29ee080a6d5b.s.103	Dailymed.627146d8-fa8e-4c8b-b703-29ee080a6d5b.s.103.e.2	Increase_Interaction	C54355	Simvastatin: Co-administration of multiple doses of 10 mg of <LABELDRUG> with 80 mg <PRECIPITANT> resulted in a 77% increase in exposure to <PRECIPITANT> compared to <PRECIPITANT> alone. 
Dailymed.627146d8-fa8e-4c8b-b703-29ee080a6d5b.s.108	Dailymed.627146d8-fa8e-4c8b-b703-29ee080a6d5b.s.108.e.2	Increase_Interaction	C54355	Co-administration of a 180 mg daily dose of <PRECIPITANT> with 5 mg <LABELDRUG> in elderly hypertensive patients resulted in a 60% increase in <LABELDRUG> systemic exposure. 
Dailymed.627146d8-fa8e-4c8b-b703-29ee080a6d5b.s.110	Dailymed.627146d8-fa8e-4c8b-b703-29ee080a6d5b.s.110.e.1	Increase_Interaction	C54355	"However, <PRECIPITANT> (e.g., ketoconazole, itraconazole, ritonavir) may increase the plasma concentrations of <LABELDRUG> to a greater extent. "
Dailymed.63cf5651-d52c-4d27-9fd4-ed9cd9724dff.s.73	Dailymed.63cf5651-d52c-4d27-9fd4-ed9cd9724dff.s.73.e.3	Decrease_Interaction	C54356	"Simultaneous administration of <PRECIPITANT> with <LABELDRUG> reduced the absorption of <PRECIPITANT> by approximately 28% to 37%, possibly due to the high magnesium content in <LABELDRUG> tablets. "
Dailymed.63cf5651-d52c-4d27-9fd4-ed9cd9724dff.s.75	Dailymed.63cf5651-d52c-4d27-9fd4-ed9cd9724dff.s.75.e.0	Increase_Interaction	C54357	Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and <PRECIPITANT> therapy. 
Dailymed.63cf5651-d52c-4d27-9fd4-ed9cd9724dff.s.75	Dailymed.63cf5651-d52c-4d27-9fd4-ed9cd9724dff.s.75.e.3	Increase_Interaction	C54357	Increased serum <PRECIPITANT> levels and symptoms of <PRECIPITANT> toxicity have been reported in patients receiving concomitant <PRECIPITANT> and ACE inhibitor therapy. 
Dailymed.63cf5651-d52c-4d27-9fd4-ed9cd9724dff.s.77	Dailymed.63cf5651-d52c-4d27-9fd4-ed9cd9724dff.s.77.e.0	Increase_Interaction	C54357	"If a <PRECIPITANT> is also used, it may increase the risk of lithium toxicity."
Dailymed.63cf5651-d52c-4d27-9fd4-ed9cd9724dff.s.77	Dailymed.63cf5651-d52c-4d27-9fd4-ed9cd9724dff.s.77.e.1	Increase_Interaction	C54357	"If a diuretic is also used, it may increase the risk of <PRECIPITANT> toxicity."
Dailymed.6b17b98b-e06d-42ed-925f-69aa2699dead.s.30	Dailymed.6b17b98b-e06d-42ed-925f-69aa2699dead.s.30.e.3	Decrease_Interaction	C54356	Animal studies indicate that <LABELDRUG> may be ineffective if the patient has recently received a <PRECIPITANT>. 
Dailymed.6bbc032a-3cc4-4b1d-8124-1784214a2821.s.114	Dailymed.6bbc032a-3cc4-4b1d-8124-1784214a2821.s.114.e.1	Decrease_Interaction	C54606	Concurrent administration of bile acid sequestering agent <PRECIPITANT> reduces the systemic exposure and peak plasma concentration of <LABELDRUG>. 
Dailymed.6bbc032a-3cc4-4b1d-8124-1784214a2821.s.121	Dailymed.6bbc032a-3cc4-4b1d-8124-1784214a2821.s.121.e.2	Increase_Interaction	C54357	Other <PRECIPITANT>   additive effect or potentiation.
Dailymed.6bbc032a-3cc4-4b1d-8124-1784214a2821.s.122	Dailymed.6bbc032a-3cc4-4b1d-8124-1784214a2821.s.122.e.3	Decrease_Interaction	C54358	Cholestyramine and Colestipol Resins   absorption of hydrochlorothiazide is impaired in the presence of <PRECIPITANT>. 
Dailymed.6bbc032a-3cc4-4b1d-8124-1784214a2821.s.122	Dailymed.6bbc032a-3cc4-4b1d-8124-1784214a2821.s.122.e.0	Decrease_Interaction	C54358	Cholestyramine and Colestipol Resins   absorption of <PRECIPITANT> is impaired in the presence of anionic exchange resins. 
Dailymed.6bbc032a-3cc4-4b1d-8124-1784214a2821.s.123	Dailymed.6bbc032a-3cc4-4b1d-8124-1784214a2821.s.123.e.1	Decrease_Interaction	C54356	"Single doses of either cholestyramine or <PRECIPITANT> bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively."
Dailymed.6bbc032a-3cc4-4b1d-8124-1784214a2821.s.123	Dailymed.6bbc032a-3cc4-4b1d-8124-1784214a2821.s.123.e.0	Decrease_Interaction	C54356	"Single doses of either <PRECIPITANT> or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively."
Dailymed.6bbc032a-3cc4-4b1d-8124-1784214a2821.s.125	Dailymed.6bbc032a-3cc4-4b1d-8124-1784214a2821.s.125.e.5	Decrease_Interaction	C54358	Pressor Amines (e.g. Norepinephrine)   possible decreased response to <PRECIPITANT> but not sufficient to preclude their use.
Dailymed.6bbc032a-3cc4-4b1d-8124-1784214a2821.s.128	Dailymed.6bbc032a-3cc4-4b1d-8124-1784214a2821.s.128.e.0	Increase_Interaction	C54357	<PRECIPITANT> reduce the renal clearance of lithium and add a high risk of lithium toxicity. 
Dailymed.6bbc032a-3cc4-4b1d-8124-1784214a2821.s.128	Dailymed.6bbc032a-3cc4-4b1d-8124-1784214a2821.s.128.e.3	Increase_Interaction	C54357	Diuretic agents reduce the renal clearance of <PRECIPITANT> and add a high risk of <PRECIPITANT> toxicity. 
Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.71	Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.71.e.0	Increase_Interaction	C54602	"Co-administration of a <PRECIPITANT> (e.g., gemfibrozil) may increase exposure (both Cmax and AUC) to <LABELDRUG>. "
Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.72	Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.72.e.0	Decrease_Interaction	C54356	"Co-administration of a <PRECIPITANT> (e.g., rifampin) may decrease exposure to <LABELDRUG>. "
Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.91	Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.91.e.2	Increase_Interaction	C54602	Human pharmacokinetic studies with an oral formulation of <LABELDRUG> (<LABELDRUG> diethanolamine) indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor <PRECIPITANT> increases exposure (both Cmax and AUC) to <LABELDRUG>. 
Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.92	Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.92.e.1	Decrease_Interaction	C54356	Co-administration of the CYP2C8 enzyme inducer <PRECIPITANT> decreases exposure to <LABELDRUG>. 
Dailymed.6e453a4f-34b9-4f07-92b6-bfc28609ce22.s.167	Dailymed.6e453a4f-34b9-4f07-92b6-bfc28609ce22.s.167.e.0	Increase_Interaction	C54357	"Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with <PRECIPITANT>, including ACE inhibitors. "
Dailymed.6e453a4f-34b9-4f07-92b6-bfc28609ce22.s.167	Dailymed.6e453a4f-34b9-4f07-92b6-bfc28609ce22.s.167.e.4	Increase_Interaction	C54357	"<PRECIPITANT>: <PRECIPITANT> toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. "
Dailymed.6e453a4f-34b9-4f07-92b6-bfc28609ce22.s.174	Dailymed.6e453a4f-34b9-4f07-92b6-bfc28609ce22.s.174.e.4	Increase_Interaction	C54357	Other <PRECIPITANT> - additive effect or potentiation.
Dailymed.6e453a4f-34b9-4f07-92b6-bfc28609ce22.s.176	Dailymed.6e453a4f-34b9-4f07-92b6-bfc28609ce22.s.176.e.1	Decrease_Interaction	C54356	"Single doses of either cholestyramine or <PRECIPITANT> bind the <LABELDRUG> and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively."
Dailymed.6e453a4f-34b9-4f07-92b6-bfc28609ce22.s.176	Dailymed.6e453a4f-34b9-4f07-92b6-bfc28609ce22.s.176.e.0	Decrease_Interaction	C54356	"Single doses of either <PRECIPITANT> or colestipol resins bind the <LABELDRUG> and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively."
Dailymed.6e453a4f-34b9-4f07-92b6-bfc28609ce22.s.178	Dailymed.6e453a4f-34b9-4f07-92b6-bfc28609ce22.s.178.e.5	Decrease_Interaction	C54358	"Pressor amines (eg, norepinephrine) - possible decreased response to <PRECIPITANT> but not sufficient to preclude their use."
Dailymed.6e453a4f-34b9-4f07-92b6-bfc28609ce22.s.181	Dailymed.6e453a4f-34b9-4f07-92b6-bfc28609ce22.s.181.e.2	Increase_Interaction	C54357	<PRECIPITANT> reduce the renal clearance of lithium and add a high risk of lithium toxicity. 
Dailymed.6e453a4f-34b9-4f07-92b6-bfc28609ce22.s.181	Dailymed.6e453a4f-34b9-4f07-92b6-bfc28609ce22.s.181.e.3	Increase_Interaction	C54357	Diuretic agents reduce the renal clearance of <PRECIPITANT> and add a high risk of <PRECIPITANT> toxicity. 
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.55	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.55.e.1	Increase_Interaction	C54357	"It has been reported that <LABELDRUG> decreases neuromuscular transmission in patients with Duchenne's muscular dystrophy, and that <LABELDRUG> prolongs recovery from the neuromuscular blocking agent <PRECIPITANT>. "
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.69	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.69.e.0	Increase_Interaction	C54357	"Clinically significant interactions have been reported with <PRECIPITANT> (e.g. erythromycin, ritonavir) causing elevation of plasma levels of <LABELDRUG> while inducers of CYP3A4 (e.g. rifampin) have caused a lowering of plasma levels of <LABELDRUG>. "
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.69	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.69.e.8	Decrease_Interaction	C54358	"Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g. erythromycin, ritonavir) causing elevation of plasma levels of <LABELDRUG> while <PRECIPITANT> (e.g. rifampin) have caused a lowering of plasma levels of <LABELDRUG>. "
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.72	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.72.e.1	Increase_Interaction	C54357	"Chronic <LABELDRUG> treatment can increase serum <PRECIPITANT> levels by 50 to 75% during the first week of therapy, and this can result in <PRECIPITANT> toxicity. "
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.74	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.74.e.5	Increase_Interaction	C54357	"<LABELDRUG> may reduce total body clearance and extrarenal clearance of <PRECIPITANT> by 27% and 29%, respectively. "
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.79	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.79.e.6	Increase_Interaction	C54357	Increased sensitivity to the effects of <PRECIPITANT> (neurotoxicity) has been reported during concomitant <LABELDRUG>-<PRECIPITANT> therapy with either no change or an increase in serum <PRECIPITANT> levels. 
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.80	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.80.e.6	Increase_Interaction	C54357	Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and <PRECIPITANT> therapy. 
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.80	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.80.e.2	Increase_Interaction	C54357	Increased serum <PRECIPITANT> levels and symptoms of <PRECIPITANT> toxicity have been reported in patients receiving concomitant <PRECIPITANT> and ACE inhibitor therapy. 
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.82	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.82.e.0	Increase_Interaction	C54357	"If a <PRECIPITANT> is also used, the risk of lithium toxicity may be increased."
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.82	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.82.e.3	Increase_Interaction	C54357	"If a diuretic is also used, the risk of <PRECIPITANT> toxicity may be increased."
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.96	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.96.e.2	Increase_Interaction	C54357	There has been a report of increased <PRECIPITANT> levels during <LABELDRUG> therapy.
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.98	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.98.e.1	Increase_Interaction	C54357	There are reports that <LABELDRUG> may result in higher concentrations of the alpha-agonists <PRECIPITANT> and terazosin.
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.98	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.98.e.2	Increase_Interaction	C54357	There are reports that <LABELDRUG> may result in higher concentrations of the alpha-agonists prazosin and <PRECIPITANT>.
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.104	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.104.e.0	Increase_Interaction	C54357	Drug interaction studies have indicated that the maximum concentrations of <PRECIPITANT> and propanolol are increased after the administration of <LABELDRUG>. 
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.104	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.104.e.1	Increase_Interaction	C54357	Drug interaction studies have indicated that the maximum concentrations of metoprolol and <PRECIPITANT> are increased after the administration of <LABELDRUG>. 
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.115	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.115.e.3	Increase_Interaction	C54355	Co-administration of multiple doses of 10 mg of <LABELDRUG> with 80 mg <PRECIPITANT> resulted in exposure to <PRECIPITANT> 2.5-fold that following <PRECIPITANT> alone. 
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.125	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.125.e.1	Increase_Interaction	C54357	<LABELDRUG> may increase <PRECIPITANT> concentrations during combined therapy. 
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.127	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.127.e.0	Decrease_Interaction	C54356	Therapy with <PRECIPITANT> may markedly reduce oral <LABELDRUG> bioavailability. 
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.128	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.128.e.1	Increase_Interaction	C54355	There have been reports that erythromycin and <PRECIPITANT> may increase concentrations of <LABELDRUG>.
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.128	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.128.e.0	Increase_Interaction	C54355	There have been reports that <PRECIPITANT> and telithromycin may increase concentrations of <LABELDRUG>.
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.129	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.129.e.0	Decrease_Interaction	C54356	<PRECIPITANT> therapy may increase <LABELDRUG> clearance.
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.130	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.130.e.3	Increase_Interaction	C54357	"<LABELDRUG> therapy may increase serum levels of cyclosporin, sirolimus and <PRECIPITANT>."
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.130	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.130.e.2	Increase_Interaction	C54357	"<LABELDRUG> therapy may increase serum levels of cyclosporin, <PRECIPITANT> and tacrolimus."
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.130	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.130.e.1	Increase_Interaction	C54357	"<LABELDRUG> therapy may increase serum levels of <PRECIPITANT>, sirolimus and tacrolimus."
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.131	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.131.e.5	Increase_Interaction	C54357	<LABELDRUG> therapy may inhibit the clearance and increase the plasma levels of <PRECIPITANT>.
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.132	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.132.e.3	Increase_Interaction	C54357	"Due to metabolism via the CYP enzyme system, there have been reports that <LABELDRUG> may increase the concentrations of <PRECIPITANT>, midazolam, almotriptan and imipramine."
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.132	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.132.e.5	Increase_Interaction	C54357	"Due to metabolism via the CYP enzyme system, there have been reports that <LABELDRUG> may increase the concentrations of buspirone, midazolam, <PRECIPITANT> and imipramine."
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.132	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.132.e.6	Increase_Interaction	C54357	"Due to metabolism via the CYP enzyme system, there have been reports that <LABELDRUG> may increase the concentrations of buspirone, midazolam, almotriptan and <PRECIPITANT>."
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.132	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.132.e.4	Increase_Interaction	C54357	"Due to metabolism via the CYP enzyme system, there have been reports that <LABELDRUG> may increase the concentrations of buspirone, <PRECIPITANT>, almotriptan and imipramine."
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.135	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.135.e.1	Increase_Interaction	C54355	"When <LABELDRUG> and <PRECIPITANT> are administered together, the potential inhibition of P-gp and/or CYP3A by <LABELDRUG> may lead to increased exposure to <PRECIPITANT> (see PRECAUTIONS - Drug Interactions )."
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.136	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.136.e.3	Increase_Interaction	C54355	"Concentrations of <LABELDRUG> may be increased by the concomitant administration of <PRECIPITANT> such as ritonavir, and reduced by the concomitant administration of sulfinpyrazone, or St John s Wort."
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.136	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.136.e.7	Decrease_Interaction	C54355	"Concentrations of <LABELDRUG> may be increased by the concomitant administration of protease inhibitors such as ritonavir, and reduced by the concomitant administration of <PRECIPITANT>, or St John s Wort."
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.136	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.136.e.8	Decrease_Interaction	C54355	"Concentrations of <LABELDRUG> may be increased by the concomitant administration of protease inhibitors such as ritonavir, and reduced by the concomitant administration of sulfinpyrazone, or <PRECIPITANT>."
Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.137	Dailymed.7023927e-1829-49c0-5c81-693489000d1c.s.137.e.0	Increase_Interaction	C54355	Concentrations of <PRECIPITANT> may be increased by the administration of <LABELDRUG>.
Dailymed.725d4e73-6c83-477a-adc6-0ae4a133a844.s.73	Dailymed.725d4e73-6c83-477a-adc6-0ae4a133a844.s.73.e.2	Increase_Interaction	C54355	"Multiple dose co-administration of <LABELDRUG> and <PRECIPITANT> resulted in an approximately 2-fold increase in <LABELDRUG> exposure in healthy volunteers, therefore, limit the dose of <LABELDRUG> to 5 mg once daily when co-administered with <PRECIPITANT> see Clinical Pharmacology (12.3)."
Dailymed.725d4e73-6c83-477a-adc6-0ae4a133a844.s.74	Dailymed.725d4e73-6c83-477a-adc6-0ae4a133a844.s.74.e.3	Increase_Interaction	C54355	Multiple dose co-administration of <LABELDRUG> and <PRECIPITANT> resulted in an about 2-fold increase in <LABELDRUG> exposure in healthy volunteers. 
Dailymed.741f71b5-5a7a-43dc-9937-066d99c50707.s.33	Dailymed.741f71b5-5a7a-43dc-9937-066d99c50707.s.33.e.3	Decrease_Interaction	C54358	<LABELDRUG> may decrease the bioavailability of tetracyclines or <PRECIPITANT> via this mechanism.
Dailymed.741f71b5-5a7a-43dc-9937-066d99c50707.s.33	Dailymed.741f71b5-5a7a-43dc-9937-066d99c50707.s.33.e.4	Decrease_Interaction	C54358	<LABELDRUG> may decrease the bioavailability of <PRECIPITANT> or fluoroquinolones via this mechanism.
Dailymed.741f71b5-5a7a-43dc-9937-066d99c50707.s.38	Dailymed.741f71b5-5a7a-43dc-9937-066d99c50707.s.38.e.3	Decrease_Interaction	C54358	@item <LABELDRUG> may decrease the bioavailability of <PRECIPITANT> or fluoroquinolones. 
Dailymed.741f71b5-5a7a-43dc-9937-066d99c50707.s.38	Dailymed.741f71b5-5a7a-43dc-9937-066d99c50707.s.38.e.4	Decrease_Interaction	C54358	@item <LABELDRUG> may decrease the bioavailability of tetracyclines or <PRECIPITANT>. 
Dailymed.741f71b5-5a7a-43dc-9937-066d99c50707.s.43	Dailymed.741f71b5-5a7a-43dc-9937-066d99c50707.s.43.e.4	Decrease_Interaction	C54358	"In a study of 15 healthy subjects, a co-administered single dose of 4 <LABELDRUG> tablets (approximately 2.7 g) decreased the bioavailability of <PRECIPITANT> by approximately 50%."
Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.43	Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.43.e.2	Increase_Interaction	C54355	Coadministration of <PRECIPITANT> and <LABELDRUG> resulted in markedly increased plasma concentrations of <LABELDRUG>. 
Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.104	Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.104.e.2	Increase_Interaction	C54355	"Concomitant administration of both a <PRECIPITANT> (such as fluconazole or amiodarone) and a strong CYP3A inhibitor (e.g., ketoconazole, itraconazole) or a moderate CYP3A inhibitor (e.g., amprenavir, erythromycin, fluconazole, diltiazem) with <LABELDRUG> will likely lead to large increases in plasma concentrations of <LABELDRUG>. "
Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.104	Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.104.e.4	Increase_Interaction	C54355	"Concomitant administration of both a CYP2C9 inhibitor (such as fluconazole or amiodarone) and a <PRECIPITANT> (e.g., ketoconazole, itraconazole) or a moderate CYP3A inhibitor (e.g., amprenavir, erythromycin, fluconazole, diltiazem) with <LABELDRUG> will likely lead to large increases in plasma concentrations of <LABELDRUG>. "
Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.104	Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.104.e.5	Increase_Interaction	C54355	"Concomitant administration of both a CYP2C9 inhibitor (such as fluconazole or amiodarone) and a strong CYP3A inhibitor (e.g., ketoconazole, itraconazole) or a <PRECIPITANT> (e.g., amprenavir, erythromycin, fluconazole, diltiazem) with <LABELDRUG> will likely lead to large increases in plasma concentrations of <LABELDRUG>. "
Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.107	Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.107.e.3	Decrease_Interaction	C54358	Consequently plasma concentrations of <PRECIPITANT> will be decreased when <LABELDRUG> is coadministered. 
Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.111	Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.111.e.2	Decrease_Interaction	C54358	"<PRECIPITANT>, including oral, injectable, transdermal, and implantable forms, may not be reliable when <LABELDRUG> is coadministered. "
Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.113	Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.113.e.3	Decrease_Interaction	C54358	"An interaction study demonstrated that coadministration of <LABELDRUG> and a combination oral hormonal contraceptive produced average decreases of <PRECIPITANT> and ethinyl estradiol levels of 14% and 31%, respectively. "
Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.113	Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.113.e.4	Decrease_Interaction	C54358	"An interaction study demonstrated that coadministration of <LABELDRUG> and a combination oral hormonal contraceptive produced average decreases of norethindrone and <PRECIPITANT> levels of 14% and 31%, respectively. "
Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.119	Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.119.e.2	Increase_Interaction	C54355	Steady-state <LABELDRUG> plasma concentrations were 3- to 4-fold higher than in the absence of <PRECIPITANT>. 
Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.120	Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.120.e.3	Decrease_Interaction	C54358	Coadministration of <LABELDRUG> decreased the plasma concentrations of <PRECIPITANT> (a CYP3A substrate) by approximately 50%.
Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.124	Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.124.e.3	Decrease_Interaction	C54358	Coadministration of <LABELDRUG> decreased the plasma concentrations of <PRECIPITANT> by approximately 40%. 
Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.126	Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.126.e.3	Decrease_Interaction	C54358	<LABELDRUG> is also expected to reduce plasma concentrations of other <PRECIPITANT>. 
Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.132	Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.132.e.2	Increase_Interaction	C54355	"In normal volunteers, coadministration of <LABELDRUG> 125 mg twice daily and <PRECIPITANT> 400/100 mg twice daily increased the trough concentrations of <LABELDRUG> on Days 4 and 10 approximately 48-fold and 5-fold, respectively, compared with those measured after <LABELDRUG> administered alone. "
Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.136	Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.136.e.2	Decrease_Interaction	C54358	"Coadministration of <LABELDRUG> decreased the plasma concentrations of <PRECIPITANT> (a CYP3A substrate), and its active -hydroxy acid metabolite, by approximately 50%. "
Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.138	Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.138.e.2	Decrease_Interaction	C54358	"<LABELDRUG> is also expected to reduce plasma concentrations of other <PRECIPITANT>, such as lovastatin and atorvastatin. "
Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.142	Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.142.e.2	Increase_Interaction	C54355	"Coadministration of <LABELDRUG> and <PRECIPITANT> in normal volunteers resulted in a mean 6-fold increase in <LABELDRUG> trough levels after the first concomitant dose (likely due to inhibition of OATP by <PRECIPITANT>), but about a 60% decrease in <LABELDRUG> levels at steady-state. "
Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.147	Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.147.e.3	Increase_Interaction	C54355	Coadministration of <PRECIPITANT> and <LABELDRUG> resulted in markedly increased plasma concentrations of <LABELDRUG> in animals. 
Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.150	Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.150.e.2	Increase_Interaction	C54355	"Coadministration of <LABELDRUG> 125 mg twice daily and <PRECIPITANT>, a potent CYP3A inhibitor, increased the plasma concentrations of <LABELDRUG> by approximately 2-fold in normal volunteers. "
Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.153	Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.153.e.2	Decrease_Interaction	C54358	"Coadministration of <LABELDRUG> 500 mg twice daily for 6 days in normal volunteers decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and <PRECIPITANT> (a CYP3A substrate) by 29 and 38%, respectively. "
Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.153	Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.153.e.4	Decrease_Interaction	C54358	"Coadministration of <LABELDRUG> 500 mg twice daily for 6 days in normal volunteers decreased the plasma concentrations of both <PRECIPITANT> (a CYP2C9 substrate) and R-warfarin (a CYP3A substrate) by 29 and 38%, respectively. "
Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.158	Dailymed.749e42fb-2fe0-45dd-9268-b43bb3f4081c.s.158.e.2	Decrease_Interaction	C54358	"In normal volunteers, coadministration of multiple doses of 125 mg twice daily <LABELDRUG> and 80 mg three times daily <PRECIPITANT> resulted in a reduction of <PRECIPITANT> plasma concentrations by 63% and increased <LABELDRUG> plasma concentrations by 50%. "
Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.43	Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.43.e.6	Increase_Interaction	C54610	"Studies showed that <LABELDRUG> increased the AUC of midazolam and <PRECIPITANT> by 3- to 4-fold and the Cmax by 2-fold, compared to placebo. "
Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.43	Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.43.e.5	Increase_Interaction	C54610	"Studies showed that <LABELDRUG> increased the AUC of <PRECIPITANT> and triazolam by 3- to 4-fold and the Cmax by 2-fold, compared to placebo. "
Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.44	Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.44.e.2	Increase_Interaction	C54611	The elimination half-life of <PRECIPITANT> and triazolam also increased (1.5- to 2.5-fold) during coadministration with <LABELDRUG>. 
Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.44	Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.44.e.3	Increase_Interaction	C54611	The elimination half-life of midazolam and <PRECIPITANT> also increased (1.5- to 2.5-fold) during coadministration with <LABELDRUG>. 
Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.48	Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.48.e.4	Increase_Interaction	C54357	Administration of <LABELDRUG> concomitantly with <PRECIPITANT> in five normal volunteers resulted in increased <PRECIPITANT> levels in all subjects and bioavailability of <PRECIPITANT> was increased approximately 50%. 
Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.52	Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.52.e.6	Increase_Interaction	C54610	"In nine healthy subjects, <LABELDRUG> significantly increased the mean <PRECIPITANT> AUC 5.5-fold and Cmax 4.1-fold compared to placebo. "
Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.54	Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.54.e.0	Increase_Interaction	C54357	Enhanced effects and increased toxicity of <PRECIPITANT> may be possible during concomitant administration with <LABELDRUG>. 
Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.57	Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.57.e.3	Increase_Interaction	C54357	"Concomitant administration of <LABELDRUG> with <PRECIPITANT> has been reported to result in elevated serum levels of <PRECIPITANT> (40% to 72% increase), resulting in toxicity in some cases. "
Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.60	Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.60.e.6	Increase_Interaction	C54355	A study in six healthy volunteers has shown a significant increase in peak <LABELDRUG> plasma levels (58%) and AUC (53%) after a 1-week course of <PRECIPITANT> 1200 mg/day and a single dose of <LABELDRUG> 60 mg. 
Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.70	Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.70.e.2	Increase_Interaction	C54357	"In renal and cardiac transplant recipients, a reduction of <PRECIPITANT> dose ranging from 15% to 48% was necessary to maintain <PRECIPITANT> trough concentrations similar to those seen prior to the addition of <LABELDRUG>. "
Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.74	Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.74.e.3	Increase_Interaction	C54357	Administration of <LABELDRUG> with <PRECIPITANT> in 24 healthy male subjects increased plasma <PRECIPITANT> concentrations approximately 20%. 
Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.78	Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.78.e.3	Increase_Interaction	C54613	"<LABELDRUG> significantly increases the AUC(0 ) of <PRECIPITANT> by 51%, T by 36%, and decreases its CLoral by 33%. "
Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.81	Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.81.e.3	Decrease_Interaction	C54356	Coadministration of <PRECIPITANT> with <LABELDRUG> lowered the <LABELDRUG> plasma concentrations to undetectable levels. 
Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.84	Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.84.e.2	Increase_Interaction	C54613	<LABELDRUG> is an inhibitor of CYP3A4 and has been shown to increase significantly the AUC of some <PRECIPITANT>. 
Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.87	Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.87.e.3	Increase_Interaction	C54355	"In a healthy volunteer cross-over study (N 10), co-administration of a single 20 mg dose of <PRECIPITANT> at the end of a 14 day regimen with 120 mg BID <LABELDRUG> SR resulted in a 5-fold increase in mean <PRECIPITANT> AUC versus <PRECIPITANT> alone. "
Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.89	Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.89.e.3	Increase_Interaction	C54355	"Computer-based simulations showed that at a daily dose of 480 mg of <LABELDRUG>, an 8- to 9-fold mean increase in <PRECIPITANT> AUC can be expected. "
Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.91	Dailymed.77fd7414-85aa-4161-87ff-dbff9e97ee02.s.91.e.8	Increase_Interaction	C54610	"In a ten-subject randomized, open label, 4-way cross-over study, co-administration of <LABELDRUG> (120 mg BID <LABELDRUG> SR for 2 weeks) with a single 20 mg dose of <PRECIPITANT> resulted in 3- to 4-fold increase in mean <PRECIPITANT> AUC and Cmax versus <PRECIPITANT> alone. "
Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.91	Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.91.e.0	Increase_Interaction	C54357	<PRECIPITANT> has been shown to have an additive effect (see CLINICAL PHARMACOLOGY: Clinical Studies ). 
Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.116	Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.116.e.1	Increase_Interaction	C54355	"When <LABELDRUG> was given with cyclosporine or <PRECIPITANT>, the blood concentrations of <LABELDRUG> were significantly increased. "
Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.116	Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.116.e.0	Increase_Interaction	C54355	"When <LABELDRUG> was given with <PRECIPITANT> or itraconazole, the blood concentrations of <LABELDRUG> were significantly increased. "
Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.131	Dailymed.78a3bdb0-c945-45cf-b75d-066dbf1d152c.s.131.e.3	Increase_Interaction	C54357	Simvastatin: Co-administration of <PRECIPITANT> with <LABELDRUG> increases the systemic exposure of <PRECIPITANT>. 
Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.14	Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.14.e.3	Increase_Interaction	C54357	Concomitant administration of <LABELDRUG> and <PRECIPITANT>-containing drugs leads to increased <PRECIPITANT> levels and <PRECIPITANT> toxicity in some individuals. 
Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.15	Dailymed.7977516c-15bf-4fa5-8772-59c6efbe3dc5.s.15.e.2	Increase_Interaction	C54357	Such patients should be closely monitored for signs of toxicity and have their <PRECIPITANT> dosage adjusted as necessary.
Dailymed.79ba021e-183c-4b4d-822e-4ff5ef54ca61.s.56	Dailymed.79ba021e-183c-4b4d-822e-4ff5ef54ca61.s.56.e.2	Increase_Interaction	C54357	Oral administration of <LABELDRUG> markedly decreases the first-pass metabolism of <PRECIPITANT> and subsequently increases its oral bioavailability. 
Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.56	Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.56.e.3	Increase_Interaction	C54355	@item <PRECIPITANT> increase <LABELDRUG> levels (7.1)
Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.57	Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.57.e.3	Decrease_Interaction	C54356	@item <PRECIPITANT> decrease <LABELDRUG> levels (7.1)
Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.60	Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.60.e.3	Increase_Interaction	C54355	@item <PRECIPITANT> may significantly increase <LABELDRUG> levels (7.3)
Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.62	Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.62.e.2	Increase_Interaction	C54357	"@item <PRECIPITANT> levels can increase by 50 to 75%, reduce digoxin dose (7.5)"
Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.62	Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.62.e.5	Increase_Interaction	C54357	"@item Digoxin levels can increase by 50 to 75%, reduce <PRECIPITANT> dose (7.5)"
Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.63	Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.63.e.2	Increase_Interaction	C54357	@item <PRECIPITANT> elimination inhibited resulting in elevated ethanol levels (7.6)
Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.63	Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.63.e.5	Increase_Interaction	C54357	@item Alcohol elimination inhibited resulting in elevated <PRECIPITANT> levels (7.6)
Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.66	Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.66.e.1	Increase_Interaction	C54355	"Clinically significant interactions have been reported with <PRECIPITANT> (e.g., erythromycin, ritonavir) causing elevation of plasma levels of <LABELDRUG>. "
Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.68	Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.68.e.1	Decrease_Interaction	C54356	"<PRECIPITANT> (e.g., rifampin) have caused a lowering of plasma levels of <LABELDRUG>."
Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.71	Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.71.e.2	Increase_Interaction	C54355	Co-administration of multiple doses of 10 mg of <LABELDRUG> with 80 mg <PRECIPITANT> resulted in exposure to <PRECIPITANT> 2.5-fold that following <PRECIPITANT> alone. 
Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.76	Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.76.e.3	Increase_Interaction	C54355	<PRECIPITANT> may significantly increase concentrations of <LABELDRUG>. 
Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.77	Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.77.e.2	Increase_Interaction	C54357	"<PRECIPITANT> given to nine healthy volunteers increased S- and R- <LABELDRUG> AUC0-12 by 36% and 28%, respectively. "
Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.78	Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.78.e.2	Increase_Interaction	C54602	"Steady state Cmax and Cmin of S-<LABELDRUG> increased by 57% and 16.7%, respectively with <PRECIPITANT> compared to control. "
Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.90	Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.90.e.2	Increase_Interaction	C54357	A decrease in metoprolol and <PRECIPITANT> clearance has been observed when either drug is administered concomitantly with <LABELDRUG>. 
Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.90	Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.90.e.4	Increase_Interaction	C54357	A decrease in <PRECIPITANT> and propranolol clearance has been observed when either drug is administered concomitantly with <LABELDRUG>. 
Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.95	Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.95.e.3	Increase_Interaction	C54357	"Chronic <LABELDRUG> treatment can increase serum <PRECIPITANT> levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity. "
Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.95	Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.95.e.6	Increase_Interaction	C54357	"Chronic <LABELDRUG> treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in <PRECIPITANT> toxicity. "
Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.96	Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.96.e.3	Increase_Interaction	C54357	In patients with hepatic cirrhosis the influence of <LABELDRUG> on <PRECIPITANT> pharmacokinetics is magnified. 
Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.97	Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.97.e.3	Increase_Interaction	C54357	"<LABELDRUG> may reduce total body clearance and extra-renal clearance of <PRECIPITANT> by 27% and 29%, respectively. "
Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.101	Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.101.e.3	Increase_Interaction	C54357	<LABELDRUG> has been found to significantly inhibit <PRECIPITANT> elimination resulting in elevated blood <PRECIPITANT> concentrations that may prolong the intoxicating effects of alcohol.
Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.108	Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.108.e.3	Increase_Interaction	C54357	<LABELDRUG> can increase <PRECIPITANT> levels. 
Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.109	Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.109.e.2	Decrease_Interaction	C54356	"The absorption of <LABELDRUG> can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the <PRECIPITANT>. "
Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.110	Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.110.e.3	Increase_Interaction	C54357	Concomitant administration of R <LABELDRUG> can decrease the clearance of <PRECIPITANT>.
Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.116	Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.116.e.3	Increase_Interaction	C54357	There has been a report of increased <PRECIPITANT> levels during <LABELDRUG> therapy.
Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.130	Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.130.e.3	Increase_Interaction	C54357	<LABELDRUG> therapy may increase <PRECIPITANT> concentrations during combined therapy. 
Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.133	Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.133.e.3	Increase_Interaction	C54357	<LABELDRUG> therapy may increase serum levels of <PRECIPITANT>.
Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.145	Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.145.e.2	Decrease_Interaction	C54356	<PRECIPITANT> therapy may increase <LABELDRUG> clearance.
Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.147	Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.147.e.2	Decrease_Interaction	C54356	Therapy with <PRECIPITANT> may markedly reduce oral <LABELDRUG> bioavailability.
Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.149	Dailymed.7c822705-827f-43c7-8c27-35bc31cf6484.s.149.e.2	Increase_Interaction	C54357	<LABELDRUG> may inhibit the clearance and increase the plasma levels of <PRECIPITANT>.
Dailymed.7dff29d9-522d-40eb-a9d9-42377912d640.s.34	Dailymed.7dff29d9-522d-40eb-a9d9-42377912d640.s.34.e.0	Increase_Interaction	C54357	Coadministration of <PRECIPITANT> or cimetidine with <LABELDRUG> has been reported to reduce clearance from the plasma and may result in toxic accumulation of the drug (see CLINICAL PHARMACOLOGY).
Dailymed.7dff29d9-522d-40eb-a9d9-42377912d640.s.34	Dailymed.7dff29d9-522d-40eb-a9d9-42377912d640.s.34.e.1	Increase_Interaction	C54357	Coadministration of propranolol or <PRECIPITANT> with <LABELDRUG> has been reported to reduce clearance from the plasma and may result in toxic accumulation of the drug (see CLINICAL PHARMACOLOGY).
Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.72	Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.72.e.1	Increase_Interaction	C54355	"<LABELDRUG> increases exposure to <PRECIPITANT> [see Drug Interactions (7.3), Clinical Pharmacology (12.3)]."
Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.83	Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.83.e.1	Increase_Interaction	C54355	"Concomitant use of ketoconazole as well as other <PRECIPITANT> such as itraconazole, voriconazole, ritonavir, clarithromycin, and nefazodone is contraindicated because exposure to <LABELDRUG> is significantly increased [see Contraindications (4), Clinical Pharmacology (12.3)]."
Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.85	Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.85.e.0	Increase_Interaction	C54355	Patients should avoid <PRECIPITANT> beverages while taking <LABELDRUG> because exposure to <LABELDRUG> is significantly increased [see Clinical Pharmacology (12.3)].
Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.87	Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.87.e.1	Decrease_Interaction	C54356	"Avoid rifampin or other <PRECIPITANT> such as phenobarbital, carbamazepine, phenytoin, and St John's wort because they decrease exposure to <LABELDRUG> significantly [see Clinical Pharmacology (12.3)]."
Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.89	Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.89.e.2	Increase_Interaction	C54355	Verapamil and <PRECIPITANT> are moderate CYP 3A inhibitors and increase <LABELDRUG> exposure. 
Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.89	Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.89.e.1	Increase_Interaction	C54355	<PRECIPITANT> and diltiazem are moderate CYP 3A inhibitors and increase <LABELDRUG> exposure. 
Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.93	Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.93.e.1	Increase_Interaction	C54357	<LABELDRUG> increased <PRECIPITANT>/<PRECIPITANT> acid exposure. 
Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.98	Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.98.e.1	Increase_Interaction	C54357	"<LABELDRUG> increased the exposure of <PRECIPITANT> (verapamil, diltiazem or nifedipine). "
Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.101	Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.101.e.1	Increase_Interaction	C54357	"<LABELDRUG> can increase plasma concentrations of tacrolimus, sirolimus, and other <PRECIPITANT> when given orally. "
Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.104	Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.104.e.2	Increase_Interaction	C54357	<LABELDRUG> increased the exposure of propranolol and <PRECIPITANT>. 
Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.104	Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.104.e.1	Increase_Interaction	C54357	<LABELDRUG> increased the exposure of <PRECIPITANT> and metoprolol. 
Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.106	Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.106.e.0	Increase_Interaction	C54357	"Other <PRECIPITANT>, including other beta-blockers, tricyclic antidepressants, and selective serotonin reuptake inhibitors (SSRIs) may have increased exposure upon co-administration with <LABELDRUG> [see Drug Interactions (7.1), Clinical Pharmacology (12.3)]."
Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.109	Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.109.e.1	Increase_Interaction	C54357	<LABELDRUG> increased <PRECIPITANT> exposure by inhibiting the P-gp transporter. 
Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.113	Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.113.e.0	Increase_Interaction	C54357	Exposure to <PRECIPITANT> is higher when it is administered with <LABELDRUG> than when it is administered alone.
Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.114	Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.114.e.0	Increase_Interaction	C54357	Other <PRECIPITANT> are expected to have increased exposure when co-administered with <LABELDRUG>.
Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.116	Dailymed.7fa41601-7fb5-4155-8e50-2ae903f0d2d6.s.116.e.1	Increase_Interaction	C54357	When co-administered with <LABELDRUG> exposure to <PRECIPITANT> was slightly higher than when warfarin was administered alone. 
Dailymed.80e9d61d-9674-4ac4-b84c-79a875d408dd.s.44	Dailymed.80e9d61d-9674-4ac4-b84c-79a875d408dd.s.44.e.3	Increase_Interaction	C54357	"The <PRECIPITANT> component of <LABELDRUG> may potentiate the action of other antihypertensive drugs, especially ganglionic or peripheral adrenergic-blocking drugs. "
Dailymed.80e9d61d-9674-4ac4-b84c-79a875d408dd.s.44	Dailymed.80e9d61d-9674-4ac4-b84c-79a875d408dd.s.44.e.2	Increase_Interaction	C54357	"The thiazide component of <LABELDRUG> may potentiate the action of other <PRECIPITANT>, especially ganglionic or peripheral adrenergic-blocking drugs. "
Dailymed.80e9d61d-9674-4ac4-b84c-79a875d408dd.s.160	Dailymed.80e9d61d-9674-4ac4-b84c-79a875d408dd.s.160.e.2	Increase_Interaction	C54357	Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving <PRECIPITANT> during therapy with lithium. 
Dailymed.80e9d61d-9674-4ac4-b84c-79a875d408dd.s.160	Dailymed.80e9d61d-9674-4ac4-b84c-79a875d408dd.s.160.e.3	Increase_Interaction	C54357	Increased serum <PRECIPITANT> levels and symptoms of <PRECIPITANT> toxicity have been reported in patients receiving ACE inhibitors during therapy with <PRECIPITANT>. 
Dailymed.80e9d61d-9674-4ac4-b84c-79a875d408dd.s.161	Dailymed.80e9d61d-9674-4ac4-b84c-79a875d408dd.s.161.e.2	Increase_Interaction	C54357	"Because renal clearance of lithium is reduced by <PRECIPITANT>, the risk of lithium toxicity is presumably raised further when, as in therapy with <LABELDRUG>, a thiazide diuretic is coadministered with the ACE inhibitor. "
Dailymed.80e9d61d-9674-4ac4-b84c-79a875d408dd.s.161	Dailymed.80e9d61d-9674-4ac4-b84c-79a875d408dd.s.161.e.3	Increase_Interaction	C54357	"Because renal clearance of <PRECIPITANT> is reduced by thiazides, the risk of <PRECIPITANT> toxicity is presumably raised further when, as in therapy with <LABELDRUG>, a thiazide diuretic is coadministered with the ACE inhibitor. "
Dailymed.80e9d61d-9674-4ac4-b84c-79a875d408dd.s.161	Dailymed.80e9d61d-9674-4ac4-b84c-79a875d408dd.s.161.e.6	Increase_Interaction	C54357	"Because renal clearance of lithium is reduced by thiazides, the risk of lithium toxicity is presumably raised further when, as in therapy with <LABELDRUG>, a thiazide diuretic is coadministered with the <PRECIPITANT>. "
Dailymed.80e9d61d-9674-4ac4-b84c-79a875d408dd.s.161	Dailymed.80e9d61d-9674-4ac4-b84c-79a875d408dd.s.161.e.8	Increase_Interaction	C54357	"Because renal clearance of lithium is reduced by thiazides, the risk of lithium toxicity is presumably raised further when, as in therapy with <LABELDRUG>, a <PRECIPITANT> is coadministered with the ACE inhibitor. "
Dailymed.80e9d61d-9674-4ac4-b84c-79a875d408dd.s.164	Dailymed.80e9d61d-9674-4ac4-b84c-79a875d408dd.s.164.e.2	Decrease_Interaction	C54356	"Simultaneous administration of <PRECIPITANT> with <LABELDRUG> reduced the absorption of <PRECIPITANT> by approximately 28% to 37%, possibly due to the high magnesium content in <LABELDRUG> tablets. "
Dailymed.80e9d61d-9674-4ac4-b84c-79a875d408dd.s.165	Dailymed.80e9d61d-9674-4ac4-b84c-79a875d408dd.s.165.e.2	Decrease_Interaction	C54356	This interaction should be considered if coprescribing <LABELDRUG> and tetracycline or other <PRECIPITANT>.
Dailymed.80e9d61d-9674-4ac4-b84c-79a875d408dd.s.165	Dailymed.80e9d61d-9674-4ac4-b84c-79a875d408dd.s.165.e.4	Decrease_Interaction	C54356	This interaction should be considered if coprescribing <LABELDRUG> and <PRECIPITANT> or other drugs that interact with magnesium.
Dailymed.80e9d61d-9674-4ac4-b84c-79a875d408dd.s.178	Dailymed.80e9d61d-9674-4ac4-b84c-79a875d408dd.s.178.e.5	Decrease_Interaction	C54356	"Single doses of either cholestyramine or <PRECIPITANT> resins bind the <LABELDRUG> and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively."
Dailymed.80e9d61d-9674-4ac4-b84c-79a875d408dd.s.178	Dailymed.80e9d61d-9674-4ac4-b84c-79a875d408dd.s.178.e.6	Decrease_Interaction	C54356	"Single doses of either <PRECIPITANT> or colestipol resins bind the <LABELDRUG> and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively."
Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.36	Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.36.e.3	Increase_Interaction	C54357	"The thiazide component of <LABELDRUG> may potentiate the action of other <PRECIPITANT>, especially ganglionic or peripheral adrenergic-blocking drugs. "
Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.126	Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.126.e.3	Increase_Interaction	C54357	Lithium: Renal clearance of lithium is reduced by <PRECIPITANT> and increase the risk of lithium toxicity. 
Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.126	Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.126.e.2	Increase_Interaction	C54357	Lithium: Renal clearance of <PRECIPITANT> is reduced by thiazides and increase the risk of <PRECIPITANT> toxicity. 
Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.127	Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.127.e.6	Increase_Interaction	C54357	Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving <PRECIPITANT> during therapy with lithium. 
Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.127	Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.127.e.2	Increase_Interaction	C54357	Increased serum <PRECIPITANT> levels and symptoms of <PRECIPITANT> toxicity have been reported in patients receiving ACE inhibitors during therapy with <PRECIPITANT>. 
Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.144	Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.144.e.0	Decrease_Interaction	C54356	"Single doses of either <PRECIPITANT> or colestipol resins bind the <LABELDRUG> and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively."
Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.144	Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.144.e.1	Decrease_Interaction	C54356	"Single doses of either cholestyramine or <PRECIPITANT> bind the <LABELDRUG> and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively."
Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.145	Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.145.e.3	Increase_Interaction	C54357	Digitalis glycosides: <PRECIPITANT>-induced hypokalemia or hypomagnesemia may predispose the patients to digoxin toxicity
Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.145	Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.145.e.2	Increase_Interaction	C54357	Digitalis glycosides: Thiazide-induced hypokalemia or hypomagnesemia may predispose the patients to <PRECIPITANT> toxicity
Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.148	Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.148.e.5	Increase_Interaction	C54357	"Antineoplastic agents (e.g., cyclophosphamide, methotrexate): Concomitant use of <PRECIPITANT> may reduce renal excretion of cytotoxic agents and enhance their myelosuppressive effects."
Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.148	Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.148.e.8	Increase_Interaction	C54357	"Antineoplastic agents (e.g., cyclophosphamide, methotrexate): Concomitant use of thiazide diuretics may reduce renal excretion of <PRECIPITANT> and enhance their myelosuppressive effects."
Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.149	Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.149.e.0	Increase_Interaction	C54357	"Drugs that alter gastrointestinal motility: The bioavailability of thiazide-type diuretics may be increased by <PRECIPITANT> (e.g., atropine, biperiden), apparently due to a decrease in gastrointestinal motility and the stomach emptying rate. "
Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.149	Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.149.e.7	Increase_Interaction	C54357	"Drugs that alter gastrointestinal motility: The bioavailability of <PRECIPITANT> may be increased by anticholinergic agents (e.g., atropine, biperiden), apparently due to a decrease in gastrointestinal motility and the stomach emptying rate. "
Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.150	Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.150.e.0	Decrease_Interaction	C54358	"Conversely, <PRECIPITANT> may decrease the bioavailability of thiazide diuretics."
Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.150	Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.150.e.3	Decrease_Interaction	C54358	"Conversely, pro-kinetic drugs may decrease the bioavailability of <PRECIPITANT>."
Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.153	Dailymed.81e77f65-a1b0-4c1c-9e7c-fc9de8c14636.s.153.e.3	Decrease_Interaction	C54358	Pressor amines: <LABELDRUG> may reduce the response to <PRECIPITANT> such as noradrenaline but the clinical significance of this effect is not sufficient to preclude their use.
Dailymed.833c7a0b-5f64-4363-94d5-9a179049113a.s.64	Dailymed.833c7a0b-5f64-4363-94d5-9a179049113a.s.64.e.2	Increase_Interaction	C54355	"When <LABELDRUG> was given with <PRECIPITANT> or itraconazole, the blood concentrations of <LABELDRUG> were significantly increased. "
Dailymed.833c7a0b-5f64-4363-94d5-9a179049113a.s.64	Dailymed.833c7a0b-5f64-4363-94d5-9a179049113a.s.64.e.3	Increase_Interaction	C54355	"When <LABELDRUG> was given with cyclosporine or <PRECIPITANT>, the blood concentrations of <LABELDRUG> were significantly increased. "
Dailymed.87713d73-5dcc-4158-8890-60efdbd28c05.s.85	Dailymed.87713d73-5dcc-4158-8890-60efdbd28c05.s.85.e.5	Increase_Interaction	C54610	"Coadministration of <PRECIPITANT> with oral <LABELDRUG> resulted in a 1.8- and 1.4-fold increase in <PRECIPITANT> Cmax and AUC, respectively. "
Dailymed.87713d73-5dcc-4158-8890-60efdbd28c05.s.90	Dailymed.87713d73-5dcc-4158-8890-60efdbd28c05.s.90.e.0	Increase_Interaction	C54355	"@item <PRECIPITANT> may increase the exposure of <LABELDRUG> and are contraindicated (4.2, 7.1)."
Dailymed.87713d73-5dcc-4158-8890-60efdbd28c05.s.92	Dailymed.87713d73-5dcc-4158-8890-60efdbd28c05.s.92.e.2	Increase_Interaction	C54357	"@item Exposure to coadministered <PRECIPITANT> may be increased and <PRECIPITANT> levels should be monitored (5.4, 7.2)."
Dailymed.87713d73-5dcc-4158-8890-60efdbd28c05.s.95	Dailymed.87713d73-5dcc-4158-8890-60efdbd28c05.s.95.e.1	Increase_Interaction	C54602	"Coadministration of oral <LABELDRUG> 10 mg with <PRECIPITANT> 200 mg resulted in 4- and 11-fold increases in Cmax and AUC of <LABELDRUG>, respectively see Contraindications (4.2)."
Dailymed.87713d73-5dcc-4158-8890-60efdbd28c05.s.98	Dailymed.87713d73-5dcc-4158-8890-60efdbd28c05.s.98.e.4	Increase_Interaction	C54355	"<LABELDRUG> 40 mg/day increased the mean AUC values by approximately 2- and 3-fold for 1 mg intravenous or 2 mg <PRECIPITANT>, respectively. "
Dailymed.87713d73-5dcc-4158-8890-60efdbd28c05.s.99	Dailymed.87713d73-5dcc-4158-8890-60efdbd28c05.s.99.e.3	Increase_Interaction	C54355	<LABELDRUG> 30 mg/day resulted in a 3-fold increase in the AUC of <PRECIPITANT>. 
Dailymed.87713d73-5dcc-4158-8890-60efdbd28c05.s.100	Dailymed.87713d73-5dcc-4158-8890-60efdbd28c05.s.100.e.5	Increase_Interaction	C54611	Oral <LABELDRUG> 40 mg twice daily resulted in a 2-fold increase in the AUC and half-life of <PRECIPITANT> see Warnings and Precautions (5.3).
Dailymed.87713d73-5dcc-4158-8890-60efdbd28c05.s.101	Dailymed.87713d73-5dcc-4158-8890-60efdbd28c05.s.101.e.0	Increase_Interaction	C54357	"Coadministration of a 0.5 mg dose of <PRECIPITANT>, a P-glycoprotein substrate, with oral <LABELDRUG> 40 mg twice daily resulted in a 30% reduction in clearance and 79% and 43% increases in <PRECIPITANT> Cmax and AUC values, respectively see Warnings and Precautions (5.4)."
Dailymed.87713d73-5dcc-4158-8890-60efdbd28c05.s.102	Dailymed.87713d73-5dcc-4158-8890-60efdbd28c05.s.102.e.5	Increase_Interaction	C54357	"<LABELDRUG> (40 mg/day for 4 days) administered with a single 25 mg dose of warfarin, which undergoes major metabolism by CYP2C9 and minor metabolism by CYP3A, increased the mean <PRECIPITANT> AUC and <PRECIPITANT> Cmax by 14% and 17%, respectively. "
Dailymed.886e050c-dd22-4f35-ac3b-243f091125c3.s.12	Dailymed.886e050c-dd22-4f35-ac3b-243f091125c3.s.12.e.1	Decrease_Interaction	C54607	The administration of <LABELDRUG> concomitantly with a known <PRECIPITANT> (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration. 
Dailymed.8b8ad213-1dc8-454e-a524-075685c0e1a8.s.83	Dailymed.8b8ad213-1dc8-454e-a524-075685c0e1a8.s.83.e.1	Increase_Interaction	C54357	"<LABELDRUG> can exacerbate the effects of myocardial depressants or <PRECIPITANT>, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide."
Dailymed.8b8ad213-1dc8-454e-a524-075685c0e1a8.s.83	Dailymed.8b8ad213-1dc8-454e-a524-075685c0e1a8.s.83.e.15	Increase_Interaction	C54357	"<LABELDRUG> can exacerbate the effects of myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or <PRECIPITANT>, such as disopyramide."
Dailymed.8b8ad213-1dc8-454e-a524-075685c0e1a8.s.83	Dailymed.8b8ad213-1dc8-454e-a524-075685c0e1a8.s.83.e.0	Increase_Interaction	C54357	"<LABELDRUG> can exacerbate the effects of <PRECIPITANT> or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide."
Dailymed.8b8ad213-1dc8-454e-a524-075685c0e1a8.s.84	Dailymed.8b8ad213-1dc8-454e-a524-075685c0e1a8.s.84.e.0	Increase_Interaction	C54355	<PRECIPITANT> can be expected to increase plasma levels of <LABELDRUG>. 
Dailymed.8b8ad213-1dc8-454e-a524-075685c0e1a8.s.93	Dailymed.8b8ad213-1dc8-454e-a524-075685c0e1a8.s.93.e.0	Increase_Interaction	C54355	"<PRECIPITANT>: <PRECIPITANT>, a CYP2D6 inhibitor, administered at 20 mg per day for 21 days prior to a single 10 mg dose of <LABELDRUG> to 10 healthy adults, led to an 8-fold increase in the AUC and 3-fold increase in Cmax for d-<LABELDRUG> [see Drug Interactions (7)]."
Dailymed.8b8ad213-1dc8-454e-a524-075685c0e1a8.s.95	Dailymed.8b8ad213-1dc8-454e-a524-075685c0e1a8.s.95.e.0	Increase_Interaction	C54355	<PRECIPITANT> (400 mg twice daily) causes a 23% increase in the plasma levels of d-<LABELDRUG>.
Dailymed.8b8ad213-1dc8-454e-a524-075685c0e1a8.s.97	Dailymed.8b8ad213-1dc8-454e-a524-075685c0e1a8.s.97.e.5	Decrease_Interaction	C54615	Sildenafil: The co-administration of <LABELDRUG> and <PRECIPITANT> decreased AUC and Cmax of <PRECIPITANT> by 21 and 23% respectively. 
Dailymed.8e4b636e-ee9c-4111-779d-28c8369d283b.s.54	Dailymed.8e4b636e-ee9c-4111-779d-28c8369d283b.s.54.e.3	Increase_Interaction	C54357	"In a pharmacokinetic substudy in patients with congestive heart failure receiving <PRECIPITANT> or digoxin in whom therapy with <LABELDRUG> was initiated, apparent oral clearance values for <PRECIPITANT> (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87. "
Dailymed.8e4b636e-ee9c-4111-779d-28c8369d283b.s.54	Dailymed.8e4b636e-ee9c-4111-779d-28c8369d283b.s.54.e.4	Increase_Interaction	C54357	"In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or <PRECIPITANT> in whom therapy with <LABELDRUG> was initiated, apparent oral clearance values for furosemide (n = 23) and <PRECIPITANT> (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87. "
Dailymed.8e4b636e-ee9c-4111-779d-28c8369d283b.s.56	Dailymed.8e4b636e-ee9c-4111-779d-28c8369d283b.s.56.e.3	Increase_Interaction	C54357	"However, patients on <PRECIPITANT> may show elevations of <PRECIPITANT> concentrations after initiation of therapy with <LABELDRUG>, which may be clinically significant in patients prone to <PRECIPITANT> toxicity."
Dailymed.938ab0b5-8377-404a-8f61-5c630bda5932.s.58	Dailymed.938ab0b5-8377-404a-8f61-5c630bda5932.s.58.e.3	Increase_Interaction	C54357	<LABELDRUG> has been reported to increase the plasma levels and cardiovascular effects of <PRECIPITANT>. 
Dailymed.938ab0b5-8377-404a-8f61-5c630bda5932.s.63	Dailymed.938ab0b5-8377-404a-8f61-5c630bda5932.s.63.e.3	Increase_Interaction	C54357	Concurrent use of <LABELDRUG> and <PRECIPITANT> can lead to high serum concentrations of <PRECIPITANT> (and toxicity) due to competition at the renal tubule for secretion.
Dailymed.938ab0b5-8377-404a-8f61-5c630bda5932.s.69	Dailymed.938ab0b5-8377-404a-8f61-5c630bda5932.s.69.e.2	Decrease_Interaction	C54358	"<PRECIPITANT> can displace protein-bound phenytoin and valproic acid, leading to a decrease in the total concentration of phenytoin and an increase in serum valproic acid levels."
Dailymed.938ab0b5-8377-404a-8f61-5c630bda5932.s.69	Dailymed.938ab0b5-8377-404a-8f61-5c630bda5932.s.69.e.3	Decrease_Interaction	C54358	"Salicylic acid can displace protein-bound <PRECIPITANT> and valproic acid, leading to a decrease in the total concentration of <PRECIPITANT> and an increase in serum valproic acid levels."
Dailymed.938ab0b5-8377-404a-8f61-5c630bda5932.s.69	Dailymed.938ab0b5-8377-404a-8f61-5c630bda5932.s.69.e.6	Increase_Interaction	C54357	"Salicylic acid can displace protein-bound phenytoin and <PRECIPITANT>, leading to a decrease in the total concentration of phenytoin and an increase in serum <PRECIPITANT> levels."
Dailymed.938ab0b5-8377-404a-8f61-5c630bda5932.s.75	Dailymed.938ab0b5-8377-404a-8f61-5c630bda5932.s.75.e.5	Decrease_Interaction	C54356	"The effectiveness of <PRECIPITANT> in patients with underlying renal or cardiovascular disease may be diminished by the concomitant administration of <LABELDRUG> due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and fluid retention."
Dailymed.938ab0b5-8377-404a-8f61-5c630bda5932.s.77	Dailymed.938ab0b5-8377-404a-8f61-5c630bda5932.s.77.e.3	Increase_Interaction	C54357	"<PRECIPITANT> can inhibit renal clearance of methotrexate, leading to bone marrow toxicity, especially in the elderly or renal impaired."
Dailymed.938ab0b5-8377-404a-8f61-5c630bda5932.s.77	Dailymed.938ab0b5-8377-404a-8f61-5c630bda5932.s.77.e.4	Increase_Interaction	C54357	"Salicylate can inhibit renal clearance of <PRECIPITANT>, leading to bone marrow toxicity, especially in the elderly or renal impaired."
Dailymed.938ab0b5-8377-404a-8f61-5c630bda5932.s.81	Dailymed.938ab0b5-8377-404a-8f61-5c630bda5932.s.81.e.3	Increase_Interaction	C54357	"Moderate doses of <LABELDRUG> may increase the effectiveness of <PRECIPITANT>, leading to hypoglycemia."
Dailymed.94ae6054-b7ae-4212-a567-4f803af8f2c7.s.79	Dailymed.94ae6054-b7ae-4212-a567-4f803af8f2c7.s.79.e.2	Increase_Interaction	C54357	"@item <PRECIPITANT>: Increased serum <PRECIPITANT> levels, toxicity symptoms."
Dailymed.94ae6054-b7ae-4212-a567-4f803af8f2c7.s.86	Dailymed.94ae6054-b7ae-4212-a567-4f803af8f2c7.s.86.e.2	Increase_Interaction	C54357	Simvastatin: Co-administration of <PRECIPITANT> with <LABELDRUG> increases the systemic exposure of <PRECIPITANT>. 
Dailymed.94ae6054-b7ae-4212-a567-4f803af8f2c7.s.96	Dailymed.94ae6054-b7ae-4212-a567-4f803af8f2c7.s.96.e.2	Increase_Interaction	C54357	Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving <PRECIPITANT> during therapy with lithium. 
Dailymed.94ae6054-b7ae-4212-a567-4f803af8f2c7.s.96	Dailymed.94ae6054-b7ae-4212-a567-4f803af8f2c7.s.96.e.3	Increase_Interaction	C54357	Lithium: Increased serum <PRECIPITANT> levels and symptoms of <PRECIPITANT> toxicity have been reported in patients receiving ACE inhibitors during therapy with <PRECIPITANT>. 
Dailymed.97a9e8bf-91ed-4256-97d4-f9504bb01373.s.74	Dailymed.97a9e8bf-91ed-4256-97d4-f9504bb01373.s.74.e.2	Increase_Interaction	C54357	"@item Lithium: Increase serum <PRECIPITANT> levels, symptoms of <PRECIPITANT> toxicity (7.3)"
Dailymed.97a9e8bf-91ed-4256-97d4-f9504bb01373.s.83	Dailymed.97a9e8bf-91ed-4256-97d4-f9504bb01373.s.83.e.2	Decrease_Interaction	C54356	"The bioavailability of <LABELDRUG>at was reduced by <PRECIPITANT>, however, and this was associated with a decrease in plasma ACE inhibition."
Dailymed.97a9e8bf-91ed-4256-97d4-f9504bb01373.s.89	Dailymed.97a9e8bf-91ed-4256-97d4-f9504bb01373.s.89.e.3	Increase_Interaction	C54357	Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and <PRECIPITANT> therapy. 
Dailymed.97a9e8bf-91ed-4256-97d4-f9504bb01373.s.89	Dailymed.97a9e8bf-91ed-4256-97d4-f9504bb01373.s.89.e.2	Increase_Interaction	C54357	Increased serum <PRECIPITANT> and symptoms of <PRECIPITANT> toxicity have been reported in patients receiving concomitant <PRECIPITANT> and ACE inhibitor therapy. 
Dailymed.97a9e8bf-91ed-4256-97d4-f9504bb01373.s.91	Dailymed.97a9e8bf-91ed-4256-97d4-f9504bb01373.s.91.e.2	Increase_Interaction	C54357	Use of a <PRECIPITANT> may further increase the risk of lithium toxicity.
Dailymed.97a9e8bf-91ed-4256-97d4-f9504bb01373.s.91	Dailymed.97a9e8bf-91ed-4256-97d4-f9504bb01373.s.91.e.3	Increase_Interaction	C54357	Use of a diuretic may further increase the risk of <PRECIPITANT> toxicity.
Dailymed.a11548a0-9c0f-4729-907c-75d8f99a6c85.s.47	Dailymed.a11548a0-9c0f-4729-907c-75d8f99a6c85.s.47.e.0	Decrease_Interaction	C54607	"Concurrent use of <PRECIPITANT> increases the metabolic clearance of <LABELDRUG>, resulting in a shortened elimination half-life of <LABELDRUG>. "
Dailymed.a3d05b02-d7ea-4e8f-90b0-d6cd9cd169c8.s.24	Dailymed.a3d05b02-d7ea-4e8f-90b0-d6cd9cd169c8.s.24.e.7	Increase_Interaction	C54357	"For example, rapid potassium removal may create arrhythmias in cardiac patients using <PRECIPITANT> or similar drugs, <PRECIPITANT> toxicity may be masked by elevated potassium or <LABELDRUG>, or by hypocalcemia. "
Dailymed.a3d05b02-d7ea-4e8f-90b0-d6cd9cd169c8.s.25	Dailymed.a3d05b02-d7ea-4e8f-90b0-d6cd9cd169c8.s.25.e.0	Increase_Interaction	C54357	Correction of electrolytes by dialysis may precipitate signs and symptoms of <PRECIPITANT> excess. 
Dailymed.a3d05b02-d7ea-4e8f-90b0-d6cd9cd169c8.s.26	Dailymed.a3d05b02-d7ea-4e8f-90b0-d6cd9cd169c8.s.26.e.2	Increase_Interaction	C54357	"Conversely, toxicity may occur at suboptimal dosages of <PRECIPITANT> if potassium is low or <LABELDRUG> high. "
Dailymed.a4195473-51a9-40f1-8678-1478ebca2d84.s.59	Dailymed.a4195473-51a9-40f1-8678-1478ebca2d84.s.59.e.2	Increase_Interaction	C54355	<PRECIPITANT> has been shown to increase the bioavailability of <LABELDRUG> HCl. 
Dailymed.a55a39ff-1bd5-428b-a64f-c44262e2f3ed.s.74	Dailymed.a55a39ff-1bd5-428b-a64f-c44262e2f3ed.s.74.e.0	Increase_Interaction	C54355	<PRECIPITANT> cause increased exposure [see DRUG INTERACTIONS (7.1)].
Dailymed.a55a39ff-1bd5-428b-a64f-c44262e2f3ed.s.76	Dailymed.a55a39ff-1bd5-428b-a64f-c44262e2f3ed.s.76.e.1	Increase_Interaction	C54602	"A pharmacokinetic study evaluating the administration of a single dose of <LABELDRUG> 100 mg with <PRECIPITANT> 200 mg two times a day, a strong inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of <LABELDRUG> and a 5.4-fold increase in AUC of <LABELDRUG>."
Dailymed.a55a39ff-1bd5-428b-a64f-c44262e2f3ed.s.77	Dailymed.a55a39ff-1bd5-428b-a64f-c44262e2f3ed.s.77.e.1	Increase_Interaction	C54602	"Administration of <LABELDRUG> with <PRECIPITANT> (e.g., erythromycin 500 mg BID, verapamil 240 mg once daily, saquinavir 1200 mg three times a day, fluconazole 200 mg once daily) resulted in increases in Cmax of <LABELDRUG> ranging from 1.4- to 1.6-fold and AUC from 2.0- to 2.9-fold."
Dailymed.a55a39ff-1bd5-428b-a64f-c44262e2f3ed.s.78	Dailymed.a55a39ff-1bd5-428b-a64f-c44262e2f3ed.s.78.e.0	Increase_Interaction	C54355	<PRECIPITANT> caused only a small increase (about 25%) in exposure.
Dailymed.a6ad506a-a3f9-45be-ae03-24313b9a9b7c.s.46	Dailymed.a6ad506a-a3f9-45be-ae03-24313b9a9b7c.s.46.e.3	Increase_Interaction	C54357	"Concomitant administration of <LABELDRUG> with <PRECIPITANT> has been reported to result in elevated plasma levels of <PRECIPITANT>, resulting in toxicity in some cases."
Dailymed.a6ad506a-a3f9-45be-ae03-24313b9a9b7c.s.48	Dailymed.a6ad506a-a3f9-45be-ae03-24313b9a9b7c.s.48.e.4	Increase_Interaction	C54357	Administration of <LABELDRUG> concomitantly with <PRECIPITANT> in five normal volunteers resulted in increased <PRECIPITANT> levels in all subjects and the bioavailability of <PRECIPITANT> was increased approximately 50%. 
Dailymed.a6ad506a-a3f9-45be-ae03-24313b9a9b7c.s.51	Dailymed.a6ad506a-a3f9-45be-ae03-24313b9a9b7c.s.51.e.3	Increase_Interaction	C54355	"Cimetidine: A study in six healthy volunteers has shown a significant increase in peak <LABELDRUG> plasma levels (58%) and area-under-the-curve (53%) after a 1 week course of <PRECIPITANT> at 1,200 mg per day and <LABELDRUG> 60 mg per day. "
Dailymed.a6ad506a-a3f9-45be-ae03-24313b9a9b7c.s.52	Dailymed.a6ad506a-a3f9-45be-ae03-24313b9a9b7c.s.52.e.5	Increase_Interaction	C54355	"<PRECIPITANT> produced smaller, nonsignificant increases. "
Dailymed.a6ad506a-a3f9-45be-ae03-24313b9a9b7c.s.58	Dailymed.a6ad506a-a3f9-45be-ae03-24313b9a9b7c.s.58.e.4	Increase_Interaction	C54357	Digitalis: Administration of <LABELDRUG> with <PRECIPITANT> in 24 healthy male subjects increased plasma <PRECIPITANT> concentrations approximately 20%. 
Dailymed.a6ad506a-a3f9-45be-ae03-24313b9a9b7c.s.64	Dailymed.a6ad506a-a3f9-45be-ae03-24313b9a9b7c.s.64.e.3	Increase_Interaction	C54357	Statins: <LABELDRUG> is an inhibitor of CYP3A4 and has been shown to increase significantly the AUC of some <PRECIPITANT>. 
Dailymed.a6ad506a-a3f9-45be-ae03-24313b9a9b7c.s.67	Dailymed.a6ad506a-a3f9-45be-ae03-24313b9a9b7c.s.67.e.4	Increase_Interaction	C54355	"In a healthy volunteer cross-over study (N 10), co-administration of a single 20 mg dose of <PRECIPITANT> at the end of a 14 day regimen with 120 mg twice daily <LABELDRUG> SR resulted in a 5-fold higher mean <PRECIPITANT> AUC compared with <PRECIPITANT> alone. "
Dailymed.a6ad506a-a3f9-45be-ae03-24313b9a9b7c.s.68	Dailymed.a6ad506a-a3f9-45be-ae03-24313b9a9b7c.s.68.e.3	Increase_Interaction	C54355	High average steady-state exposures of <LABELDRUG> would result in a greater increase in <PRECIPITANT> exposure. 
Dailymed.a6ad506a-a3f9-45be-ae03-24313b9a9b7c.s.69	Dailymed.a6ad506a-a3f9-45be-ae03-24313b9a9b7c.s.69.e.2	Increase_Interaction	C54355	A daily dose of 480 mg of <LABELDRUG> would be expected to result in an 8-fold higher mean <PRECIPITANT> AUC compared with <PRECIPITANT> alone. 
Dailymed.a6ad506a-a3f9-45be-ae03-24313b9a9b7c.s.71	Dailymed.a6ad506a-a3f9-45be-ae03-24313b9a9b7c.s.71.e.3	Increase_Interaction	C54610	"In a ten-subject randomized, open label, 4-way cross-over study, co-administration of <LABELDRUG> (120 mg twice daily <LABELDRUG> SR for 2 weeks) with a single 20 mg dose of <PRECIPITANT> resulted in 3- to 4-fold higher mean <PRECIPITANT> AUC and Cmax values compared with <PRECIPITANT> alone. "
Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.65	Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.65.e.2	Increase_Interaction	C54357	"Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some <PRECIPITANT>. "
Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.65	Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.65.e.3	Increase_Interaction	C54357	"Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with <PRECIPITANT>, and with some angiotensin II receptor antagonists. "
Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.65	Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.65.e.4	Increase_Interaction	C54357	"Reversible increases in serum <PRECIPITANT> concentrations and toxicity have been reported during concomitant administration of <PRECIPITANT> with ACE inhibitors, and with some angiotensin II receptor antagonists. "
Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.66	Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.66.e.3	Increase_Interaction	C54357	An increase in serum <PRECIPITANT> concentration has been reported during concomitant administration of <PRECIPITANT> with <LABELDRUG>. 
Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.73	Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.73.e.2	Increase_Interaction	C54357	@item Lithium: Reversible increases in serum <PRECIPITANT> concentrations and toxicity (7).
Dailymed.abd6a2ca-40c2-485c-bc53-db1c652505ed.s.27	Dailymed.abd6a2ca-40c2-485c-bc53-db1c652505ed.s.27.e.4	Increase_Interaction	C54355	Co-administration of multiple doses of 10 mg of <LABELDRUG> with 80 mg <PRECIPITANT> resulted in a 77% increase in exposure to <PRECIPITANT> compared to <PRECIPITANT> alone. 
Dailymed.abd6a2ca-40c2-485c-bc53-db1c652505ed.s.36	Dailymed.abd6a2ca-40c2-485c-bc53-db1c652505ed.s.36.e.0	Increase_Interaction	C54355	Co-administration of a 180 mg daily dose of <PRECIPITANT> with 5 mg <LABELDRUG> in elderly hypertensive patients resulted in a 60% increase in <LABELDRUG> systemic exposure. 
Dailymed.abd6a2ca-40c2-485c-bc53-db1c652505ed.s.44	Dailymed.abd6a2ca-40c2-485c-bc53-db1c652505ed.s.44.e.4	Increase_Interaction	C54357	A prospective study in renal transplant patients (N=11) showed on an average of 40% increase in trough <PRECIPITANT> levels when concomitantly treated with <LABELDRUG>.
Dailymed.acb6e57b-af44-432f-a4de-a293a2e20121.s.57	Dailymed.acb6e57b-af44-432f-a4de-a293a2e20121.s.57.e.2	Increase_Interaction	C54357	"It has been reported that <LABELDRUG> decreases neuromuscular transmission in patients with Duchenne's muscular dystrophy, and that <LABELDRUG> prolongs recovery from the neuromuscular blocking agent <PRECIPITANT>. "
Dailymed.acb6e57b-af44-432f-a4de-a293a2e20121.s.72	Dailymed.acb6e57b-af44-432f-a4de-a293a2e20121.s.72.e.0	Increase_Interaction	C54357	A decrease in <PRECIPITANT> and propranolol clearance has been observed when either drug is administered concomitantly with <LABELDRUG>. 
Dailymed.acb6e57b-af44-432f-a4de-a293a2e20121.s.72	Dailymed.acb6e57b-af44-432f-a4de-a293a2e20121.s.72.e.1	Increase_Interaction	C54357	A decrease in metoprolol and <PRECIPITANT> clearance has been observed when either drug is administered concomitantly with <LABELDRUG>. 
Dailymed.acb6e57b-af44-432f-a4de-a293a2e20121.s.76	Dailymed.acb6e57b-af44-432f-a4de-a293a2e20121.s.76.e.3	Increase_Interaction	C54357	"However, chronic <LABELDRUG> treatment can increase serum <PRECIPITANT> levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity. "
Dailymed.acb6e57b-af44-432f-a4de-a293a2e20121.s.78	Dailymed.acb6e57b-af44-432f-a4de-a293a2e20121.s.78.e.2	Increase_Interaction	C54357	"<LABELDRUG> may reduce total body clearance and extrarenal clearance of <PRECIPITANT> by 27% and 29%, respectively. "
Dailymed.acb6e57b-af44-432f-a4de-a293a2e20121.s.98	Dailymed.acb6e57b-af44-432f-a4de-a293a2e20121.s.98.e.2	Increase_Interaction	C54357	There has been a report of increased <PRECIPITANT> levels during <LABELDRUG> therapy.
Dailymed.acb6e57b-af44-432f-a4de-a293a2e20121.s.101	Dailymed.acb6e57b-af44-432f-a4de-a293a2e20121.s.101.e.2	Increase_Interaction	C54357	"<LABELDRUG> has been found to inhibit <PRECIPITANT> elimination significantly, resulting in elevated blood <PRECIPITANT> concentrations that may prolong the intoxicating effects of alcohol (see CLINICAL PHARMACOLOGY, Pharmacokinetics and metabolism)."
Dailymed.acb6e57b-af44-432f-a4de-a293a2e20121.s.111	Dailymed.acb6e57b-af44-432f-a4de-a293a2e20121.s.111.e.4	Increase_Interaction	C54357	"<PRECIPITANT> levels have been observed sometimes to increase, sometimes to decrease, and sometimes to be unchanged. "
Dailymed.acb6e57b-af44-432f-a4de-a293a2e20121.s.114	Dailymed.acb6e57b-af44-432f-a4de-a293a2e20121.s.114.e.3	Increase_Interaction	C54357	<LABELDRUG> therapy may increase <PRECIPITANT> concentrations during combined therapy. 
Dailymed.acb6e57b-af44-432f-a4de-a293a2e20121.s.117	Dailymed.acb6e57b-af44-432f-a4de-a293a2e20121.s.117.e.3	Decrease_Interaction	C54356	Therapy with <PRECIPITANT> may markedly reduce oral <LABELDRUG> bioavailability.
Dailymed.acb6e57b-af44-432f-a4de-a293a2e20121.s.119	Dailymed.acb6e57b-af44-432f-a4de-a293a2e20121.s.119.e.3	Decrease_Interaction	C54356	<PRECIPITANT> therapy may increase <LABELDRUG> clearance.
Dailymed.acb6e57b-af44-432f-a4de-a293a2e20121.s.121	Dailymed.acb6e57b-af44-432f-a4de-a293a2e20121.s.121.e.3	Increase_Interaction	C54357	<LABELDRUG> therapy may increase serum levels of <PRECIPITANT>.
Dailymed.acb6e57b-af44-432f-a4de-a293a2e20121.s.123	Dailymed.acb6e57b-af44-432f-a4de-a293a2e20121.s.123.e.5	Increase_Interaction	C54357	<LABELDRUG> may inhibit the clearance and increase the plasma levels of <PRECIPITANT>.
Dailymed.acb6e57b-af44-432f-a4de-a293a2e20121.s.128	Dailymed.acb6e57b-af44-432f-a4de-a293a2e20121.s.128.e.4	Increase_Interaction	C54357	Clinical data and animal studies suggest that <LABELDRUG> may potentiate the activity of <PRECIPITANT>. 
Dailymed.ad8916e7-206e-409e-2582-30d072845dd4.s.7	Dailymed.ad8916e7-206e-409e-2582-30d072845dd4.s.7.e.2	Decrease_Interaction	C54356	"<LABELDRUG> I.V. decreased the rate of <PRECIPITANT> absorption without altering the relative oral bioavailability, this delay in <PRECIPITANT> absorption was reversed by the combination of atropine and intravenous metoclopramide during pretreatment for anesthesia. "
Dailymed.aea9c02c-eddf-435f-969c-e8ac9aaddadd.s.35	Dailymed.aea9c02c-eddf-435f-969c-e8ac9aaddadd.s.35.e.2	Increase_Interaction	C54357	Correction of electrolytes by dialysis may precipitate signs and symptoms of <PRECIPITANT> excess. 
Dailymed.aea9c02c-eddf-435f-969c-e8ac9aaddadd.s.36	Dailymed.aea9c02c-eddf-435f-969c-e8ac9aaddadd.s.36.e.2	Increase_Interaction	C54357	"Conversely, toxicity may occur at suboptimal dosages of <PRECIPITANT> if potassium is low or <LABELDRUG> high. "
Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.50	Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.50.e.0	Increase_Interaction	C54357	Other <PRECIPITANT> - additive effect or potentiation.
Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.51	Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.51.e.0	Decrease_Interaction	C54356	"<PRECIPITANT> and colestipol resins - <PRECIPITANT> and colestipol resins bind the <LABELDRUG> and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively."
Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.51	Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.51.e.1	Decrease_Interaction	C54356	"Cholestyramine and <PRECIPITANT> - Cholestyramine and <PRECIPITANT> bind the <LABELDRUG> and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively."
Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.53	Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.53.e.5	Decrease_Interaction	C54358	"Pressor amines (e.g., norepinephrine) - possible decreased response to <PRECIPITANT> but not sufficient to preclude their use."
Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.54	Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.54.e.3	Increase_Interaction	C54357	"Skeletal <PRECIPITANT>s, nondepolarizing (e.g., tubocurarine) - possible increased responsiveness to the <PRECIPITANT>."
Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.56	Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.56.e.0	Increase_Interaction	C54357	<PRECIPITANT> reduce the renal clearance of lithium and greatly increase the risk of lithium toxicity. 
Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.56	Dailymed.afbefaff-97c4-4f84-b989-1595f882a885.s.56.e.5	Increase_Interaction	C54357	Diuretic agents reduce the renal clearance of <PRECIPITANT> and greatly increase the risk of <PRECIPITANT> toxicity. 
Dailymed.b078dae2-664d-4144-847a-3b9d9b557402.s.98	Dailymed.b078dae2-664d-4144-847a-3b9d9b557402.s.98.e.2	Increase_Interaction	C54357	"Co-administration of <LABELDRUG> and <PRECIPITANT> increases the exposure to both <PRECIPITANT> and <PRECIPITANT>at by a factor of about 2 (see PRECAUTIONS, Drug Interactions )."
Dailymed.b078dae2-664d-4144-847a-3b9d9b557402.s.111	Dailymed.b078dae2-664d-4144-847a-3b9d9b557402.s.111.e.2	Increase_Interaction	C54357	"Digoxin : When <LABELDRUG> was co-administered with <PRECIPITANT>, median increases in <PRECIPITANT> peak plasma concentration (49%) and in trough concentration (20%) were observed. "
Dailymed.b078dae2-664d-4144-847a-3b9d9b557402.s.113	Dailymed.b078dae2-664d-4144-847a-3b9d9b557402.s.113.e.3	Increase_Interaction	C54357	Lithium : Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with <PRECIPITANT>. 
Dailymed.b078dae2-664d-4144-847a-3b9d9b557402.s.113	Dailymed.b078dae2-664d-4144-847a-3b9d9b557402.s.113.e.2	Increase_Interaction	C54357	Lithium : Reversible increases in serum <PRECIPITANT> concentrations and toxicity have been reported during concomitant administration of <PRECIPITANT> with angiotensin converting enzyme inhibitors. 
Dailymed.b078dae2-664d-4144-847a-3b9d9b557402.s.114	Dailymed.b078dae2-664d-4144-847a-3b9d9b557402.s.114.e.2	Increase_Interaction	C54357	Cases have also been reported with <PRECIPITANT> including <LABELDRUG>. 
Dailymed.b078dae2-664d-4144-847a-3b9d9b557402.s.120	Dailymed.b078dae2-664d-4144-847a-3b9d9b557402.s.120.e.3	Increase_Interaction	C54610	"Ramipril and Ramiprilat : Co-administration of <LABELDRUG> 80 mg once daily and <PRECIPITANT> 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of <PRECIPITANT> 2.3 and 2.1 fold, respectively, and Cmax and AUC of <PRECIPITANT>at 2.4 and 1.5 fold, respectively. "
Dailymed.b078dae2-664d-4144-847a-3b9d9b557402.s.122	Dailymed.b078dae2-664d-4144-847a-3b9d9b557402.s.122.e.6	Increase_Interaction	C54357	"When co-administering <LABELDRUG> and <PRECIPITANT>, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to <PRECIPITANT> and <PRECIPITANT>at in the presence of <LABELDRUG>."
Dailymed.b078dae2-664d-4144-847a-3b9d9b557402.s.123	Dailymed.b078dae2-664d-4144-847a-3b9d9b557402.s.123.e.3	Decrease_Interaction	C54358	"Warfarin : <LABELDRUG> administered for 10 days slightly decreased the mean <PRECIPITANT> trough plasma concentration, this decrease did not result in a change in International Normalized Ratio (INR)."
Dailymed.b078dae2-664d-4144-847a-3b9d9b557402.s.130	Dailymed.b078dae2-664d-4144-847a-3b9d9b557402.s.130.e.2	Increase_Interaction	C54357	@item Other <PRECIPITANT> : Additive effect or potentiation.
Dailymed.b078dae2-664d-4144-847a-3b9d9b557402.s.132	Dailymed.b078dae2-664d-4144-847a-3b9d9b557402.s.132.e.6	Decrease_Interaction	C54356	"Single doses of either cholestyramine or <PRECIPITANT> resins bind the <LABELDRUG> and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively."
Dailymed.b078dae2-664d-4144-847a-3b9d9b557402.s.132	Dailymed.b078dae2-664d-4144-847a-3b9d9b557402.s.132.e.5	Decrease_Interaction	C54356	"Single doses of either <PRECIPITANT> or colestipol resins bind the <LABELDRUG> and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively."
Dailymed.b078dae2-664d-4144-847a-3b9d9b557402.s.134	Dailymed.b078dae2-664d-4144-847a-3b9d9b557402.s.134.e.5	Decrease_Interaction	C54358	"@item Pressor amines (e.g., norepinephrine) : Possible decreased response to <PRECIPITANT> but not sufficient to preclude their use."
Dailymed.b078dae2-664d-4144-847a-3b9d9b557402.s.137	Dailymed.b078dae2-664d-4144-847a-3b9d9b557402.s.137.e.2	Increase_Interaction	C54357	<PRECIPITANT> reduce the renal clearance of lithium and add a high risk of lithium toxicity. 
Dailymed.b078dae2-664d-4144-847a-3b9d9b557402.s.137	Dailymed.b078dae2-664d-4144-847a-3b9d9b557402.s.137.e.3	Increase_Interaction	C54357	Diuretic agents reduce the renal clearance of <PRECIPITANT> and add a high risk of <PRECIPITANT> toxicity. 
Dailymed.b2d6e17b-f14a-463b-a662-03c9387c63dd.s.67	Dailymed.b2d6e17b-f14a-463b-a662-03c9387c63dd.s.67.e.3	Increase_Interaction	C54357	"Lithium renal clearance is reduced by <PRECIPITANT>, such as <LABELDRUG>, increasing the risk of lithium toxicity. "
Dailymed.b2d6e17b-f14a-463b-a662-03c9387c63dd.s.67	Dailymed.b2d6e17b-f14a-463b-a662-03c9387c63dd.s.67.e.2	Increase_Interaction	C54357	"<PRECIPITANT> renal clearance is reduced by diuretics, such as <LABELDRUG>, increasing the risk of lithium toxicity. "
Dailymed.b2d6e17b-f14a-463b-a662-03c9387c63dd.s.67	Dailymed.b2d6e17b-f14a-463b-a662-03c9387c63dd.s.67.e.8	Increase_Interaction	C54357	"Lithium renal clearance is reduced by diuretics, such as <LABELDRUG>, increasing the risk of <PRECIPITANT> toxicity. "
Dailymed.b2d6e17b-f14a-463b-a662-03c9387c63dd.s.69	Dailymed.b2d6e17b-f14a-463b-a662-03c9387c63dd.s.69.e.3	Increase_Interaction	C54357	"@item Renal clearance of lithium is reduced by <PRECIPITANT>, such as <LABELDRUG> increasing the risk of lithium toxicity (7)"
Dailymed.b2d6e17b-f14a-463b-a662-03c9387c63dd.s.69	Dailymed.b2d6e17b-f14a-463b-a662-03c9387c63dd.s.69.e.2	Increase_Interaction	C54357	"@item Renal clearance of <PRECIPITANT> is reduced by diuretics, such as <LABELDRUG> increasing the risk of <PRECIPITANT> toxicity (7)"
Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.31	Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.31.e.1	Decrease_Interaction	C54356	The concomitant use of <LABELDRUG> with <PRECIPITANT> (e.g. rifampin) reduces exposure to <LABELDRUG> and should generally be avoided [see Clinical Pharmacology (12.3)].
Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.33	Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.33.e.0	Increase_Interaction	C54355	Concomitant use of <PRECIPITANT> in patients with renal impairment is expected to produce increased exposure of <LABELDRUG> compared to that seen with either factor alone.
Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.37	Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.37.e.1	Decrease_Interaction	C54356	"The concomitant use of <LABELDRUG> with <PRECIPITANT> (e.g., rifampin) reduces exposure to <LABELDRUG> and should generally be avoided [see Clinical Pharmacology (12.3)]."
Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.39	Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.39.e.0	Increase_Interaction	C54355	Concomitant use of <PRECIPITANT> in patients with renal impairment is expected to produce increased exposure of <LABELDRUG> compared to that seen with either factor alone.
Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.46	Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.46.e.0	Decrease_Interaction	C54615	"<PRECIPITANT>: <PRECIPITANT> 600 mg once daily for 7 days followed by a single dose of <LABELDRUG> decreased its AUC and Cmax by 66% and 67%, respectively. "
Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.51	Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.51.e.1	Increase_Interaction	C54355	Dronedarone: Simultaneous administration of <LABELDRUG> and <PRECIPITANT> (administered once or twice daily) increases exposure to <LABELDRUG> by 70 to 140% compared to <LABELDRUG> alone. 
Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.53	Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.53.e.3	Increase_Interaction	C54602	"Ketoconazole: <PRECIPITANT> increased <LABELDRUG> AUC and Cmax values by 138% and 135%, respectively, after a single dose of 400 mg, and 153%, and 149%, respectively, after multiple daily doses of 400 mg."
Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.54	Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.54.e.4	Increase_Interaction	C54602	"Verapamil: When <LABELDRUG> was coadministered with <PRECIPITANT>, the Cmax and AUC of <LABELDRUG> were increased. "
Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.56	Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.56.e.10	Increase_Interaction	C54355	"If <PRECIPITANT> is present in the gut when <LABELDRUG> is taken, it will increase exposure to <LABELDRUG> with the greatest increase observed when a single dose of immediate-release <PRECIPITANT> is given one hour prior to <LABELDRUG> (AUC increased by a factor of 2.4). "
Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.60	Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.60.e.3	Decrease_Interaction	C54356	The increase in exposure was mitigated by a 65% increase in the renal clearance of <LABELDRUG> in the presence of <PRECIPITANT>. 
Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.65	Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.65.e.0	Increase_Interaction	C54602	"Concomitant <PRECIPITANT> administration increased <LABELDRUG> s AUC and Cmax by 53% and 56%, respectively."
Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.68	Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.68.e.4	Increase_Interaction	C54602	"Clopidogrel: When <LABELDRUG> was given concomitantly with a loading dose of 300 mg or 600 mg <PRECIPITANT>, the <LABELDRUG> AUC and Cmax increased by approximately 30% and 40%, respectively. "
Dailymed.bb05420c-fd24-4672-9f62-fdd313819287.s.30	Dailymed.bb05420c-fd24-4672-9f62-fdd313819287.s.30.e.0	Increase_Interaction	C54357	"<PRECIPITANT>: <PRECIPITANT> (e.g., reserpine) may have an additive effect when given with beta-blocking agents or monoamine oxidase (MAO) inhibitors. "
Dailymed.bb05420c-fd24-4672-9f62-fdd313819287.s.30	Dailymed.bb05420c-fd24-4672-9f62-fdd313819287.s.30.e.3	Increase_Interaction	C54357	"Catecholamine-depleting drugs: Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with <PRECIPITANT> or monoamine oxidase (MAO) inhibitors. "
Dailymed.bb05420c-fd24-4672-9f62-fdd313819287.s.30	Dailymed.bb05420c-fd24-4672-9f62-fdd313819287.s.30.e.4	Increase_Interaction	C54357	"Catecholamine-depleting drugs: Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents or <PRECIPITANT>. "
Dailymed.bb05420c-fd24-4672-9f62-fdd313819287.s.40	Dailymed.bb05420c-fd24-4672-9f62-fdd313819287.s.40.e.0	Increase_Interaction	C54355	CYP2D6 Inhibitors: <PRECIPITANT> may increase the plasma concentration of <LABELDRUG> which would mimic the pharmacokinetics of CYP2D6 poor metabolizer (see Pharmacokinetics section). 
Dailymed.bb05420c-fd24-4672-9f62-fdd313819287.s.43	Dailymed.bb05420c-fd24-4672-9f62-fdd313819287.s.43.e.0	Increase_Interaction	C54355	Hydralazine: Concomitant administration of <PRECIPITANT> may inhibit presystemic metabolism of <LABELDRUG> leading to increased concentrations of <LABELDRUG>.
Dailymed.bcdeafac-f4ef-4dda-bdb7-1f819c33bb76.s.26	Dailymed.bcdeafac-f4ef-4dda-bdb7-1f819c33bb76.s.26.e.0	Increase_Interaction	C54355	"<PRECIPITANT>, which has been shown to increase significantly the bioavailability of <LABELDRUG> and other dihydropyridine type calcium channel blockers, should not be taken with <LABELDRUG>."
Dailymed.bcdeafac-f4ef-4dda-bdb7-1f819c33bb76.s.26	Dailymed.bcdeafac-f4ef-4dda-bdb7-1f819c33bb76.s.26.e.4	Increase_Interaction	C54355	"Grapefruit juice, which has been shown to increase significantly the bioavailability of <LABELDRUG> and other <PRECIPITANT>, should not be taken with <LABELDRUG>."
Dailymed.bcdeafac-f4ef-4dda-bdb7-1f819c33bb76.s.34	Dailymed.bcdeafac-f4ef-4dda-bdb7-1f819c33bb76.s.34.e.0	Increase_Interaction	C54602	A 30 to 45% increase in AUC and Cmax of <LABELDRUG> was observed with concomitant administration of <PRECIPITANT> 400 mg twice daily. 
Dailymed.bcdeafac-f4ef-4dda-bdb7-1f819c33bb76.s.39	Dailymed.bcdeafac-f4ef-4dda-bdb7-1f819c33bb76.s.39.e.0	Decrease_Interaction	C54356	Coadministration of <PRECIPITANT> with a dose bioequivalent to 34 mg <LABELDRUG> tablets in epileptic patients lowered the <LABELDRUG> plasma concentrations to undetectable levels. 
Dailymed.bcdeafac-f4ef-4dda-bdb7-1f819c33bb76.s.44	Dailymed.bcdeafac-f4ef-4dda-bdb7-1f819c33bb76.s.44.e.0	Decrease_Interaction	C54356	"<PRECIPITANT> at 648 mg bid decreased the bioavailability (AUC) of <LABELDRUG> by 26%, but not the peak concentration. "
Dailymed.bcdeafac-f4ef-4dda-bdb7-1f819c33bb76.s.45	Dailymed.bcdeafac-f4ef-4dda-bdb7-1f819c33bb76.s.45.e.3	Increase_Interaction	C54357	Immediate release <LABELDRUG> increased plasma <PRECIPITANT> concentrations by about 20%. 
Dailymed.bd936e35-1af8-42da-bcc0-f22489d68574.s.10	Dailymed.bd936e35-1af8-42da-bcc0-f22489d68574.s.10.e.3	Increase_Interaction	C54357	<PRECIPITANT> may add to or potentiate the action of other antihypertensive drugs.
Dailymed.bd936e35-1af8-42da-bcc0-f22489d68574.s.10	Dailymed.bd936e35-1af8-42da-bcc0-f22489d68574.s.10.e.2	Increase_Interaction	C54357	Thiazides may add to or potentiate the action of other <PRECIPITANT>.
Dailymed.bd936e35-1af8-42da-bcc0-f22489d68574.s.45	Dailymed.bd936e35-1af8-42da-bcc0-f22489d68574.s.45.e.6	Increase_Interaction	C54356	Cholestyramine and colestipol resins - Both <PRECIPITANT> and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract.
Dailymed.bd936e35-1af8-42da-bcc0-f22489d68574.s.45	Dailymed.bd936e35-1af8-42da-bcc0-f22489d68574.s.45.e.5	Increase_Interaction	C54356	Cholestyramine and <PRECIPITANT> resins - Both cholestyramine and <PRECIPITANT> resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract.
Dailymed.bd936e35-1af8-42da-bcc0-f22489d68574.s.47	Dailymed.bd936e35-1af8-42da-bcc0-f22489d68574.s.47.e.5	Decrease_Interaction	C54358	"Pressor amines (e.g., norepinephrine) - possible decreased response to <PRECIPITANT> but not sufficient to preclude their use."
Dailymed.bd936e35-1af8-42da-bcc0-f22489d68574.s.50	Dailymed.bd936e35-1af8-42da-bcc0-f22489d68574.s.50.e.2	Increase_Interaction	C54357	<PRECIPITANT> reduce the renal clearance of lithium and add a high risk of lithium toxicity. 
Dailymed.bd936e35-1af8-42da-bcc0-f22489d68574.s.50	Dailymed.bd936e35-1af8-42da-bcc0-f22489d68574.s.50.e.3	Increase_Interaction	C54357	Diuretic agents reduce the renal clearance of <PRECIPITANT> and add a high risk of <PRECIPITANT> toxicity. 
Dailymed.bf3007e2-8fcc-48de-8fd5-55e95033d62f.s.176	Dailymed.bf3007e2-8fcc-48de-8fd5-55e95033d62f.s.176.e.0	Increase_Interaction	C54357	"Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with <PRECIPITANT>, including ACE inhibitors. "
Dailymed.bf3007e2-8fcc-48de-8fd5-55e95033d62f.s.176	Dailymed.bf3007e2-8fcc-48de-8fd5-55e95033d62f.s.176.e.5	Increase_Interaction	C54357	"<PRECIPITANT>: <PRECIPITANT> toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. "
Dailymed.bf3007e2-8fcc-48de-8fd5-55e95033d62f.s.177	Dailymed.bf3007e2-8fcc-48de-8fd5-55e95033d62f.s.177.e.2	Increase_Interaction	C54357	A few cases of <PRECIPITANT> toxicity have been reported in patients receiving concomitant <LABELDRUG> and <PRECIPITANT> and were reversible upon discontinuation of both drugs. 
Dailymed.bf3007e2-8fcc-48de-8fd5-55e95033d62f.s.184	Dailymed.bf3007e2-8fcc-48de-8fd5-55e95033d62f.s.184.e.0	Increase_Interaction	C54357	Other <PRECIPITANT>   additive effect or potentiation.
Dailymed.bf3007e2-8fcc-48de-8fd5-55e95033d62f.s.186	Dailymed.bf3007e2-8fcc-48de-8fd5-55e95033d62f.s.186.e.0	Decrease_Interaction	C54356	"Single doses of either <PRECIPITANT> or colestipol resins bind the <LABELDRUG> and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively."
Dailymed.bf3007e2-8fcc-48de-8fd5-55e95033d62f.s.186	Dailymed.bf3007e2-8fcc-48de-8fd5-55e95033d62f.s.186.e.1	Decrease_Interaction	C54356	"Single doses of either cholestyramine or <PRECIPITANT> bind the <LABELDRUG> and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively."
Dailymed.bf3007e2-8fcc-48de-8fd5-55e95033d62f.s.188	Dailymed.bf3007e2-8fcc-48de-8fd5-55e95033d62f.s.188.e.5	Decrease_Interaction	C54358	"Pressor amines (e.g., norepinephrine)   possible decreased response to <PRECIPITANT> but not sufficient to preclude their use."
Dailymed.bf3007e2-8fcc-48de-8fd5-55e95033d62f.s.191	Dailymed.bf3007e2-8fcc-48de-8fd5-55e95033d62f.s.191.e.0	Increase_Interaction	C54357	<PRECIPITANT> reduce the renal clearance of lithium and add a high risk of lithium toxicity. 
Dailymed.bf3007e2-8fcc-48de-8fd5-55e95033d62f.s.191	Dailymed.bf3007e2-8fcc-48de-8fd5-55e95033d62f.s.191.e.6	Increase_Interaction	C54357	Diuretic agents reduce the renal clearance of <PRECIPITANT> and add a high risk of <PRECIPITANT> toxicity. 
Dailymed.bf79c059-2ad6-4644-cc9b-44217515a780.s.47	Dailymed.bf79c059-2ad6-4644-cc9b-44217515a780.s.47.e.0	Increase_Interaction	C54357	Coadministration of <PRECIPITANT> with <LABELDRUG> has been reported to reduce the clearance of <LABELDRUG> from the plasma and may result in toxic accumulation of the drug.
Dailymed.c21325a9-cd57-4e39-98f2-0727ed8abb2d.s.27	Dailymed.c21325a9-cd57-4e39-98f2-0727ed8abb2d.s.27.e.1	Increase_Interaction	C54357	The effects of <LABELDRUG> on <PRECIPITANT> including alcohol may be additive.
Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.128	Dailymed.c4caf469-f684-4f6d-98e8-b6a2fff1de98.s.128.e.1	Decrease_Interaction	C54615	"Administration of <LABELDRUG> within 2 hours of <PRECIPITANT> should be avoided because it may result in a reduction in Cmax and AUC of 26% and 20%, respectively and consequently in a 25% reduction in the bradycardic effect at rest. "
Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.114	Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.114.e.0	Increase_Interaction	C54357	"It has been reported that <LABELDRUG> decreases neuromuscular transmission in patients with Duchenne's muscular dystrophy, prolongs recovery from the neuromuscular blocking agent <PRECIPITANT>, and causes a worsening of myasthenia gravis. "
Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.129	Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.129.e.1	Increase_Interaction	C54355	"Clinically significant interactions have been reported with <PRECIPITANT> (e.g., erythromycin, ritonavir) causing elevation of plasma levels of <LABELDRUG> while inducers of CYP3A4 (e.g., rifampin) have caused a lowering of plasma levels of <LABELDRUG>."
Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.129	Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.129.e.6	Decrease_Interaction	C54358	"Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g., erythromycin, ritonavir) causing elevation of plasma levels of <LABELDRUG> while <PRECIPITANT> (e.g., rifampin) have caused a lowering of plasma levels of <LABELDRUG>."
Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.132	Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.132.e.3	Increase_Interaction	C54355	Co-administration of multiple doses of 10 mg of <LABELDRUG> with 80 mg <PRECIPITANT> resulted in exposure to <PRECIPITANT> 2.5-fold that following <PRECIPITANT> alone. 
Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.137	Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.137.e.1	Increase_Interaction	C54357	<LABELDRUG> may increase blood <PRECIPITANT> concentrations and prolong its effects.
Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.141	Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.141.e.1	Increase_Interaction	C54355	<PRECIPITANT> may significantly increase concentrations of <LABELDRUG>. 
Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.142	Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.142.e.0	Increase_Interaction	C54357	"<PRECIPITANT> given to nine healthy volunteers increased S- and R- <LABELDRUG> AUC0 12 by 36% and 28%, respectively. "
Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.143	Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.143.e.0	Increase_Interaction	C54602	"Steady state Cmax and Cmin of S-<LABELDRUG> increased by 57% and 16.7%, respectively, with <PRECIPITANT> compared to control. "
Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.155	Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.155.e.1	Increase_Interaction	C54357	A decrease in <PRECIPITANT> and propranolol clearance has been observed when either drug is administered concomitantly with <LABELDRUG>. 
Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.155	Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.155.e.2	Increase_Interaction	C54357	A decrease in metoprolol and <PRECIPITANT> clearance has been observed when either drug is administered concomitantly with <LABELDRUG>. 
Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.159	Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.159.e.3	Increase_Interaction	C54357	"However, chronic <LABELDRUG> treatment can increase serum <PRECIPITANT> levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity. "
Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.159	Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.159.e.6	Increase_Interaction	C54357	"However, chronic <LABELDRUG> treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in <PRECIPITANT> toxicity. "
Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.161	Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.161.e.5	Increase_Interaction	C54357	"<LABELDRUG> may reduce total body clearance and extrarenal clearance of <PRECIPITANT> by 27% and 29%, respectively. "
Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.182	Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.182.e.0	Increase_Interaction	C54357	There has been a report of increased <PRECIPITANT> levels during <LABELDRUG> therapy.
Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.196	Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.196.e.1	Increase_Interaction	C54357	<LABELDRUG> therapy may increase <PRECIPITANT> concentrations during combined therapy. 
Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.199	Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.199.e.0	Decrease_Interaction	C54356	Therapy with <PRECIPITANT> may markedly reduce oral <LABELDRUG> bioavailability.
Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.201	Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.201.e.0	Decrease_Interaction	C54356	<PRECIPITANT> therapy may increase <LABELDRUG> clearance.
Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.203	Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.203.e.1	Increase_Interaction	C54357	<LABELDRUG> therapy may increase serum levels of <PRECIPITANT>.
Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.205	Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.205.e.1	Increase_Interaction	C54357	<LABELDRUG> may inhibit the clearance and increase the plasma levels of <PRECIPITANT>.
Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.210	Dailymed.c56b20d8-eeee-4d87-94a1-ae186f9b550e.s.210.e.3	Increase_Interaction	C54357	Clinical data and animal studies suggest that <LABELDRUG> may potentiate the activity of <PRECIPITANT>. 
Dailymed.c57982f2-c7da-488a-7ea9-b9609439ac68.s.100	Dailymed.c57982f2-c7da-488a-7ea9-b9609439ac68.s.100.e.2	Increase_Interaction	C54357	Modest increases in mean trough <PRECIPITANT> concentrations were observed following initiation of <LABELDRUG> treatment in 21 renal transplant subjects suffering from chronic vascular rejection. 
Dailymed.c57982f2-c7da-488a-7ea9-b9609439ac68.s.107	Dailymed.c57982f2-c7da-488a-7ea9-b9609439ac68.s.107.e.2	Increase_Interaction	C54357	<PRECIPITANT> concentrations are increased by about 15% when digoxin and <LABELDRUG> are administered concomitantly. 
Dailymed.c57982f2-c7da-488a-7ea9-b9609439ac68.s.110	Dailymed.c57982f2-c7da-488a-7ea9-b9609439ac68.s.110.e.0	Decrease_Interaction	C54356	<PRECIPITANT> reduced plasma concentrations of <LABELDRUG> by about 70% [see Clinical Pharmacology (12.5)]. 
Dailymed.c57982f2-c7da-488a-7ea9-b9609439ac68.s.111	Dailymed.c57982f2-c7da-488a-7ea9-b9609439ac68.s.111.e.0	Increase_Interaction	C54613	<PRECIPITANT> increased AUC by about 30% but caused no change in Cmax[see Clinical Pharmacology (12.5)].
Dailymed.c57982f2-c7da-488a-7ea9-b9609439ac68.s.113	Dailymed.c57982f2-c7da-488a-7ea9-b9609439ac68.s.113.e.1	Increase_Interaction	C54357	"<PRECIPITANT>, and its metabolite desethyl amiodarone, inhibitors of CYP2C9 and P-glycoprotein, increased concentrations of the S(-)-enantiomer of <LABELDRUG> by at least 2-fold [see Clinical Pharmacology (12.5)]. "
Dailymed.c57982f2-c7da-488a-7ea9-b9609439ac68.s.113	Dailymed.c57982f2-c7da-488a-7ea9-b9609439ac68.s.113.e.2	Increase_Interaction	C54357	"Amiodarone, and its <PRECIPITANT>, inhibitors of CYP2C9 and P-glycoprotein, increased concentrations of the S(-)-enantiomer of <LABELDRUG> by at least 2-fold [see Clinical Pharmacology (12.5)]. "
Dailymed.c57982f2-c7da-488a-7ea9-b9609439ac68.s.126	Dailymed.c57982f2-c7da-488a-7ea9-b9609439ac68.s.126.e.2	Increase_Interaction	C54355	"In a pharmacokinetic trial conducted in 106 Japanese subjects with heart failure, coadministration of small loading and maintenance doses of <PRECIPITANT> with <LABELDRUG> resulted in at least a 2-fold increase in the steady-state trough concentrations of S(-)-<LABELDRUG> [see Drug Interactions (7.6)]."
Dailymed.c57982f2-c7da-488a-7ea9-b9609439ac68.s.128	Dailymed.c57982f2-c7da-488a-7ea9-b9609439ac68.s.128.e.1	Increase_Interaction	C54605	"In a pharmacokinetic trial conducted in 10 healthy male subjects, <PRECIPITANT> (1,000 mg/day) increased the steady-state AUC of <LABELDRUG> by 30% with no change in Cmax [see Drug Interactions (7.5)]."
Dailymed.c57982f2-c7da-488a-7ea9-b9609439ac68.s.130	Dailymed.c57982f2-c7da-488a-7ea9-b9609439ac68.s.130.e.4	Increase_Interaction	C54357	"Following concomitant administration of <LABELDRUG> (25 mg once daily) and <PRECIPITANT> (0.25 mg once daily) for 14 days, steady-state AUC and trough concentrations of <PRECIPITANT> were increased by 14% and 16%, respectively, in 12 hypertensive subjects [see Drug Interactions (7.4)]."
Dailymed.c57982f2-c7da-488a-7ea9-b9609439ac68.s.137	Dailymed.c57982f2-c7da-488a-7ea9-b9609439ac68.s.137.e.1	Decrease_Interaction	C54606	"In a pharmacokinetic trial conducted in 8 healthy male subjects, <PRECIPITANT> (600 mg daily for 12 days) decreased the AUC and Cmax of <LABELDRUG> by about 70% [see Drug Interactions (7.5)]."
Dailymed.ca68879c-0214-4d7c-93b0-bdaf8ef23f8e.s.15	Dailymed.ca68879c-0214-4d7c-93b0-bdaf8ef23f8e.s.15.e.3	Increase_Interaction	C54357	Adenosine: <LABELDRUG> has been reported to increase the plasma levels and cardiovascular effects of <PRECIPITANT>. 
Dailymed.cb97d4a0-89ed-407c-a763-209386b6f75c.s.14	Dailymed.cb97d4a0-89ed-407c-a763-209386b6f75c.s.14.e.1	Decrease_Interaction	C54356	"Do not add <LABELDRUG> Injection, USP to any alkaline diluent solution since <LABELDRUG> is inactivated in <PRECIPITANT>."
Dailymed.cb97d4a0-89ed-407c-a763-209386b6f75c.s.64	Dailymed.cb97d4a0-89ed-407c-a763-209386b6f75c.s.64.e.1	Increase_Interaction	C54357	"Because <PRECIPITANT> is metabolized by monoamine oxidase (MAO), inhibition of this enzyme prolongs and potentiates the effect of <PRECIPITANT>. "
Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.36	Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.36.e.0	Increase_Interaction	C54602	"Co-administration of a <PRECIPITANT> (e.g., gemfibrozil) may increase exposure (both Cmax and AUC) to <LABELDRUG>. "
Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.37	Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.37.e.0	Decrease_Interaction	C54356	"Co-administration of a <PRECIPITANT> (e.g., rifampin) may decrease exposure to <LABELDRUG>. "
Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.55	Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.55.e.1	Increase_Interaction	C54602	Human pharmacokinetic studies with an oral formulation of <LABELDRUG> (<LABELDRUG> diolamine) indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor <PRECIPITANT> increases exposure (both Cmax and AUC) to <LABELDRUG>. 
Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.56	Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.56.e.1	Decrease_Interaction	C54356	Co-administration of the CYP2C8 enzyme inducer <PRECIPITANT> decreases exposure to <LABELDRUG>. 
Dailymed.ce141ca0-d734-11df-8537-0002a5d5c51b.s.32	Dailymed.ce141ca0-d734-11df-8537-0002a5d5c51b.s.32.e.0	Increase_Interaction	C54357	<PRECIPITANT>: <PRECIPITANT> increases CARDENE plasma levels. 
Dailymed.ce141ca0-d734-11df-8537-0002a5d5c51b.s.32	Dailymed.ce141ca0-d734-11df-8537-0002a5d5c51b.s.32.e.1	Increase_Interaction	C54357	Cimetidine: Cimetidine increases <PRECIPITANT> plasma levels. 
Dailymed.ce141ca0-d734-11df-8537-0002a5d5c51b.s.34	Dailymed.ce141ca0-d734-11df-8537-0002a5d5c51b.s.34.e.0	Increase_Interaction	C54357	Digoxin: Some <PRECIPITANT> may increase the concentration of digitalis preparations in the blood. 
Dailymed.ce141ca0-d734-11df-8537-0002a5d5c51b.s.34	Dailymed.ce141ca0-d734-11df-8537-0002a5d5c51b.s.34.e.3	Increase_Interaction	C54357	Digoxin: Some calcium blockers may increase the concentration of <PRECIPITANT> in the blood. 
Dailymed.ce141ca0-d734-11df-8537-0002a5d5c51b.s.39	Dailymed.ce141ca0-d734-11df-8537-0002a5d5c51b.s.39.e.3	Increase_Interaction	C54357	Cyclosporine: Concomitant administration of <LABELDRUG> and <PRECIPITANT> results in elevated plasma <PRECIPITANT> levels. 
Dailymed.cfb9309f-e0df-4a55-9542-0e869fce05fb.s.52	Dailymed.cfb9309f-e0df-4a55-9542-0e869fce05fb.s.52.e.4	Increase_Interaction	C54357	"Digoxin : When <LABELDRUG> was co-administered with <PRECIPITANT>, median increases in <PRECIPITANT> peak plasma concentration (49%) and in trough concentration (20%) were observed. "
Dailymed.cfb9309f-e0df-4a55-9542-0e869fce05fb.s.54	Dailymed.cfb9309f-e0df-4a55-9542-0e869fce05fb.s.54.e.0	Increase_Interaction	C54357	Lithium : Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with <PRECIPITANT> including <LABELDRUG>. 
Dailymed.cfb9309f-e0df-4a55-9542-0e869fce05fb.s.54	Dailymed.cfb9309f-e0df-4a55-9542-0e869fce05fb.s.54.e.5	Increase_Interaction	C54357	Lithium : Reversible increases in serum <PRECIPITANT> concentrations and toxicity have been reported during concomitant administration of <PRECIPITANT> with angiotensin II receptor antagonists including <LABELDRUG>. 
Dailymed.cfb9309f-e0df-4a55-9542-0e869fce05fb.s.60	Dailymed.cfb9309f-e0df-4a55-9542-0e869fce05fb.s.60.e.9	Increase_Interaction	C54610	"Ramipril and Ramiprilat : Co-administration of <LABELDRUG> 80 mg once daily and <PRECIPITANT> 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of <PRECIPITANT> 2.3- and 2.1-fold, respectively, and Cmax and AUC of <PRECIPITANT>at 2.4- and 1.5-fold, respectively. "
Dailymed.cfb9309f-e0df-4a55-9542-0e869fce05fb.s.60	Dailymed.cfb9309f-e0df-4a55-9542-0e869fce05fb.s.60.e.10	Increase_Interaction	C54610	"Ramipril and Ramiprilat : Co-administration of <LABELDRUG> 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of <PRECIPITANT> 2.4- and 1.5-fold, respectively. "
Dailymed.cfb9309f-e0df-4a55-9542-0e869fce05fb.s.62	Dailymed.cfb9309f-e0df-4a55-9542-0e869fce05fb.s.62.e.5	Increase_Interaction	C54357	"When co-administering <LABELDRUG> and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and <PRECIPITANT> in the presence of <LABELDRUG>. "
Dailymed.cfb9309f-e0df-4a55-9542-0e869fce05fb.s.62	Dailymed.cfb9309f-e0df-4a55-9542-0e869fce05fb.s.62.e.4	Increase_Interaction	C54357	"When co-administering <LABELDRUG> and <PRECIPITANT>, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to <PRECIPITANT> and <PRECIPITANT>at in the presence of <LABELDRUG>. "
Dailymed.d0caec89-96ec-411d-a933-63eda74a6da7.s.41	Dailymed.d0caec89-96ec-411d-a933-63eda74a6da7.s.41.e.3	Increase_Interaction	C54357	Simvastatin: Coadministration of <PRECIPITANT> with <LABELDRUG> increases the systemic exposure of <PRECIPITANT>. 
Dailymed.d0caec89-96ec-411d-a933-63eda74a6da7.s.43	Dailymed.d0caec89-96ec-411d-a933-63eda74a6da7.s.43.e.0	Increase_Interaction	C54355	CYP3A4 Inhibitors: Coadministration with <PRECIPITANT> result in increased systemic exposure to <LABELDRUG> warranting dose reduction. 
Dailymed.d0caec89-96ec-411d-a933-63eda74a6da7.s.59	Dailymed.d0caec89-96ec-411d-a933-63eda74a6da7.s.59.e.0	Increase_Interaction	C54355	"Coadministration of <PRECIPITANT> (rifampin, cyclosporine) or efflux transporter (ritonavir) may increase the systemic exposure to <LABELDRUG>."
Dailymed.d44637a7-b980-4bb1-832c-f5a0f73f8259.s.35	Dailymed.d44637a7-b980-4bb1-832c-f5a0f73f8259.s.35.e.3	Increase_Interaction	C54357	<PRECIPITANT> may add to or potentiate the action of other antihypertensive drugs.
Dailymed.d44637a7-b980-4bb1-832c-f5a0f73f8259.s.35	Dailymed.d44637a7-b980-4bb1-832c-f5a0f73f8259.s.35.e.2	Increase_Interaction	C54357	Thiazides may add to or potentiate the action of other <PRECIPITANT>.
Dailymed.d44637a7-b980-4bb1-832c-f5a0f73f8259.s.105	Dailymed.d44637a7-b980-4bb1-832c-f5a0f73f8259.s.105.e.2	Increase_Interaction	C54357	<PRECIPITANT> reduce the renal clearance of lithium and add a high risk of lithium toxicity.
Dailymed.d44637a7-b980-4bb1-832c-f5a0f73f8259.s.105	Dailymed.d44637a7-b980-4bb1-832c-f5a0f73f8259.s.105.e.3	Increase_Interaction	C54357	Diuretic agents reduce the renal clearance of <PRECIPITANT> and add a high risk of <PRECIPITANT> toxicity.
Dailymed.d44637a7-b980-4bb1-832c-f5a0f73f8259.s.109	Dailymed.d44637a7-b980-4bb1-832c-f5a0f73f8259.s.109.e.2	Increase_Interaction	C54611	Digoxin: <LABELDRUG> has been shown to increase the half-life of <PRECIPITANT>. 
Dailymed.d44637a7-b980-4bb1-832c-f5a0f73f8259.s.110	Dailymed.d44637a7-b980-4bb1-832c-f5a0f73f8259.s.110.e.2	Increase_Interaction	C54357	This may result in increased serum <PRECIPITANT> levels and subsequent digitalis toxicity. 
Dailymed.d44637a7-b980-4bb1-832c-f5a0f73f8259.s.110	Dailymed.d44637a7-b980-4bb1-832c-f5a0f73f8259.s.110.e.5	Increase_Interaction	C54357	This may result in increased serum digoxin levels and subsequent <PRECIPITANT> toxicity. 
Dailymed.d5b85158-b0d6-4855-9d07-8d1b3ad9ab71.s.60	Dailymed.d5b85158-b0d6-4855-9d07-8d1b3ad9ab71.s.60.e.2	Decrease_Interaction	C54358	"As with other <PRECIPITANT>, blood concentrations of dialyzable drugs may be reduced by dialysis. "
Dailymed.d5b85158-b0d6-4855-9d07-8d1b3ad9ab71.s.60	Dailymed.d5b85158-b0d6-4855-9d07-8d1b3ad9ab71.s.60.e.3	Decrease_Interaction	C54358	"As with other dialysis solutions, blood concentrations of <PRECIPITANT> may be reduced by dialysis. "
Dailymed.d669ff68-ddcf-42f6-913c-d8f1aedbd9c4.s.49	Dailymed.d669ff68-ddcf-42f6-913c-d8f1aedbd9c4.s.49.e.3	Increase_Interaction	C54357	"In a pharmacokinetic substudy in patients with congestive heart failure receiving <PRECIPITANT> or digoxin in whom therapy with <LABELDRUG> was initiated, apparent oral clearance values for <PRECIPITANT> (n 23) and digoxin (n 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87. "
Dailymed.d669ff68-ddcf-42f6-913c-d8f1aedbd9c4.s.49	Dailymed.d669ff68-ddcf-42f6-913c-d8f1aedbd9c4.s.49.e.4	Increase_Interaction	C54357	"In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or <PRECIPITANT> in whom therapy with <LABELDRUG> was initiated, apparent oral clearance values for furosemide (n 23) and <PRECIPITANT> (n 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87. "
Dailymed.d669ff68-ddcf-42f6-913c-d8f1aedbd9c4.s.51	Dailymed.d669ff68-ddcf-42f6-913c-d8f1aedbd9c4.s.51.e.2	Increase_Interaction	C54357	"However, patients on <PRECIPITANT> may show elevations of <PRECIPITANT> concentrations after initiation of therapy with <LABELDRUG>, which may be clinically significant in patients prone to <PRECIPITANT> toxicity."
Dailymed.d669ff68-ddcf-42f6-913c-d8f1aedbd9c4.s.54	Dailymed.d669ff68-ddcf-42f6-913c-d8f1aedbd9c4.s.54.e.2	Increase_Interaction	C54357	@item Patients on <PRECIPITANT>: elevations of <PRECIPITANT> concentrations clinically significant in patients prone to <PRECIPITANT> toxicity (7)
Dailymed.d76a0419-05ee-437e-884c-65807aea9569.s.77	Dailymed.d76a0419-05ee-437e-884c-65807aea9569.s.77.e.8	Increase_Interaction	C54355	"Coadministration of <PRECIPITANT> (rifampin, cyclosporine) or efflux transporter (ritonavir) may increase the systemic exposure to <LABELDRUG>."
Dailymed.d76a0419-05ee-437e-884c-65807aea9569.s.90	Dailymed.d76a0419-05ee-437e-884c-65807aea9569.s.90.e.2	Increase_Interaction	C54357	Lithium - <PRECIPITANT> increase the risk of lithium toxicity. 
Dailymed.d76a0419-05ee-437e-884c-65807aea9569.s.90	Dailymed.d76a0419-05ee-437e-884c-65807aea9569.s.90.e.3	Increase_Interaction	C54357	Lithium - Diuretic agents increase the risk of <PRECIPITANT> toxicity. 
Dailymed.d76a0419-05ee-437e-884c-65807aea9569.s.98	Dailymed.d76a0419-05ee-437e-884c-65807aea9569.s.98.e.2	Decrease_Interaction	C54358	@item Cholestyramine and <PRECIPITANT>: Reduced absorption of thiazides (12.3).
Dailymed.d76a0419-05ee-437e-884c-65807aea9569.s.98	Dailymed.d76a0419-05ee-437e-884c-65807aea9569.s.98.e.4	Decrease_Interaction	C54358	@item <PRECIPITANT> and colestipol: Reduced absorption of thiazides (12.3).
Dailymed.d76a0419-05ee-437e-884c-65807aea9569.s.98	Dailymed.d76a0419-05ee-437e-884c-65807aea9569.s.98.e.3	Decrease_Interaction	C54358	@item Cholestyramine and colestipol: Reduced absorption of <PRECIPITANT> (12.3).
Dailymed.d76a0419-05ee-437e-884c-65807aea9569.s.99	Dailymed.d76a0419-05ee-437e-884c-65807aea9569.s.99.e.2	Increase_Interaction	C54357	@item Lithium: <PRECIPITANT> increase risk of lithium toxicity. 
Dailymed.d76a0419-05ee-437e-884c-65807aea9569.s.99	Dailymed.d76a0419-05ee-437e-884c-65807aea9569.s.99.e.3	Increase_Interaction	C54357	@item Lithium: Diuretics increase risk of <PRECIPITANT> toxicity. 
Dailymed.d7f569dc-6bed-42dc-9bec-940a9e6b090d.s.31	Dailymed.d7f569dc-6bed-42dc-9bec-940a9e6b090d.s.31.e.6	Decrease_Interaction	C54356	"If a patient receiving <LABELDRUG> is also taking <PRECIPITANT>, the hypotensive effect of <LABELDRUG> may be reduced, necessitating an increase in the <LABELDRUG> dose. "
Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.24	Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.24.e.2	Increase_Interaction	C54357	"During administration of multiple oral doses of <LABELDRUG> to healthy subjects stabilized on a maintenance dose of <PRECIPITANT>, a 13% - 19% increase in plasma <PRECIPITANT> levels occurred at six hours postdose."
Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.25	Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.25.e.7	Increase_Interaction	C54357	"In a study involving healthy subjects receiving <LABELDRUG> and <PRECIPITANT> concurrently, plasma <LABELDRUG> levels were increased about 20% and <PRECIPITANT> levels were increased about 30% compared to control values. "
Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.34	Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.34.e.3	Decrease_Interaction	C54356	"Limited data in patients receiving known <PRECIPITANT> (phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of <LABELDRUG> elimination. "
Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.35	Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.35.e.5	Increase_Interaction	C54603	"In healthy subjects receiving <PRECIPITANT> (1 gm daily) for one week, plasma <LABELDRUG> levels increased by about 30% and half-life increased by about 10%."
Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.36	Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.36.e.3	Increase_Interaction	C54355	"When <PRECIPITANT> is added to <LABELDRUG> therapy, plasma <LABELDRUG> levels may increase two-fold or more in some patients, if <LABELDRUG> dosage is not reduced. "
Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.38	Dailymed.da585354-87e0-4f8c-90e9-3cbc3496a27a.s.38.e.2	Increase_Interaction	C54355	"<PRECIPITANT>, such as quinidine, might increase the plasma concentrations of <LABELDRUG> in patients that are on chronic <LABELDRUG> therapy, especially if these patients are extensive metabolizers."
Dailymed.de358060-f54a-4f36-a0d5-3f34122aba53.s.111	Dailymed.de358060-f54a-4f36-a0d5-3f34122aba53.s.111.e.2	Increase_Interaction	C54357	Other <PRECIPITANT> additive effect or potentiation. 
Dailymed.de358060-f54a-4f36-a0d5-3f34122aba53.s.113	Dailymed.de358060-f54a-4f36-a0d5-3f34122aba53.s.113.e.2	Decrease_Interaction	C54356	"Single doses of either cholestyramine or <PRECIPITANT> resins bind the <LABELDRUG> and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively. "
Dailymed.de358060-f54a-4f36-a0d5-3f34122aba53.s.113	Dailymed.de358060-f54a-4f36-a0d5-3f34122aba53.s.113.e.4	Decrease_Interaction	C54356	"Single doses of either <PRECIPITANT> or colestipol resins bind the <LABELDRUG> and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively. "
Dailymed.de358060-f54a-4f36-a0d5-3f34122aba53.s.115	Dailymed.de358060-f54a-4f36-a0d5-3f34122aba53.s.115.e.5	Decrease_Interaction	C54358	"Pressor amines (e.g., norepinephrine) possible decreased response to <PRECIPITANT> but not sufficient to preclude their use. "
Dailymed.de358060-f54a-4f36-a0d5-3f34122aba53.s.118	Dailymed.de358060-f54a-4f36-a0d5-3f34122aba53.s.118.e.3	Increase_Interaction	C54357	<PRECIPITANT> reduce the renal clearance of lithium and add a high risk of lithium toxicity. 
Dailymed.de358060-f54a-4f36-a0d5-3f34122aba53.s.118	Dailymed.de358060-f54a-4f36-a0d5-3f34122aba53.s.118.e.2	Increase_Interaction	C54357	Diuretic agents reduce the renal clearance of <PRECIPITANT> and add a high risk of <PRECIPITANT> toxicity. 
Dailymed.e04aa152-b08d-47f7-b976-f8bee4c386db.s.64	Dailymed.e04aa152-b08d-47f7-b976-f8bee4c386db.s.64.e.2	Decrease_Interaction	C54358	There have been rare reports of an interaction between <PRECIPITANT> and <LABELDRUG> (with a decreased plasma level of <PRECIPITANT>).
Dailymed.e04aa152-b08d-47f7-b976-f8bee4c386db.s.69	Dailymed.e04aa152-b08d-47f7-b976-f8bee4c386db.s.69.e.6	Increase_Interaction	C54355	A study in six healthy volunteers has shown a significant increase in peak <LABELDRUG> plasma levels (80%) and area-under-the-curve (74%) after a one week course of <PRECIPITANT> at 1000 mg per day and <LABELDRUG> at 40 mg per day. 
Dailymed.e04aa152-b08d-47f7-b976-f8bee4c386db.s.70	Dailymed.e04aa152-b08d-47f7-b976-f8bee4c386db.s.70.e.1	Increase_Interaction	C54355	"<PRECIPITANT> produced smaller, non-significant increases. "
Dailymed.e04aa152-b08d-47f7-b976-f8bee4c386db.s.75	Dailymed.e04aa152-b08d-47f7-b976-f8bee4c386db.s.75.e.5	Increase_Interaction	C54602	Co-administration of <LABELDRUG> with <PRECIPITANT> resulted in approximately a 2-fold increase in <LABELDRUG> AUC and Cmax with no change in half-life. 
Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66	Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66.e.3	Decrease_Interaction	C54356	"If phenytoin or other <PRECIPITANT> are taken concurrently with <LABELDRUG> or <LABELDRUG> CR, lower plasma levels of <LABELDRUG> may occur. "
Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66	Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66.e.4	Decrease_Interaction	C54356	"If <PRECIPITANT> or other hepatic enzyme inducers are taken concurrently with <LABELDRUG> or <LABELDRUG> CR, lower plasma levels of <LABELDRUG> may occur. "
Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.71	Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.71.e.8	Increase_Interaction	C54355	Concomitant administration of <LABELDRUG> and <PRECIPITANT> resulted in slight increases in plasma <LABELDRUG> levels and slight decreases in plasma <PRECIPITANT> levels. 
Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.74	Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.74.e.0	Decrease_Interaction	C54358	"Although potent inhibitors of cytochrome P450 3A4 (e.g., ketoconazole) have not been studied clinically, in vitro studies have shown that <PRECIPITANT> and oleandomycin inhibit the metabolism of <LABELDRUG>. "
Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.74	Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.74.e.1	Decrease_Interaction	C54358	"Although potent inhibitors of cytochrome P450 3A4 (e.g., ketoconazole) have not been studied clinically, in vitro studies have shown that erythromycin and <PRECIPITANT> inhibit the metabolism of <LABELDRUG>. "
Dailymed.e2eb7dad-3ea3-439c-dcbb-d1d61aa49dfc.s.36	Dailymed.e2eb7dad-3ea3-439c-dcbb-d1d61aa49dfc.s.36.e.1	Increase_Interaction	C54357	Drug Interactions <LABELDRUG> may add to or potentiate the action of other <PRECIPITANT>.
Dailymed.e2eb7dad-3ea3-439c-dcbb-d1d61aa49dfc.s.39	Dailymed.e2eb7dad-3ea3-439c-dcbb-d1d61aa49dfc.s.39.e.2	Increase_Interaction	C54357	<LABELDRUG> and related drugs may increase the responsiveness to <PRECIPITANT>.
Dailymed.e2eb7dad-3ea3-439c-dcbb-d1d61aa49dfc.s.42	Dailymed.e2eb7dad-3ea3-439c-dcbb-d1d61aa49dfc.s.42.e.2	Increase_Interaction	C54357	"<PRECIPITANT> renal clearance is reduced by <LABELDRUG>, increasing the risk of lithium toxicity."
Dailymed.e2eb7dad-3ea3-439c-dcbb-d1d61aa49dfc.s.42	Dailymed.e2eb7dad-3ea3-439c-dcbb-d1d61aa49dfc.s.42.e.6	Increase_Interaction	C54357	"Lithium renal clearance is reduced by <LABELDRUG>, increasing the risk of <PRECIPITANT> toxicity."
Dailymed.e6328460-a57b-450b-a48c-6dcd4b476360.s.24	Dailymed.e6328460-a57b-450b-a48c-6dcd4b476360.s.24.e.2	Decrease_Interaction	C54358	@item <LABELDRUG> decreases the bioavailability of <PRECIPITANT> by approximately 50%. 
Dailymed.e6328460-a57b-450b-a48c-6dcd4b476360.s.31	Dailymed.e6328460-a57b-450b-a48c-6dcd4b476360.s.31.e.4	Decrease_Interaction	C54358	"In a study of 15 healthy subjects, a co-administered single dose of 2.8 grams of <LABELDRUG> hydrochloride decreased the bioavailability of <PRECIPITANT> by approximately 50%."
Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.120	Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.120.e.0	Increase_Interaction	C54355	"Since <LABELDRUG> is a substrate for CYP3A and CYP2C8, <PRECIPITANT> may decrease the metabolism and increase serum concentration of <LABELDRUG>. "
Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.124	Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.124.e.3	Increase_Interaction	C54355	A case report of one patient taking <LABELDRUG> 200 mg and <PRECIPITANT> 800 mg three times a day resulted in increases in <LABELDRUG> concentrations from 0.9 mg/L to 1.3 mg/L. 
Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.127	Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.127.e.0	Increase_Interaction	C54355	Consider monitoring for <LABELDRUG> toxicity and serial measurement of <LABELDRUG> serum concentration during concomitant <PRECIPITANT> therapy.
Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.132	Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.132.e.3	Increase_Interaction	C54355	<PRECIPITANT> inhibits CYP3A and can increase serum <LABELDRUG> levels.
Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.137	Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.137.e.0	Increase_Interaction	C54602	"<PRECIPITANT> given to healthy volunteers increased <LABELDRUG> AUC by 50% and Cmax by 84%, resulting in increased plasma levels of <LABELDRUG>. "
Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.140	Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.140.e.1	Increase_Interaction	C54357	This inhibition can result in unexpectedly high plasma levels of other <PRECIPITANT> or are substrates for p-glycoprotein. 
Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.143	Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.143.e.6	Increase_Interaction	C54357	"Cyclosporine (CYP3A substrate) administered in combination with oral <LABELDRUG> has been reported to produce persistently elevated plasma concentrations of <PRECIPITANT> resulting in elevated creatinine, despite reduction in dose of <PRECIPITANT>."
Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.148	Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.148.e.3	Increase_Interaction	C54357	"Lower starting and maintenance doses of other <PRECIPITANT> (e.g., atorvastatin) may be required as <LABELDRUG> may increase the plasma concentration of these drugs."
Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.150	Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.150.e.3	Increase_Interaction	C54357	"Cardiac glycosides : In patients receiving <PRECIPITANT> therapy, administration of oral <LABELDRUG> regularly results in an increase in serum <PRECIPITANT> concentration that may reach toxic levels with resultant clinical toxicity. "
Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.151	Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.151.e.2	Increase_Interaction	C54357	<LABELDRUG> taken concomitantly with <PRECIPITANT> increases the serum <PRECIPITANT> concentration by 70% after one day. 
Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.152	Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.152.e.3	Increase_Interaction	C54357	"On administration of oral <LABELDRUG>, review the need for <PRECIPITANT> therapy and reduce the dose of <PRECIPITANT> by approximately 50% or discontinue <PRECIPITANT>. "
Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.153	Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.153.e.4	Increase_Interaction	C54357	"If <PRECIPITANT> treatment is continued, monitor serum levels closely and observe patients for clinical evidence of toxicity."
Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.156	Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.156.e.2	Increase_Interaction	C54357	"There have been case reports of increased steady-state levels of <PRECIPITANT>, procainamide, and phenytoin during concomitant therapy with <LABELDRUG>. "
Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.156	Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.156.e.3	Increase_Interaction	C54357	"There have been case reports of increased steady-state levels of quinidine, <PRECIPITANT>, and phenytoin during concomitant therapy with <LABELDRUG>. "
Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.156	Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.156.e.4	Increase_Interaction	C54357	"There have been case reports of increased steady-state levels of quinidine, procainamide, and <PRECIPITANT> during concomitant therapy with <LABELDRUG>. "
Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.157	Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.157.e.3	Decrease_Interaction	C54356	<PRECIPITANT> decreases serum <LABELDRUG> levels. 
Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.158	Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.158.e.2	Increase_Interaction	C54357	<LABELDRUG> taken concomitantly with <PRECIPITANT> increases <PRECIPITANT> serum concentration by 33% after two days. 
Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.159	Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.159.e.2	Increase_Interaction	C54357	"<LABELDRUG> taken concomitantly with <PRECIPITANT> for less than seven days increases plasma concentrations of <PRECIPITANT> and n-acetyl <PRECIPITANT> by 55% and 33%, respectively. "
Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.159	Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.159.e.3	Increase_Interaction	C54357	"<LABELDRUG> taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and <PRECIPITANT> by 55% and 33%, respectively. "
Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.160	Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.160.e.3	Increase_Interaction	C54357	Reduce <PRECIPITANT> and procainamide doses by one-third when either is administered with <LABELDRUG>.
Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.160	Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.160.e.4	Increase_Interaction	C54357	Reduce quinidine and <PRECIPITANT> doses by one-third when either is administered with <LABELDRUG>.
Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.161	Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.161.e.2	Increase_Interaction	C54357	"Plasma levels of <PRECIPITANT> have been reported to increase in the presence of oral <LABELDRUG>, adjust the dose of <PRECIPITANT> when these drugs are administered concomitantly. "
Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.162	Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.162.e.0	Increase_Interaction	C54357	"In general, initiate any added <PRECIPITANT> at a lower than usual dose and monitor the patient carefully."
Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.180	Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.180.e.0	Decrease_Interaction	C54356	Administration of <PRECIPITANT> concomitantly with oral <LABELDRUG> has been shown to result in decreases in serum concentrations of <LABELDRUG> and desethyl<LABELDRUG>.
Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.192	Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.192.e.3	Decrease_Interaction	C54356	<PRECIPITANT> increases enterohepatic elimination of <LABELDRUG> and may reduce its serum levels and t.
Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.198	Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.198.e.5	Increase_Interaction	C54357	"In addition to the interactions noted above, chronic ( 2 weeks) oral <LABELDRUG> administration impairs metabolism of phenytoin, dextromethorphan, and <PRECIPITANT>."
Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.198	Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.198.e.3	Increase_Interaction	C54357	"In addition to the interactions noted above, chronic ( 2 weeks) oral <LABELDRUG> administration impairs metabolism of <PRECIPITANT>, dextromethorphan, and methotrexate."
Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.198	Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.198.e.4	Increase_Interaction	C54357	"In addition to the interactions noted above, chronic ( 2 weeks) oral <LABELDRUG> administration impairs metabolism of phenytoin, <PRECIPITANT>, and methotrexate."
Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.199	Dailymed.e9108958-b8d7-4fba-87c3-9a32990de551.s.199.e.3	Increase_Interaction	C54357	"@item Since <LABELDRUG> is a substrate for CYP3A and CYP2C8, <PRECIPITANT> may decrease the metabolism and increase serum concentration of <LABELDRUG>."
Dailymed.e9481622-7cc6-418a-acb6-c5450daae9b0.s.41	Dailymed.e9481622-7cc6-418a-acb6-c5450daae9b0.s.41.e.0	Decrease_Interaction	C54356	"<PRECIPITANT> reduces absorption of <LABELDRUG>, thereby lowering <LABELDRUG> plasma concentration see Overdosage (10)."
Dailymed.e9481622-7cc6-418a-acb6-c5450daae9b0.s.47	Dailymed.e9481622-7cc6-418a-acb6-c5450daae9b0.s.47.e.0	Increase_Interaction	C54355	<PRECIPITANT> and P-gp increase exposure to <LABELDRUG> and increase the risk of bleeding. 
Dailymed.e9481622-7cc6-418a-acb6-c5450daae9b0.s.48	Dailymed.e9481622-7cc6-418a-acb6-c5450daae9b0.s.48.e.0	Decrease_Interaction	C54356	<PRECIPITANT> and P-gp decrease exposure to <LABELDRUG> and increase the risk of stroke.
Dailymed.e9481622-7cc6-418a-acb6-c5450daae9b0.s.49	Dailymed.e9481622-7cc6-418a-acb6-c5450daae9b0.s.49.e.2	Increase_Interaction	C54355	@item <PRECIPITANT> increase blood levels of <LABELDRUG>: Reduce <LABELDRUG> dose to 2.5 mg or avoid concomitant use. 
Dailymed.e9481622-7cc6-418a-acb6-c5450daae9b0.s.51	Dailymed.e9481622-7cc6-418a-acb6-c5450daae9b0.s.51.e.0	Decrease_Interaction	C54356	@item Simultaneous use of <PRECIPITANT> reduces blood levels of <LABELDRUG>: Avoid concomitant use. 
Dailymed.e9481622-7cc6-418a-acb6-c5450daae9b0.s.54	Dailymed.e9481622-7cc6-418a-acb6-c5450daae9b0.s.54.e.3	Increase_Interaction	C54355	"The dose of <LABELDRUG> should be decreased to 2.5 mg twice daily when it is coadministered with <PRECIPITANT>, (e.g., ketoconazole, itraconazole, ritonavir, or clarithromycin) see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)."
Dailymed.eadfe464-720b-4dcd-a0d8-45dba706bd33.s.62	Dailymed.eadfe464-720b-4dcd-a0d8-45dba706bd33.s.62.e.4	Increase_Interaction	C54357	"Patients receiving high doses of <PRECIPITANT>s concomitantly with <LABELDRUG>, as in rheumatic disease, may experience <PRECIPITANT> toxicity at lower doses because of competitive renal excretory sites."
Dailymed.eadfe464-720b-4dcd-a0d8-45dba706bd33.s.65	Dailymed.eadfe464-720b-4dcd-a0d8-45dba706bd33.s.65.e.6	Increase_Interaction	C54357	<LABELDRUG> has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of <PRECIPITANT>.
Dailymed.eadfe464-720b-4dcd-a0d8-45dba706bd33.s.66	Dailymed.eadfe464-720b-4dcd-a0d8-45dba706bd33.s.66.e.7	Increase_Interaction	C54357	Lithium generally should not be given with diuretics because they reduce <PRECIPITANT>'s renal clearance and add a high risk of <PRECIPITANT> toxicity.
Dailymed.eadfe464-720b-4dcd-a0d8-45dba706bd33.s.69	Dailymed.eadfe464-720b-4dcd-a0d8-45dba706bd33.s.69.e.2	Increase_Interaction	C54355	Potentiation occurs with <PRECIPITANT>.
Dailymed.eadfe464-720b-4dcd-a0d8-45dba706bd33.s.78	Dailymed.eadfe464-720b-4dcd-a0d8-45dba706bd33.s.78.e.0	Decrease_Interaction	C54615	"There is evidence that treatment with <PRECIPITANT> leads to decrease intestinal absorption of <LABELDRUG>, and consequently to lower peak serum <LABELDRUG> concentrations."
Dailymed.eadfe464-720b-4dcd-a0d8-45dba706bd33.s.80	Dailymed.eadfe464-720b-4dcd-a0d8-45dba706bd33.s.80.e.0	Increase_Interaction	C54357	"Conversely, <LABELDRUG> may decrease renal elimination of other <PRECIPITANT>. "
Dailymed.eed2e28c-02e2-41b6-b9ae-f7fbfecbf816.s.77	Dailymed.eed2e28c-02e2-41b6-b9ae-f7fbfecbf816.s.77.e.4	Increase_Interaction	C54355	"When <LABELDRUG> was given with cyclosporine or <PRECIPITANT>, the blood concentrations of <LABELDRUG> were significantly increased. "
Dailymed.eed2e28c-02e2-41b6-b9ae-f7fbfecbf816.s.77	Dailymed.eed2e28c-02e2-41b6-b9ae-f7fbfecbf816.s.77.e.3	Increase_Interaction	C54355	"When <LABELDRUG> was given with <PRECIPITANT> or itraconazole, the blood concentrations of <LABELDRUG> were significantly increased. "
Dailymed.eed2e28c-02e2-41b6-b9ae-f7fbfecbf816.s.88	Dailymed.eed2e28c-02e2-41b6-b9ae-f7fbfecbf816.s.88.e.0	Increase_Interaction	C54355	"Coadministration of <PRECIPITANT> (rifampin, cyclosporine) or efflux transporter (ritonavir) may increase the systemic exposure to <LABELDRUG>."
Dailymed.eefc47bc-c10f-49bb-8ef7-5999f798ab39.s.82	Dailymed.eefc47bc-c10f-49bb-8ef7-5999f798ab39.s.82.e.2	Increase_Interaction	C54602	"In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of <LABELDRUG> on day 1 of a four-day regimen of <PRECIPITANT> (400 mg twice daily) resulted in a 10% increase in mean AUC of <LABELDRUG> (p 0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of <LABELDRUG>. "
Dailymed.f09af962-f1af-44aa-b544-6643f64960f9.s.34	Dailymed.f09af962-f1af-44aa-b544-6643f64960f9.s.34.e.0	Increase_Interaction	C54355	Concomitant use of <PRECIPITANT> or cimetidine may reduce hepatic blood flow and thereby reduce <LABELDRUG> clearance.
Dailymed.f09af962-f1af-44aa-b544-6643f64960f9.s.34	Dailymed.f09af962-f1af-44aa-b544-6643f64960f9.s.34.e.1	Increase_Interaction	C54355	Concomitant use of beta-blocking agents or <PRECIPITANT> may reduce hepatic blood flow and thereby reduce <LABELDRUG> clearance.
Dailymed.f0e32589-dad9-4887-8481-bcf7f6618466.s.36	Dailymed.f0e32589-dad9-4887-8481-bcf7f6618466.s.36.e.3	Decrease_Interaction	C54356	The effects of <LABELDRUG> are antagonized by <PRECIPITANT> such as caffeine and theophylline. 
Dailymed.f0e32589-dad9-4887-8481-bcf7f6618466.s.37	Dailymed.f0e32589-dad9-4887-8481-bcf7f6618466.s.37.e.0	Decrease_Interaction	C54356	"In the presence of these <PRECIPITANT>, larger doses of <LABELDRUG> may be required or <LABELDRUG> may not be effective. "
Dailymed.f0e32589-dad9-4887-8481-bcf7f6618466.s.38	Dailymed.f0e32589-dad9-4887-8481-bcf7f6618466.s.38.e.3	Increase_Interaction	C54355	<LABELDRUG> effects are potentiated by <PRECIPITANT>. 
Dailymed.f0e32589-dad9-4887-8481-bcf7f6618466.s.39	Dailymed.f0e32589-dad9-4887-8481-bcf7f6618466.s.39.e.3	Increase_Interaction	C54355	"Thus, smaller doses of <LABELDRUG> may be effective in the presence of <PRECIPITANT>. "
Dailymed.f1b26274-a55e-4321-b96c-ce0df830f205.s.28	Dailymed.f1b26274-a55e-4321-b96c-ce0df830f205.s.28.e.4	Increase_Interaction	C54355	"The effect of <LABELDRUG> Hydrochloride Injection, USP for the management of cardiac arrhythmias is potentiated with the simultaneous or prior administration of <PRECIPITANT>."
Dailymed.f1b26274-a55e-4321-b96c-ce0df830f205.s.32	Dailymed.f1b26274-a55e-4321-b96c-ce0df830f205.s.32.e.5	Increase_Interaction	C54355	"Pretreatment with propranolol, metoprolol and <PRECIPITANT> increased the serum concentration of <LABELDRUG>. "
Dailymed.f1b26274-a55e-4321-b96c-ce0df830f205.s.32	Dailymed.f1b26274-a55e-4321-b96c-ce0df830f205.s.32.e.3	Increase_Interaction	C54355	"Pretreatment with <PRECIPITANT>, metoprolol and nadolol increased the serum concentration of <LABELDRUG>. "
Dailymed.f1b26274-a55e-4321-b96c-ce0df830f205.s.32	Dailymed.f1b26274-a55e-4321-b96c-ce0df830f205.s.32.e.4	Increase_Interaction	C54355	"Pretreatment with propranolol, <PRECIPITANT> and nadolol increased the serum concentration of <LABELDRUG>. "
Dailymed.f21512ea-c7c3-4766-b976-b2c0b5616bf0.s.28	Dailymed.f21512ea-c7c3-4766-b976-b2c0b5616bf0.s.28.e.3	Increase_Interaction	C54355	Coadministration of <PRECIPITANT> or cimetidine with <LABELDRUG> has been reported to reduce the clearance of <LABELDRUG> from the plasma and may result in toxic accumulation of the drug.
Dailymed.f21512ea-c7c3-4766-b976-b2c0b5616bf0.s.28	Dailymed.f21512ea-c7c3-4766-b976-b2c0b5616bf0.s.28.e.4	Increase_Interaction	C54355	Coadministration of propranolol or <PRECIPITANT> with <LABELDRUG> has been reported to reduce the clearance of <LABELDRUG> from the plasma and may result in toxic accumulation of the drug.
Dailymed.f48911e0-705f-11dc-afc9-0002a5d5c51b.s.48	Dailymed.f48911e0-705f-11dc-afc9-0002a5d5c51b.s.48.e.3	Increase_Interaction	C54355	Simvastatin: Co-administration of multiple doses of 10 mg of <LABELDRUG> with 80 mg <PRECIPITANT> resulted in a 77% increase in exposure to <PRECIPITANT> compared to <PRECIPITANT> alone. 
Dailymed.f48911e0-705f-11dc-afc9-0002a5d5c51b.s.67	Dailymed.f48911e0-705f-11dc-afc9-0002a5d5c51b.s.67.e.0	Decrease_Interaction	C54606	Concurrent administration of bile acid sequestering agent <PRECIPITANT> reduces the systemic exposure and peak plasma concentration of <LABELDRUG>. 
Dailymed.f6eba4b6-9cd0-4c86-46a8-05a202641c89.s.101	Dailymed.f6eba4b6-9cd0-4c86-46a8-05a202641c89.s.101.e.6	Increase_Interaction	C54357	Lithium generally should not be given with diuretics because they reduce its renal clearance and increase the risk of <PRECIPITANT> toxicity. 
Dailymed.f6eba4b6-9cd0-4c86-46a8-05a202641c89.s.109	Dailymed.f6eba4b6-9cd0-4c86-46a8-05a202641c89.s.109.e.2	Increase_Interaction	C54357	<PRECIPITANT> may add to or potentiate the action of other antihypertensive drugs. 
Dailymed.f6eba4b6-9cd0-4c86-46a8-05a202641c89.s.109	Dailymed.f6eba4b6-9cd0-4c86-46a8-05a202641c89.s.109.e.3	Increase_Interaction	C54357	Thiazides may add to or potentiate the action of other <PRECIPITANT>. 
Dailymed.f6eba4b6-9cd0-4c86-46a8-05a202641c89.s.111	Dailymed.f6eba4b6-9cd0-4c86-46a8-05a202641c89.s.111.e.3	Decrease_Interaction	C54358	"The effect of <PRECIPITANT> may be decreased when used concurrently with <LABELDRUG>, dosage adjustments may be necessary."
Dailymed.f6eba4b6-9cd0-4c86-46a8-05a202641c89.s.116	Dailymed.f6eba4b6-9cd0-4c86-46a8-05a202641c89.s.116.e.3	Decrease_Interaction	C54358	The effectiveness of <PRECIPITANT> may be decreased when used concurrently with <LABELDRUG> because of alkalinization of the urine.
Dailymed.f6f3c339-2c9d-4d07-14a1-6d6c7daf26c6.s.131	Dailymed.f6f3c339-2c9d-4d07-14a1-6d6c7daf26c6.s.131.e.3	Decrease_Interaction	C54356	"In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of <LABELDRUG> alone were compared to <LABELDRUG> given concomitantly with <PRECIPITANT>, the use of <PRECIPITANT> was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant."
Dailymed.f6f3c339-2c9d-4d07-14a1-6d6c7daf26c6.s.148	Dailymed.f6f3c339-2c9d-4d07-14a1-6d6c7daf26c6.s.148.e.3	Increase_Interaction	C54357	"Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with <PRECIPITANT>, including ACE inhibitors. "
Dailymed.f6f3c339-2c9d-4d07-14a1-6d6c7daf26c6.s.148	Dailymed.f6f3c339-2c9d-4d07-14a1-6d6c7daf26c6.s.148.e.2	Increase_Interaction	C54357	"Lithium: Lithium toxicity has been reported in patients receiving <PRECIPITANT> concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. "
Dailymed.f6f3c339-2c9d-4d07-14a1-6d6c7daf26c6.s.193	Dailymed.f6f3c339-2c9d-4d07-14a1-6d6c7daf26c6.s.193.e.0	Increase_Interaction	C54357	<PRECIPITANT> 12.5 mg has been shown to provide an additive effect. 
Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.18	Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.18.e.0	Decrease_Interaction	C54356	@item Maintenance doses of <PRECIPITANT> above 100 mg reduce the effectiveness of <LABELDRUG> and should be avoided. 
Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.38	Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.38.e.0	Decrease_Interaction	C54356	"@item In PLATO, use of <LABELDRUG> with maintenance doses of <PRECIPITANT> above 100 mg decreased the effectiveness of <LABELDRUG>. "
Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.59	Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.59.e.3	Decrease_Interaction	C54356	"In PLATO, use of <LABELDRUG> with maintenance doses of <PRECIPITANT> above 100 mg decreased the effectiveness of <LABELDRUG>. "
Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.96	Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.96.e.0	Decrease_Interaction	C54356	Use of <LABELDRUG> with <PRECIPITANT> maintenance doses above 100 mg reduced the effectiveness of <LABELDRUG> see Warnings and Precautions (5.2) and Clinical Studies (14).
Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.100	Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.100.e.3	Increase_Interaction	C54357	<LABELDRUG> will result in higher serum concentrations of simvastatin and <PRECIPITANT> because these drugs are metabolized by CYP3A4. 
Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.100	Dailymed.f7b3f443-e83d-4bf2-0e96-023448fed9a8.s.100.e.2	Increase_Interaction	C54357	<LABELDRUG> will result in higher serum concentrations of <PRECIPITANT> and lovastatin because these drugs are metabolized by CYP3A4. 
Dailymed.fce692df-1e68-465e-8dda-0cb01320608c.s.50	Dailymed.fce692df-1e68-465e-8dda-0cb01320608c.s.50.e.2	Increase_Interaction	C54357	"<PRECIPITANT> when used concomitantly with <LABELDRUG>, may increase plasma levels of <LABELDRUG>."
Dailymed.fce692df-1e68-465e-8dda-0cb01320608c.s.54	Dailymed.fce692df-1e68-465e-8dda-0cb01320608c.s.54.e.3	Increase_Interaction	C54355	<PRECIPITANT> increases the concentration of <LABELDRUG> and produces greater degrees of clinical beta-blockade and may cause postural hypotension.
Dailymed.fce692df-1e68-465e-8dda-0cb01320608c.s.56	Dailymed.fce692df-1e68-465e-8dda-0cb01320608c.s.56.e.2	Increase_Interaction	C54357	The clearance of <PRECIPITANT> is reduced with administration of <LABELDRUG>. 
Dailymed.fce692df-1e68-465e-8dda-0cb01320608c.s.57	Dailymed.fce692df-1e68-465e-8dda-0cb01320608c.s.57.e.2	Increase_Interaction	C54357	<PRECIPITANT> toxicity has been reported following co-administration with <LABELDRUG>.
Dailymed.fce692df-1e68-465e-8dda-0cb01320608c.s.85	Dailymed.fce692df-1e68-465e-8dda-0cb01320608c.s.85.e.3	Decrease_Interaction	C54356	Administration of <PRECIPITANT> with <LABELDRUG> may reduce the efficacy of <LABELDRUG> in reducing blood pressure and heart rate.
Dailymed.fce692df-1e68-465e-8dda-0cb01320608c.s.91	Dailymed.fce692df-1e68-465e-8dda-0cb01320608c.s.91.e.2	Increase_Interaction	C54357	<LABELDRUG> when administered with <PRECIPITANT> increases the concentration of <PRECIPITANT>. 
Dailymed.fcfc9676-4edc-460e-6199-8161b824908f.s.66	Dailymed.fcfc9676-4edc-460e-6199-8161b824908f.s.66.e.0	Increase_Interaction	C54357	"<PRECIPITANT> (eg, reserpine) may have an additive effect when given with beta-blocking agents. "
Dailymed.fcfc9676-4edc-460e-6199-8161b824908f.s.66	Dailymed.fcfc9676-4edc-460e-6199-8161b824908f.s.66.e.5	Increase_Interaction	C54357	"Catecholamine-depleting drugs (eg, reserpine) may have an additive effect when given with <PRECIPITANT>. "
Dailymed.fcfc9676-4edc-460e-6199-8161b824908f.s.68	Dailymed.fcfc9676-4edc-460e-6199-8161b824908f.s.68.e.0	Increase_Interaction	C54357	<PRECIPITANT> may also have an additive effect when given with <LABELDRUG> (See WARNINGS).
Dailymed.fe0ced75-ccbf-4d2e-bd0d-b57e60ab913f.s.51	Dailymed.fe0ced75-ccbf-4d2e-bd0d-b57e60ab913f.s.51.e.3	Decrease_Interaction	C54356	Patients who received <PRECIPITANT> or omeprazole along with <LABELDRUG> had a higher rate of clearance of <LABELDRUG>. 
Dailymed.fe0ced75-ccbf-4d2e-bd0d-b57e60ab913f.s.51	Dailymed.fe0ced75-ccbf-4d2e-bd0d-b57e60ab913f.s.51.e.4	Decrease_Interaction	C54356	Patients who received levothyroxine or <PRECIPITANT> along with <LABELDRUG> had a higher rate of clearance of <LABELDRUG>. 
